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Abstract (University of Leicester Format) 
Nociceptin/orphanin FQ receptor ligands: pharmacological studies 
The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the 
N/OFQ peptide (NOP) receptor. At cellular level N/OFQ inhibits cAMP accumulation and Ca2+ 
conductance and stimulates K+ currents. N/OFQ regulates several biological functions both at 
central (pain, locomotion, memory, emotional responses, food intake) and peripheral (airways, 
cardiovascular, genitourinary and gastrointestinal systems) sites. Potent and selective NOP ligands 
are now required for investigating the roles played by NOP receptors in pathophysiological studies 
and for firmly defining the therapeutic indications of NOP receptor ligands.  
A novel assay to screen NOP receptor ligands has been validated with a large panel of 
ligands: the Gαqi5 chimeric protein has been used to force the NOP receptor to signal through the 
Ca2+ pathway in CHO cells. [Ca2+]i levels were monitored using the fluorometer FlexStation II. 
Data are in general agreement with classical Gi driven assay systems. 
The NOP peptide partial agonist, ZP120 was extensively characterized in vitro using 
electrically stimulated isolated tissues (mouse and rat vas deferens) and in vivo with the tail 
withdrawal assay. The selective involvement of the NOP receptor in the actions of ZP120 has been 
demonstrated in NOP(-/-) mice studies. 
A detailed pharmacological characterization of the recently identified non-peptide antagonist 
Compound 24 has been performed. Moreover in the context of a SAR study on Compound 24, a 
novel NOP ligand named Compound 35 was identified. Compound 24 and Compound 35 bound the 
human recombinant NOP receptor expressed in CHOhNOP cell membranes with high affinity (pKi 
values 9.62 and 9.14, respectively). Our findings derived from functional studies on CHOhNOP and 
bioassay studies on native receptors demonstrated that Compound 24 and Compound 35 behave as 
potent, competitive and selective non-peptide NOP antagonists. Finally, the NOP antagonist 
properties of Compound 24 have been confirmed in vivo in the mouse tail withdrawal assay. 
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Summary 
N/OFQ and its receptor share high sequence similarity with opioid peptides, particularly 
with dynorphin A, and their receptors. However N/OFQ and dynorphin use distinct molecular 
pathways to bind and activate their cognate receptors. Thus, N/OFQ and NOP receptor represent a 
novel peptidergic system, which is pharmacologically distinct from the opioid systems. At cellular 
level N/OFQ inhibits cAMP accumulation and Ca2+ conductance and stimulates K+ currents, and in 
vivo it modulates a variety of biological functions: nociception, food intake, memory processes, 
anxiety, locomotor activity, gastrointestinal motility, cardiovascular and renal functions, micturition 
and cough reflexes. 
The pharmacological characterization of new ligands for this peptide/receptor system has 
been the main aim of the studies performed during this Ph.D. program. In close collaboration with 
Prof Lambert’s group (University of Leicester) and with Medicinal Chemistry group of Prof. 
Salvadori (University of Ferrara), we performed a series of studies on novel ligands for the NOP 
receptor. The most important areas are summarized as below: 
 
 
1) Pharmacological profile of NOP receptors coupled with calcium signalling via the chimeric 
protein Gαqi5 
In this study the Gαqi5 protein was used to force the human NOP receptor to signal through 
the Ca2+ pathway in CHO cells. [Ca2+]i levels were monitored using the FlexStation II fluorometer 
and the Ca2+ dye Fluo 4 AM. Concentration response curves were generated with a panel of full and 
partial agonists while NOP antagonists were assessed in inhibition response curves. 
The following rank order of potency of antagonists was measured: SB-612111 > J-113397 = 
Trap-101 > UFP-101 > [Nphe1]N/OFQ(1-13)-NH2 >> naloxone, which is in good agreement with 
the literature. The rank order of potency of full and partial agonists is also similar to that obtained in 
previous studies with the exception of a panel of ligands (UFP-112, Ro 64-6198, ZP120, UFP-113) 
whose potency was relatively low in the Gαqi5 - NOP receptor calcium assay. Interestingly, these 
NOP ligands are characterized by slow kinetics of interaction with the NOP receptor, as 
demonstrated by bioassay experiments. This study demonstrated that the FlexStation II - Gαqi5 - 
NOP receptor calcium assay represents an adequate and useful screening tool for NOP receptor 
ligands, particularly for antagonists. 
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2) Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor 
ligand ZP120 
In previous studies, the effects of ZP120 were found to be sensitive to J-113397 in mouse 
tissues while resistant to UFP-101 in rat tissues. The aim of this study was to further investigate the 
pharmacological profile of ZP120 using mouse and rat preparations, J-113397 and UFP-101, as 
well as NOP(-/-) mice. Electrically stimulated mouse and rat vas deferens were used to characterize 
the pharmacology of ZP120 in vitro. For in vivo studies the tail withdrawal assay was performed in 
wild type (NOP(+/+)) and NOP(-/-) mice. In the mouse and rat vas deferens ZP120 mimicked the 
effects of N/OFQ showing higher potency but lower maximal effects. In both preparations, J-
113397 antagonized N/OFQ and ZP120 effects with similar pKB values (≈ 7.8). UFP-101 
antagonized the actions of N/OFQ (pKB values ≈ 7.3) but did not modify the effects of ZP120. The 
inhibitory effects of N/OFQ and ZP120 were no longer evident in vas deferens tissues taken from 
NOP(-/-) mice. In NOP(+/+) mice subjected to the tail withdrawal assay, ZP120 (1 nmol) mimicked 
the pronociceptive action of N/OFQ (10 nmol), producing longer lasting effects. The effects of both 
peptides were absent in NOP(-/-) animals. The NOP receptor ligand ZP120 is a high potency NOP 
selective partial agonist able to evoke long-lasting effects; its diverse antagonist sensitivity in 
comparison with N/OFQ may derive from different modality of binding to the NOP receptor. 
 
 
3) Pharmacological characterization of the nociceptin/orphanin FQ receptor non-peptide 
antagonist Compound 24 
Compound 24, 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4’-piperidin-1-yl]propyl} 
pyrrolidine-2-carboxamide was recently identified as a NOP ligand. In this study, the in vitro and in 
vivo pharmacological profile of Compound 24 was investigated. In vitro studies were performed 
measuring receptor and [35S]GTPγS binding and calcium mobilization in cells expressing the 
recombinant NOP receptor as well as using N/OFQ sensitive tissues. In vivo studies were conducted 
using the tail withdrawal assay in mice. Compound 24 produced a concentration-dependent 
displacement of [3H]N/OFQ binding to CHOhNOP cell membranes showing high affinity (pKi 9.62) 
and selectivity (1000 fold) over classical opioid receptors. Compound 24 antagonized with high 
potency the following in vitro effects of N/OFQ: stimulation of [35S]GTPγS binding in CHOhNOP 
cell membranes (pA2 9.98), calcium mobilization in CHOhNOP cells expressing the Gαqi5 chimeric 
protein (pKB 8.73), inhibition of electrically evoked twitches in the mouse (pA2 8.44) and rat (pKB 
8.28) vas deferens, and in the guinea pig ileum (pKB 9.12). In electrically stimulated tissues, 
Compound 24 up to 1 µM did not modify the effects of classical opioid receptor agonists. Finally in 
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vivo, in the mouse tail withdrawal assay, Compound 24 at 10 mg/kg antagonized the pronociceptive 
and antinociceptive effects of 1 nmole N/OFQ given supraspinally and spinally, respectively. The 
present study demonstrated that Compound 24 is a pure, competitive, and highly potent non-peptide 
NOP receptor selective antagonist. 
 
 
4) Blending of chemical moieties of NOP receptor ligands: identification of a novel antagonist 
In the present investigation, we performed a structure-activity analysis of Compound 24, 
focussing on its N-benzyl D-Pro, amide bond, and benzoisofurane moieties. This latter structure 
was substituted with moieties taken from known non-peptide NOP receptor ligands. Twelve 
Compound 24 derivatives were synthesised and tested in binding experiments performed on 
CHOhNOP cell membranes. Compound 24 displayed a pKi value of 9.62 while the analogues 
modified on the N-benzyl D-Pro and amide bond moieties showed very low affinities. In contrast, 
Compound 35 in which the benzoisofurane was substituted with the 2,6-dichlorophenyl moiety of 
the NOP antagonist SB-612111, showed high affinity (pKi 9.14). This novel compound was 
pharmacologically characterized in various assays where it consistently behaved as a pure, potent 
(pA2 in the range 8.0 – 9.9), competitive and NOP selective antagonist. Collectively the present 
results indicate that the N-benzyl D-Pro and amide bond of Compound 24 are crucial for biological 
activity. Moreover, a novel interesting NOP receptor antagonist was identified by blending 
chemical moieties taken from different NOP receptor ligands. 
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1. INTRODUCTION 
 
1.1  Orphan G-protein coupled receptors and the reverse pharmacology approach 
G-protein coupled receptors (GPCRs) are one of the largest family of proteins that are the 
main modulators of intercellular interactions and regulate activities in the human body and in 
particularly in the central nervous system (CNS). There are numerous GPCRs in living organisms, 
but the function of many is still unknown. The human genome encompasses ~ 800 GPCRs, of 
which more than half are olfactory and/or taste GPCRs. They are targets of most of the primary 
messengers including the neurotransmitters, all the neuropeptides, the glycoprotein hormones, lipid 
mediators and other small molecules; thus have considerable pharmaceutical interest. Drugs that are 
acting on GPCRs are used to treat numerous disorders. More than 30 % of the approximately 500 
clinically used drugs, are modulators of GPCRs function, representing around 9 % of global 
pharmaceutical sales, making GPCRs the most successful of any target class in terms of drug 
discovery (Drews, 2000). 
367 transmitter GPCRs have been identified within the human genome, the majority of these 
GPCRs have been identified on the basis of their sequence similarities, either by homology cloning 
or by bioinformatics analyses. Many of these receptors are currently ‘orphans’. 
The first step in the characterization of new orphan GPCRs is the search of the activating 
ligand. As the genomes of most studied model organism have now been sequenced, the process of 
discovery of GPCRs-ligand pairs has been reversed. Until recently, neuropeptides have been 
traditionally identified either on the basis of their chemical characteristics (Tatemoto et al., 1980) or 
of their effects in particular assay systems (Erspamer et al., 1978). Although highly successful, 
these approaches had reached a stand still by the mid 80’s. 
Through DNA recombination techniques, it is now possible to transfect the sequence of an 
orphan receptor of which the function is not yet known, into an appropriate cellular expression 
system. This leads to the use of orphan receptors as baits to isolate their natural ligands from 
mixtures of synthetic ligands, including known GPCR ligands, naturally occurring bioactive 
molecules of unknown function and randomized compounds in high-throughput screening (HTS). 
This approach has been named “reverse pharmacology”. Thus, drug identification precedes the 
mechanistic understanding of mode of action of the drug candidate. The expression system provides 
the necessary trafficking and G-protein-signalling machinery to enable the successful identification 
of the activating ligand. By exposing the transfected cell to a tissue extract containing the natural 
ligand of the orphan receptor, a change in intracellular second messengers will be induced and will 
serve as a parameter to monitor orphan receptor ligand purification. Despite the logic of the theory, 
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the process is not simple, since the physical nature of the ligand and the type of the second 
messenger response that it will generate, are unknown. However, structural features in an orphan 
GPCR will determine its relationship to known receptors and will help in evaluating the nature of 
the receptor’s ligand and its activity. Indeed, an orphan receptor which is related, even to a low 
degree, to a particular receptor family has a higher probability of sharing a ligand of the same 
physical nature and a coupling to similar G proteins. Notably this strategy has already led to several 
significant discoveries. The orphan receptor strategy was first proven to be successful with the 
discovery of the neuropeptide N/OFQ, the subject of this thesis, as the endogenous ligand of the 
oGPCR ORL-1 (Meunier et al., 1995; Reinscheid et al., 1995). 
 
 
 
 
 
 
Figure 1. The orphan receptor strategy (Civelli et al.,TRENDS in Neurosciences Vol.24 No.4 April 2001). 
The orphan receptor strategy was developed to identify the natural ligands of orphan G-protein-coupled 
receptors (GPCRs) with the aim of discovering novel transmitters (defined in the main text). This strategy 
involves: (1) expression of the cloned orphan GPCR in an heterologous cell line; (2) exposure of this 
transfected cell line to a tissue extract that is expected to contain the natural ligand; (3) recording of the 
change in second messenger response elicited by activation of the orphan GPCR; (4) fractionation of the 
tissue extract and isolation of a surrogate, the active component; (5) determination of the chemical structure 
of the active component and (6) chemical synthesis of the active component and demonstration that it 
exhibits identical activity to that of the purified ligand.  
 
 
This first successful example of orphan receptor strategy was followed by the identification 
of other novel bioactive peptides such as: hypocretins and orexins, prolactin-releasing peptide, 
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apelin, ghrelin, melanin-concentrating hormone, urotensin II, neuromedin U, metastin, neuropeptide 
B, neuropeptide W and neuropeptide S. Each of these discoveries was a landmark in its field 
(Civelli, 2005). The success in GPCRs deorphanization led to the approach being used by the 
pharmaceutical industry (Wise et al., 2004), which had mastered the HTS of thousands of ligands. 
This led to thousands of potential transmitters and unexpected ligands (also of non-peptide nature) 
being tested on dozens of oGPCRs and a revival of the reverse pharmacology approach. Table 1 
summarizes the transmitters of peptidic and non-peptidic nature identified as ligands of oGPCRs 
after 1995 (Civelli, 2005). 
 
 
Table 1. Transmitters identified as ligands of oGPCRs after N/OFQ; taken from Civelli (2005). 
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1.2 The NOP receptor 
Pharmacological studies have defined at least three subtypes of opioid receptors, termed µ, δ 
and κ receptors, that are involved in the mediation of the numerous effects, like analgesia, 
respiratory depression, miosis, constipation, sensation of well being, tolerance and dependence. 
The nomenclature for the opioid receptors remains controversial. A 1996 review and 
proposal for a novel nomenclature (Dhawan et al., 1996) based on guidelines from NC-IUPHAR 
has not been widely accepted by the research community. The 1996 proposal recommended 
replacement of the terms µ, δ, and κ with the terms OP3, OP1, and OP2, respectively. However, in 
the three years or more since the publication of this recommendation, almost all papers referring to 
opioid receptors have continued to use the well-established Greek symbol nomenclature. Since 
Greek nomenclature gave many problems in manuscript preparation and particularly WEB searches, 
this was substituited with terminology more consistent with the overall guidelines of NC-IUPHAR 
that named the opioid receptors as: DOP, MOP, and KOP (Cox et al., 2000). 
Molecular cloning of the DOP receptor (Evans et al., 1992; Kieffer et al., 1992) was soon 
followed by the cloning of the KOP and MOP receptors (Chen et al., 1993; Yasuda et al., 1993). 
Further attempts to clone additional opioid receptor types and/or subtypes, by hybridization 
screening at low stringency with opioid receptor cDNA probes, or using probes generated by 
selective amplification of genomic DNA with degenerate primers, led several laboratories to isolate 
a cDNA encoding a homologous protein with a high degree of sequence similarity to the opioid 
receptors (Bunzow et al., 1994; Chen et al., 1994; Fukuda et al., 1994; Lachowicz et al., 1995; 
Mollereau et al., 1994; Wang et al., 1994). 
The novel clone Opioid Receptor Like-1 (ORL-1) receptor displayed approximately 50 % 
identity with the traditional opioid receptors overall, with the transmembrane regions showing even 
higher homologies of up to 80 %. Despite the close homology to the other opioid receptors, opioid 
ligands displayed very low affinities towards ORL-1 receptor, thus it was considered an orphan 
receptor. ORL-1 receptor is a typical GPCR with seven predicted transmembrane domains (Figure 
2). 
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Figure 2. Schematic representation of ORL-1 receptor from Topham et al. (1998). TM helices are numbered 
1 to 7. E/IL: Extracellular/Intracellular Loop. Visible at the C-terminal of TM 6 is the Gln 286 (human 
receptor numbering) side chain. 
 
 
ORL-1 was subsequently named NOP (Nociceptin/Orphanin FQ Peptide) receptor according 
to the IUPHAR nomenclature (Cox et al., 2000). The ORL-1 receptor was identified in different 
species and showed substantial sequence identities (>90%) between species variants, namely the 
human (hNOP, (Mollereau et al., 1994)), rat (XOR1 (Wang et al., 1994); ROR-C (Fukuda et al., 
1994); LC132 (Bunzow et al., 1994), C3 (Lachowicz et al., 1995)), mouse (MOR-C (Nishi et al., 
1994)) and pig (NOP receptor, (Osinski et al., 1999b)). 
The human NOP receptor protein consists of 370 amino acids (Mollereau et al., 1994) and 
contains seven transmembrane (TM) domains. The N-terminal 44 amino acids contain 3 consensus 
sequences for N-linked glycosylation (Asn-X-Ser/Thr). There are also sites for potencial 
phosphorylation by protein kinase A (in the third intracellular loop) and protein kinase C (in the 
second intracellular loop and the C-terminal). 
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Figure 3. Alignment of the amino acid sequence of the rat NOP receptor (Hyp 8-1) with the amino acid 
sequences of the rat brain DOP, MOP and KOP. Sequences identical in at least 3 of 4 aligned sequences are 
boxed. Gaps in the alignment are indicated by a dash (-). Putative transmenbrane regions are underlined. 
Taken from Wick et al. (1994). 
 
 
The NOP sequence has 57-58% aa (amino acid) identity to each of the rat MOP (Chen et al., 
1994), DOP (Fukuda et al., 1993) and KOP (Minami et al., 1993). This percent identity is slightly 
lower than those obtained when the sequences of opioid receptors are compared to each other (62-
67%). 
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The conservation among the four receptors is highest (>70%) in the II, III, and VII 
transmembrane domains, and approximately 50% in the I, V and VI, but significantly lower (24%) 
in the IV. This high level of sequence conservation within the transmembrane domains lends weight 
to the view that the NOP receptor contains a TM binding pocket that is the structural equivalent of 
alkaloid binding pocket of the opioid receptors. Indeed, the NOP receptor has retained the ability, 
with low affinity, to bind and/or respond to opioid receptor ligands, agonist and/or antagonist such 
as etorphine and diprenorphine (Mollereau et al., 1994), buprenorphine (Wnendt et al., 1999), 
lofentanil (Butour et al., 1997), and naloxone benzoylhydrazone (Noda et al., 1998). 
The NOP receptor gene, Oprl1, is located at the q13.2-13.3 region of the human 
chromosome 20 (Peluso et al., 1998) and has been mapped to the distal region of the mouse 
chromosome 2 (Nishi et al., 1994). In terms of intron-exon organization, the NOP receptor gene is 
nearly identical to that of the MOP, DOP, and KOP receptors, suggesting that the four genes have 
evolved from a common ancestor and hence belong to the same family (Meunier, 1997). Indeed, the 
NOP receptor appears to be evolutionary as old as the opioid receptors, since NOP receptor-like 
genomic sequences have been reported in teleost (Darlison et al., 1997), in cartilaginous fish (Li et 
al., 1996), in sturgeon (Danielson et al., 2001) and in zebra fish (Gonzalez-Nunez et al., 2003).  
Although pharmacological studies have not firmly established the existence of NOP receptor 
subtypes (Calo et al., 2000b), NOP receptor heterogeneity is still an open question. NOP receptor 
heterogeneity may result from differential expression of NOP splice variants. So far, five splice 
variants of NOP mRNA have been isolated. One, identified in rat (Wang et al., 1994), encodes a 
NOP variant with an insertion (intron 5) in the second extracellular loop. The second splice variant, 
exhibiting an in frame deletion of 15 nucleotides at the 3’ end of the TMD 1 coding region (Halford 
et al., 1995; Wick et al., 1994), does encode a functional receptor and has already been isolated 
from human tissue (Peluso et al., 1998). Further, insertions of exons 3 and 4 (Curro et al., 2001) 
after the first coding exon (exon 2) in rats result in three additional splice variants (Pan et al., 1998), 
which again encode truncated and not functional receptors. 
 
1.3 Identification of nociceptin/orphanin FQ  
In 1995 Meunier et al. and Reinsheid et al. simultaneously described N/OFQ as the 
endogenous ligand for ORL-1, now known as NOP. CHO cells expressing the orphan ORL-1 were 
used to identify the endogenous ligand. Based on structural similarities with the known opioid 
receptors, both the chemical nature of the endogenous ligand (peptide) and the consequences of 
receptor activation (inhibition of cyclic AMP) were assumed to be similar to those of classical 
opioids. Consequently, cells were stimulated with forskolin to activate adenylyl cyclase and 
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increase intracellular cAMP. As a Gi/o-coupled orphan receptor, endogenous agonists at this 
receptor will inhibit the formation of cAMP. Extracts from rat (Meunier et al., 1995) or pig 
(Reinscheid et al., 1995) brain were screened. Fractions that were able to inhibit the adenylyl 
cyclase activity were further fractionated through reverse-phase high-performance liquid 
chromatography. The purification and mass spectrometry analyses identified a heptadecapeptide 
(Figure 4), the sequence of which was determined. The synthetic peptide was shown to have high 
affinity (in the nanomolar range) and to strongly inhibit forskolin-induced accumulation of cAMP 
in CHO cells expressing the NOP receptor (EC50 about 1 nM), while showing no activity in non 
transfected cells (Meunier et al., 1995). Moreover, when tested in vivo by intracerebroventricular 
(i.c.v.) injection in mice, the peptide induced hyperalgesia in the hot plate (Meunier et al., 1995) 
and tail flick (Reinscheid et al., 1995) tests. Decrease in the locomotor activity but no analgesia was 
also observed in the hot plate test (Reinscheid et al., 1995). 
The group of Meunier termed the novel peptide nociceptin, based on apparent pro-
nociceptive properties, while that of Reinscheid named it orphanin FQ, as ligand of an orphan 
receptor, whose first and last amino acids are Phe (F) and Gln (Q), respectively. 
N/OFQ shares sequence homologies with the opioid peptide ligand dynorphin A (Figure 4); 
despite the structural similarities these peptides are functionally quite distinct. N/OFQ has no 
significant affinity for any of the opioid receptors (Reinscheid et al., 1998). 
 
 
 
 
 
 
 
Figure 4. Structural similarities between dynorphin A and N/OFQ amino acid sequences (Guerrini et al., 
2000b). 
 
 
The N-terminal tetrapeptide sequences (message domains) of the two peptides are very 
similar, with the only difference of the first amino acid residue (Phe in N/OFQ and Tyr in 
dynorphin A); the C-terminal parts (address domains) of the two molecules are both enriched in 
positively charged residues, such as arginine and lysine, even if distributed in different positions.  
N/OFQ is a heptadecapeptide cleaved from the polypeptide precursor preproN/OFQ 
(ppN/OFQ). ppN/OFQ consists of a 181 amino acids in the rat, 176 amino acids in humans and 187 
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amino acids in the mouse (Mollereau et al., 1996; Nothacker et al., 1996) (Figure 5). The ppN/OFQ 
gene, that has been isolated from human, mouse and rat, is highly conserved in the three species. 
 
 
 
Figure 5. Amino acid sequence for N/OFQ precursor, ppN/OFQ (Calo et al., 2000b). 
 
 
Analysis of the nucleotide sequence of the preproN/OFQ gene revealed structural and 
organisational characteristics very similar to those of the opioid peptide precursors, in particular 
preproenkephalin and preprodynorphin, suggesting that these peptides derive from a common 
ancestor (Mollereau et al., 1996; Nothacker et al., 1996). 
The ppN/OFQ gene is located on human chromosome 8 (8p21) (Mollereau et al., 1996). In 
the ppN/OFQ sequence there are several pairs of basic amino acids that present possible sites of 
cleavage for precursor maturation or for transcriptional regulation (Zaveri et al., 2000). Therefore, 
several biologically relevant peptides may derive from the N/OFQ precursor (Figure 5). Apparently 
two additional peptides are excised from the same precursor: orphanin FQ2 and nocistatin (Okuda-
Ashitaka et al., 1998). None of them bind to NOP receptor (Mollereau et al., 1996; Nothacker et al., 
1996), and until now specific receptors for them have not been identified. The peptide following the 
N/OFQ sequence, is a heptadecapeptide terminating with the couple FQ (orphanin FQ2): it has been 
found to be biologically active, stimulating locomotor activity in mice (Florin et al., 1997) inducing 
antinociception both spinally and supraspinally (Rossi et al., 1998) and inhibiting gastrointestinal 
transit (Rossi et al., 1998). 
The second peptide, named nocistatin (NST), has been reported to act as a functional 
antagonist of N/OFQ (Okuda-Ashitaka et al., 1998). In most studies, NST was found to be inactive 
per se, but was able to reverse several effects of N/OFQ, such as induction of allodynia after spinal 
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administration in mice (Minami et al., 1998; Okuda-Ashitaka et al., 1998), inhibition of glutamate 
release from rat brain slices (Nicol et al., 1998), impairment of learning and memory in mice 
(Hiramatsu et al., 1999a), stimulation of food intake in rats (Olszewski et al., 2000). Moreover, 
NST can, per se, cause antinociception after i.c.v. administration in the rat carrageenan test 
(Nakagawa et al., 1999) or after intratechal (i.t.) administration in the rat formalin test (Yamamoto 
et al., 2001). Interestingly, nocistatin or its C-terminal hexapeptide exerts anxiogenic-like effects in 
mice; in fact it has been reported that the C-terminal hexapeptide (the most conserved region among 
species), administered i.c.v., exerts clear anxiogenic-like effects in mice, in contrast to N/OFQ, that 
in the same experimental model, acts as an anxiolytic (Gavioli et al., 2002). Very recent findings 
demonstrated that the opposite effects of N/OFQ and NST on supraspinal pain modulation result 
from their opposing effects on the excitability of central amygdala nucleus-periaqueductal gray 
projection (CeA-PAG) neurons. Electrophysiological studies showed that N/OFQ hyperpolarized 
CeA-PAG projection neurons by enhancing an inwardly rectifying potassium conductance. In 
contrast, NST depolarized CeA-PAG neurons by causing the opening of TRPC cation channels via 
a G(αq/11)-PLC-PKC pathway (Chen et al., 2009). 
In vitro studies demonstrated that bovine nocistatin (bNST) inhibited the K+-induced [3H]5-
HT release from mouse cortical synaptosomes, displaying similar efficacy but lower potency than 
N/OFQ; this inhibitory effect was not prevented either by the NOP receptor antagonist UFP-101, or 
by the non-selective opioid receptor antagonist, naloxone. In contrast to N/OFQ, bNST reduced 
[3H]5-HT release from synaptosomes obtained from NOP receptor knockout mice (Fantin et al., 
2007). 
 
1.4 Metabolism of N/OFQ 
Degradation of the N/OFQ peptide is principally via aminopeptidase N (APN), which 
releases the inactive N/OFQ(2-17) and endopeptidase (EP), which cleaves a variety of bonds to 
release inactive fragments, Figure 6 (Calo et al., 2000b). Endopeptidase 24.15 (EP 24.15) (Montiel 
et al., 1997) acts on the peptide bonds Ala7-Arg8, Ala11-Arg12, Arg12-Lys13 and releases inactive 
compounds; endopeptidase 24.11 (EP 24.11) acts on the cleavage site Lys13-Leu14 and plays a major 
role in the initial stage of N/OFQ metabolism in mouse spinal cord (Sakurada et al., 2002). C-
terminal degradation also leads to a reduction in binding affinity of N/OFQ for NOP, loss of the 4 
amino acids from the C-terminal tail as in N/OFQ(1-13) results in a 30-fold reduction in potency 
(Butour et al., 1997). However, amidation of C-terminus of N/OFQ(1-13) restores ligand affinity 
and potency, consequently N/OFQ(1-13)-NH2 is the shortest sequence retaining the full biological 
activity of the endogenous ligand (Guerrini et al., 1997). 
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Figure 6. N/OFQ metabolism by aminopeptidase N (APN) and endopeptidases (EP), from Calo et al. 
(2000b). 
 
 
1.5  NOP receptor and N/OFQ localization 
The regional distribution of N/OFQ and the NOP receptor have been well described 
(Bunzow et al., 1994; Fukuda et al., 1994; Houtani et al., 2000; Lachowicz et al., 1995; Letchworth 
et al., 2000; Mollereau et al., 1994; Neal et al., 1999a; Neal et al., 1999b; Nothacker et al., 1996; 
O'Donnell et al., 2001; Riedl et al., 1996; Wick et al., 1995). These series of publications provide 
detailed descriptions of the distribution of the NOP receptor, mRNA and binding in the brain which 
are beyond the scope of this work. They report a good correlation between receptor binding 
distributions and those seen with in situ hybridization. Regions with NOP receptor binding typically 
express NOP mRNA as well, although the levels of mRNA and NOP binding do not always closely 
match (Neal et al., 1999a). 
The NOP receptor is widely expressed in the CNS, in particular in the forebrain (cortical 
areas, olfactory regions, limbic structures: hippocampus and amygdala, thalamus), throughout the 
brainstem (central periaqueductal gray, substantia nigra, several sensory and motor nuclei), and in 
both dorsal and ventral horns of the spinal cord (Mollereau et al., 2000; Neal et al., 1999a). The 
distribution patterns have suggested the involvement of the NOP receptor system in motor and 
FGGFTGARKSARKLANQ
Q 
F + GGFTGARKSARKLANQ 
APN 
FGGFTGA + RKSARKLANQ 
FGGFTGARKSA + RKLANQ 
FGGFTGARKSAR + KLANQ 
EP 24.15 
FGGFTGARKSARK + LANQ 
FGGFTGARK + SARK 
EP 
EP 
 20 
balance control, reinforcement and reward, nociception, stress response, sexual behaviour, 
aggression and autonomic control of physiological processes (Neal et al., 1999a). 
It is worthy of mention that NOP receptors co-express with MOP receptors in the dorsal 
horn of the spinal cord, the hippocampal formation and the caudate putamen (Judd et al., 1996; 
Letchworth et al., 2000) in the midbrain periaqueductal gray and the nucleus raphe magnus 
(Houtani et al., 2000). Distribution of NOP does not always overlap that of opioid receptors: these 
anatomical differences may provide a possible explanation for the different in vivo actions of 
N/OFQ and opioids (Ikeda et al., 1998; Monteillet-Agius et al., 1998; Sim et al., 1997). 
Due to the diffuse distribution of N/OFQ peptide and NOP receptor, this novel system is 
associated with a large number of physiological responses and probably contributes to homeostasis 
by modulating neuronal circuitry (Mollereau et al., 2000). This might explain why the NOP(-/-) 
mice do not display an obvious phenotype (other than the unrestrained nociceptive response and 
dysregulation of hearing ability) (Nishi et al., 1997) and also why pharmacological effects of 
N/OFQ are sometimes contradictory (e.g. in pain and locomotor tests) depending on the locus of 
injection and dose (Mollereau et al., 2000). 
The NOP receptor mRNA has also been identified in the peripheral nervous system and 
several other organs. It is expressed in peripheral ganglia and in the immune system. It has been 
detected in rat intestine, vas deferens, skeletal muscles and spleen (Wang et al., 1994) in porcine 
gastrointestinal tract and kidney (Osinski et al., 1999b), in several guinea pig ganglia (Fischer et al., 
1998), also in rat retina and heart (Mollereau et al., 2000). 
Peluso and colleagues (Peluso et al., 1998) were the first to describe the distribution of NOP 
receptor transcripts in man, in different brain regions by RT-PCR technique: the highest 
amplification was observed in cortical areas (the frontal and temporal cortex), in the hypothalamus, 
mamillary bodies, the substantia nigra, and thalamic nuclei. Transcripts have also been detected in 
limbic structures (the hippocampus and amygdala), brainstem (the ventral tegmental area, the locus 
coeruleus) and the pituitary gland. This distribution, which is similar to that of rodents, suggests the 
participation of the NOP receptor in numerous human physiological functions, such as emotive and 
cognitive processes, neuroendocrine and sensory regulation. 
Berthele and colleagues (Berthele et al., 2003) studied the differential expression of NOP 
receptors in the human brain (cortex, basal ganglia, hippocampal area and cerebellum) by utilizing 
on-section ligand binding corroborated with mRNA detection on parallel sections of the same brain 
tissues. In general, [3H]-N/OFQ ligand binding and NOP receptor mRNA expression were 
widespread and indicative of a considerable high NOP receptor expression in these anatomical 
regions. [3H]-N/OFQ ligand binding and NOP mRNA expression studies showed that the highest 
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amounts of NOP receptor were observed in the cerebellum, in the cortex (cingulate and prefrontal 
cortex), in the striatum (caudate nucleus and the putamen) and in the lamina II, followed by laminae 
III, V and VI, in the principal neurons of the dentate gyrus and in the hippocampal area (Berthele et 
al., 2003). 
 
The localization of N/OFQ-immunoreactive fibers and terminals and/or the localization of 
the ppN/OFQ mRNA correspond reasonably well with the NOP receptor. Limbic areas highly 
express N/OFQ, in particular the bed nucleus of the stria terminals, and the amygdala nuclei (Boom 
et al., 1999; Neal et al., 1999b). A matching pattern of N/OFQ and NOP receptor expression in the 
human and rodent central nervous system has been observed (Berthele et al., 2003; Peluso et al., 
1998; Witta et al., 2004). As with the receptor, N/OFQ immunoreactivity and mRNA levels 
detected using in situ hybridization are closely correlated. N/OFQ is found in lateral septum, 
hypothalamus, ventral forebrain, claustrum, mammillary bodies, amygdala, hippocampus, thalamus, 
medial habenula, ventral tegmentum, substantia nigra, central gray, interpeduncular nucleus, locus 
coeruleus, raphe complex, solitary nucleus, nucleus ambiguous, caudal spinal trigeminal nucleus, 
and reticular formation, as well the ventral and dorsal horns of the spinal cord (Neal et al., 1999b). 
Recently N/OFQ was immunolocalized in rat lateral and medial olivocochlear efferents (Kho et al., 
2006). Although N/OFQ and opioid peptides show a similar distribution, they are not colocalized in 
nociceptive centres such as the dorsal horn, the sensory trigeminal complex or the periaqueductal 
gray (Schulz et al., 1996). 
In the periphery, mRNA of N/OFQ was detected in rat ovary, in human spleen, 
lymphocytes, and fetal, but not adult kidney (Mollereau et al., 1996; Nothacker et al., 1996). 
Furthermore, it has been shown that, under physiological conditions, N/OFQ is present in the 
human plasma (~ 10 pg/ml) (Brooks et al., 1998). In several pathological conditions such as 
postpartum depression (Gu et al., 2003), Wilson’s disease (Hantos et al., 2002), hepatocellular 
carcinoma (Horvath et al., 2004) and in acute and chronic pain states (Ko et al., 2002b), plasma 
levels of N/OFQ resulted increased. In contrast, lower N/OFQ plasma levels have been observed in 
patients suffering from fibromyalgia syndrome (Anderberg et al., 1998), cluster headache (Ertsey et 
al., 2004) and migraine without aura (Ertsey et al., 2005). After all, a very recent findings indicate 
that N/OFQ plasma levels are increased in sepsis condition (Williams et al., 2008). 
 
1.6 Cellular effects of N/OFQ 
The cellular actions of the classical opioid receptors (MOP/KOP/DOP) and the NOP 
receptor have been shown to be pertussis toxin sensitive and therefore couple to inhibitory G-
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proteins i.e. G-proteins with Gi/o alpha subunits (Reinscheid et al., 1996). G-proteins are membrane 
bound/associated heterotrimeric proteins composed of α, β, γ subunits. There are four major classes 
of G proteins including Gi/Go, Gs, Gq. 
Activation of NOP, similar to MOP, KOP, and DOP opioid receptors activation, leads to: (i) 
closing of voltage sensitive calcium channels, (ii) stimulation of potassium efflux leading to 
hyperpolarisation and (iii) reduced cyclic adenosine monophosphate (cAMP) production via 
inhibition of adenylyl cyclase. Overall this results in reduced neuronal cell excitability leading to a 
reduction in transmission of nerve impulses along with inhibition of neurotransmitter release 
(Figure 7) (Hawes et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic representation of intracellular responses to NOP receptor activation. 
 
  
N/OFQ inhibits forskolin-stimulated cellular cAMP production. Forskolin is used to directly 
activate adenylyl cyclase and consequently increase cAMP production. Elevating cAMP via other 
receptor driven systems (e.g. via the D1 dopamine receptor) is also inhibited by N/OFQ (Chan et 
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al., 1998). Both the endogenous and recombinant NOP receptors are capable of inhibiting the 
formation of cAMP with remarkably consistent EC50 values in a range of cell systems. 
The peptide also inhibits several types of voltage-gated Ca2+ channels: for example in 
human SH-SY5Y neuroblastoma cells it produces a partial inhibition of N-type Ca2+ conductance 
with an IC50 value of about 40 nM (Connor et al., 1996a), and in dissociated rat hippocampal 
neurones the peptide partially inhibits the three major types of Ca2+ channels, L, N and P/Q 
(Knoflach et al., 1996). The inhibition is no longer seen after β pertussis toxin treatment and cannot 
be prevented by high doses of naloxone. N/OFQ has been shown to mediate a pronounced 
inhibition of N-type calcium channels, whereas other calcium channel subtypes were not affected. 
N/OFQ has also been reported to increase the inwardly rectifying K+ conductance in rat 
brain slices containing the dorsal raphe nucleus (Vaughan et al., 1996), the locus coeruleus (Connor 
et al., 1996b), and the periaqueductal grey (Vaughan et al., 1997), in hippocampal slices (Madamba 
et al., 1999) and cultured hippocampal neurones (Amano et al., 2000). 
Collectively, these data are consistent with the hypothesis that N/OFQ acts primarily to 
reduce synaptic transmission and neuronal excitability in the nervous system (Meunier, 1997). In 
the CNS, studies using synaptosomes and brain slices revealed that N/OFQ inhibits the release of 
noradrenaline (NA), serotonine (5-HT), dopamine (DA), acetylcholine (Ach), γ-aminobutyric acid 
(GABA), and glutamate (Schlicker et al., 2000). 
In the peripheral nervous system, studies showed the general modulatory effects (mostly 
inhibitory) of N/OFQ on neurotransmitter release from sympathetic, parasympathetic and 
nonadrenergic-noncholinergic sensory endings. In the respiratory, cardiovascular, genitourinary and 
gastrointestinal systems N/OFQ exerts inhibitory effects (Giuliani et al., 2000). Several isolated 
tissues from different species have been shown to be sensitive to N/OFQ. In particular, the 
electrically stimulated mouse and rat vas deferes and the guinea pig ileum have been described and 
used extensively in opioid receptor pharmacology: the guinea pig ileum, whose myenteric neuronal 
network contains mainly MOP receptors (Paton, 1957) has been shown to respond to N/OFQ (Calo 
et al., 1997; Calo et al., 1996; Zhang et al., 1997); the mouse vas deferens whose nerve terminals 
contain mainly DOP receptors (Hughes et al., 1975) and the rat vas deferens, whose nerves contain 
an uncharacterized opioid receptor (Lemaire et al., 1978), have also been reported to be N/OFQ 
sensitive preparations (Berzetei-Gurske et al., 1996; Calo et al., 1997; Calo et al., 1996; Nicholson 
et al., 1998; Zhang et al., 1997). The twitch response in the three preparations is due to nerve 
activation and subsequent release of neurotransmitter since they are blocked by tetradotoxin (TTX). 
The release of NA from the sympathetic nerves is the major cause of the contractions of mouse and 
rat vas deferens, since they are blocked by the α-1 adrenoceptor antagonist prazosin. NOP receptors 
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appear to be localized in sympathetic terminals since N/OFQ inhibits twitch evoked by electrical 
field stimulation, but does not modify contractions to exogenous NA (Calo et al., 1996). Similar 
results were obtained in the guinea pig ileum since atropine and TTX sensitive contractions derive 
from the release of Ach from cholinergic terminals of the myenteric plexus without affecting 
responses to exogenous Ach, thus demonstrating the prejunctional localization of the NOP receptor. 
In the three tissues the inhibitory effect of N/OFQ is not influenced by naloxone suggesting that 
classical opioid receptors are not targeted by the peptide. 
A similar picture has been found regarding the inhibitory effects of N/OFQ on sensory fibers 
on the guinea pig bronchus (Fischer et al., 1998; Rizzi et al., 1999b), cholinergic contractions of 
human bronchus (Basso et al., 2005), renal pelvis and heart (Giuliani et al., 1996; Giuliani et al., 
1997a). The rat anococcygeus has also been described as a preparation, in which N/OFQ produces a 
concentration-dependent inhibition of the adrenergic motor response to electrical field stimulation, 
but does not affect the response to exogenous NA. In addition, selective opioid ligands do not exert 
any effect on this preparation, suggesting that in this preparation the NOP receptor occurs without 
the co-presence of the classical opioid receptors (Ho et al., 2000). In all the preparations analysed 
above, the N/OFQ-NOP receptor system displays a prejunctional inhibitory function, as do classical 
opioid receptors. 
 
1.7 Biological effects of N/OFQ 
Due to the widespread distribution of N/OFQ and NOP receptor, this peptidergic system is 
involved in a wide range of physiological responses with effects noted in the nervous system 
(central and peripheral), the cardiovascular system, the airways, the gastrointestinal tract and 
immune system. The role of this peptidergic system has been explored intensely with the 
pharmacological and biological tools available, such as i) antisense oligonucleotides targeting NOP 
receptor or ppN/OFQ gene, ii) antibodies directed against N/OFQ, iii) transgenic mice in which the 
receptor or the peptide precursor genes have been genetically eliminated, iv) available stable and 
highly potent antagonists. Some of the more well-studied and noteworthy biological actions 
modulated by this system will be described below. 
 
Pain regulation 
Since the identification of N/OFQ there has been intense interest in the role of this peptide in 
pain processing. This is based on various factors, including the similarity of distribution of receptor 
and peptide to classical opioids within the defined pain pathway and the structural similarity to 
classical opioids. Application of N/OFQ has been shown to cause hyperalgesia, allodynia and 
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analgesia. These conflicting findings are confounded by species and or strain differences in test 
animals, known to be fundamental in the supraspinal effects of nociception (Mogil et al., 1999). 
However, the route of administration and nociceptive paradigm under investigation are of 
paramount importance. 
 
Supraspinal level 
N/OFQ was shown to increase pain sensitivity in mice and rats in the two initial studies of 
the functions of this peptide (hence the name nociceptin; (Meunier et al., 1995; Reinscheid et al., 
1995)). However, the hyperalgesic effect of N/OFQ was only seen after intracerebroventricular 
(i.c.v.), but not after intrathecal (i.t.) administration. It has been demonstrated that N/OFQ’s most 
prominent role in supraspinal pain modulation is a “functional opioid antagonism” directed against 
many different opioid receptor agonists (Mogil et al., 2001). Since behavioural testing in pain 
models, in particular i.c.v. and i.t. injections, expose animals to acute stress, the apparent 
pronociceptive action seen in the initial studies may thus be interpreted as the reversal of stress-
induced antinociception rather than as a genuine pronociceptive or hyperalgesic effect (Zeilhofer et 
al., 2003). I.c.v. injection of N/OFQ was stressful, resulting in a release of central endogenous 
opioid peptides with their effects subsequently reversed by the delivered dose of N/OFQ (Lambert, 
2008). The suggestion for an anti-opioid role of N/OFQ has since been corroborated by results 
obtained in a variety of assays: indeed, it has been shown that N/OFQ counteracts the analgesic 
effect of the endogenous opioids (Tian et al., 1997a; Tian et al., 1997b) or that of exougenously 
applied morphine (Bertorelli et al., 1999; Calo et al., 1998b; Grisel et al., 1996; Zhu et al., 1997) or 
that of selective opioid receptor agonists (King et al., 1998). Worthy of mention is the fact that 
tolerance develops to the antiopioid effects of N/OFQ (Lutfy et al., 1999). 
Since the NOP receptor and classical opioid receptors largely share the same transductional 
mechanisms, it is reasonable to speculate that their opposite effects on pain threshold are due to 
distinct localisations of N/OFQ and opioid peptides and their respective receptors on the neuronal 
networks involved in pain transmission at the supraspinal level. Many studies demonstrate that the 
net effects of N/OFQ on nociception at supraspinal sites strongly depend on the activation state 
(resting versus sensitized) of pain controlling neuronal circuits (Zeilhofer et al., 2003). 
It is possible that N/OFQ plays a role in the physiological modulation of pain signals under 
normal or pathologic conditions. This question can be best answered through the use of N/OFQ 
receptor antagonists, or transgenic mice lacking the NOP receptor gene and with antisense 
oligonucletides. Indeed, the involvement of the NOP receptor in N/OFQ effects on nociception is 
supported by the following evidence: i) the pronociceptive action of N/OFQ is no longer present in 
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NOP(-/-) mice (Nishi et al., 1997; Noda et al., 1998); ii) antisense oligonucleotides targeting the 
NOP receptor prevent the effect of N/OFQ (Tian et al., 1997b; Zhu et al., 1997); the pronociceptive 
effect of N/OFQ is reversed by NOP selective antagonists: [Nphe1]N/OFQ(1-13)-NH2 (Calo et al., 
2000a; Di Giannuario et al., 2001; Rizzi et al., 2001b), UFP-101 (Calo et al., 2002b), J-113397 
(Ozaki et al., 2000; Yamamoto et al., 2001) and SB-612111 (Rizzi et al., 2007a; Zaratin et al., 
2004). 
 
Spinal level 
Many lines of evidence indicate that the spinal cord is an equally important CNS area for 
nociceptive processing and its modulation by N/OFQ and classical opioids. Neurons and fiber 
networks containing N/OFQ mRNA and N/OFQ like immunoreactivity have been located in the 
dorsal spinal cord (Lee et al., 1997; Mamiya et al., 1998; Meis et al., 1998; Meunier et al., 1995), 
and endogenously released N/OFQ can be detected following electrical field stimulation of the 
spinal cord (Lai et al., 2000). 
The role of N/OFQ in modulating pain threshold in the spinal cord is controversial. 
Although some studies reported that i.t. injection of N/OFQ produces hyperalgesia/allodynia (Hara 
et al., 1997; Inoue et al., 1999) others found no effect (Grisel et al., 1996; Reinscheid et al., 1995). 
Most of the studies, however demonstrated that i.t. N/OFQ induces an antinociceptive effect similar 
to that evoked by classical opioid receptor agonists (Candeletti et al., 2000b; Erb et al., 1997; Hao 
et al., 1998; Kamei et al., 1999; King et al., 1997; Nazzaro et al., 2007; Wang et al., 1999; Xu et 
al., 1996). While tolerance develops to the antinociceptive effect of i.t. N/OFQ upon repeated 
administration, there is no cross tolerance with morphine, suggesting that different receptors are 
involved in the actions of the two agents (Hao et al., 1997). Differences in animal species or even in 
strains, as well as in N/OFQ doses used, may account for the conflicting results reported with 
N/OFQ in the spinal cord. Worthy of mention is the work of Inoue et al. (1999) showing the dose 
response curve to N/OFQ is bell-shaped: very low doses of peptide (fmol range) cause hyperalgesia, 
while at higher doses (nmol range) N/OFQ is antinociceptive and blocks the scratching, biting and 
licking induced by i.t. substance P. 
Extremely interesting is the latest study of Ko and colleagues (Ko et al., 2006) as this is the 
first to document the inhibitory action of spinal N/OFQ in a primate species. The behavioural study 
showed that i.t. administration of N/OFQ dose-dependently produced antinociception in monkeys 
that was blocked by a NOP receptor antagonist, J-113397, but not by naltrexone. These results 
provide the first functional evidence of spinal N/OFQ-induced antinociception in primates and 
indicate that activation of spinal NOP receptors may be a potential target for spinal analgesics. 
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Collectively, the cellular mechanisms of the pronociceptive effects of N/OFQ in the spinal 
cord are still rather obscure, whereas inhibition of excitatory synaptic transmission presents as a 
clearly defined cellular mechanism underlying the spinal analgesia. The combination of opioid-like 
analgesia by N/OFQ at the level of the spinal cord with functional opioid antagonism at supraspinal 
sites, where most of the unwanted effects of classical opioids arise, has promoted the idea that NOP 
receptor agonists might be better tolerated spinally acting analgesics. It should however be noted 
that the only well studied non-peptide NOP receptor agonist Ro 64-6198 was anxiolytic, but not 
antinociceptive in acute pain models (Jenck et al., 2000); Ro 64-6198 was recently reported to have 
an antiallodynic effect mediated by NOP receptors in a neuropathic pain model (Obara et al., 2005). 
Nevertheless, further studies with other NOP receptor agonists and in chronic pain models are 
desirable. 
Nociceptive responses to acute noxious heat in NOP(-/-), ppN/OFQ(-/-) and double 
knockout mice were indistinguishable from those of NOP(+/+). However, NOP(-/-), ppN/OFQ(-/-) 
and double knockout mice showed markedly stronger nociceptive response during prolonged 
nociceptive stimulation (Depner et al., 2003). These results indicate that the N/OFQ system 
contributes significantly to endogenous pain control during prolonged nociceptive stimulation but 
does not affect acute pain sensitivity (Depner et al., 2003). 
 
There have been attempts to correlate human plasma N/OFQ levels with pain but the results 
of these studies have been contradictory. An increase in N/OFQ levels in acute and chronic pain 
compared with controls was reported (Ko et al., 2002b). However, a decrease in N/OFQ levels was 
noted in fibromyalgia syndrome (Anderberg et al., 1998) and cluster headache (Ertsey et al., 2004). 
 
Modulation of locomotor activity 
One of the seminal investigations of N/OFQ reported a dose-dependent decrease in 
locomotor activity (i.e., hypolocomotion) when the peptide was given supraspinally (Reinscheid et 
al., 1995). This effect was significant only after i.c.v. application of 10 nmol N/OFQ. This finding 
was later confirmed by other authors in mice (Nishi et al., 1997; Noble et al., 1997; Noda et al., 
1998). 
Repeated daily N/OFQ injections result in rapid development of tolerance to this depressor 
effect on locomotion behaviour (Devine et al., 1996). The action of N/OFQ is insensitive to 
naloxone (Noble et al., 1997), while it is reversed by NalBzOH (Noda et al., 1998). The locomotor-
inhibiting effects of N/OFQ seen in NOP(+/+) animals were not seen in the NOP(-/-) mice, 
confirming the involvement of the NOP receptor in the effect (Nishi et al., 1997; Noda et al., 1998). 
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However the spontaneous locomotor activity of NOP(-/-) mice is not different from that displayed 
by NOP(+/+) littermates which suggest that the N/OFQ-NOP receptor system does not play a tonic 
role in the physiological regulation of locomotion. When microinjected directly into the 
hippocampus or ventromedial hypothalamus, but not the nucleus accumbens, high doses of N/OFQ 
(10–25 nmol) significantly decrease locomotor activity (Sandin et al., 1997). 
N/OFQ has also been reported to stimulate locomotor activity and exploratory behaviour at 
very low doses (0.01-0.1 nmol) (Florin et al., 1996). This effect of N/OFQ has been related to the 
anxiolitic-like actions of the peptide (Jenck et al., 1997). Thus, N/OFQ shows a biphasic dose 
response curve for locomotor activity: stimulation at low doses (0.01-0.1 nmol), inhibition at high 
doses (1-10 nmol). 
It has been demonstrated that firing activity of dopaminergic cells of the substantia nigra, 
which express NOP receptors, is inhibited by microinjection of N/OFQ (Marti et al., 2004b). When 
microinjected into the substantia nigra, N/OFQ reduces dopamine release in the striatum and 
locomotor activity (Marti et al., 2004b). Conversely, the NOP receptor antagonists, UFP-101 and J-
113397, injected into the substantia nigra, enhanced striatal dopamine release and facilitated motor 
performance (Marti et al., 2004b). These data confirm that improvement in locomotor activity is 
due to the enhanced striatal dopamine release caused by blockade of endogenous N/OFQ signalling. 
The inhibitory role played by endogenous N/OFQ on motor activity was additionally strengthened 
by the finding that mice lacking the NOP receptor gene outperformed wild-type mice on the 
exercise stimulated locomotion (rotarod test) (Marti et al., 2004b). Microinjection of UFP-101 into 
the substantia nigra also reversed akinesia in haloperidol-treated (Marti et al., 2004a) or 6-
hydroxydopamine-hemilesioned rats (Marti et al., 2005). Enhancement of N/OFQ expression and 
release was observed in the latter parkinsonism model (Marti et al., 2005). Haloperidol-induced 
motor impairment and the dopaminergic neuronal toxicity induced by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine, but not methamphetamine, were partially abolished in ppN/OFQ(-/-) mice 
(Brown et al., 2006; Marti et al., 2005). Increased locomotor activity was observed in NOP(-/-) 
mice (Marti et al., 2004b) and in rats treated with antisense-NOP (Blakley et al., 2004) or antisense-
ppN/OFQ (Candeletti et al., 2000a). These studies suggest that endogenous N/OFQ might have a 
negative regulation in striatal dopamine levels and motor activity. 
In the last few years, using a battery of behavioural tests, the group of prof. Morari was first 
to show that NOP receptor antagonists like J-113397 attenuated parkinsonian-like symptoms in 6-
hydroxydopamine hemilesioned rats by reducing glutamate release in the SN whereas deletion of 
the NOP receptor gene conferred mice partial protection from haloperidol-induced motor 
depression (Marti et al., 2005), They subsequently showed that coadministration of the NOP 
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receptor antagonist J-113397 and L-DOPA to 6-hydroxydopamine hemilesioned rats produced an 
additive attenuation of parkinsonism: J-113397 and L-DOPA decreased thalamic GABA release 
and attenuated akinesia, their combination resulting in a more profound effect (Marti et al., 2007). 
Very recently, it has been demonstrated that Trap-101, a non-peptide NOP antagonist, changes 
motor activity in naive rats and mice and alleviates parkinsonism in 6-hydroxydopamine 
hemilesioned rats: Trap-101 stimulates motor activity at 10 mg/kg and inhibits it at 30 mg/kg (Marti 
et al., 2008); such dual action was observed in NOP(+/+) but not in NOP(-/-) mice suggesting a 
specific involvement of NOP receptors (Marti et al., 2008). Overall, the present studies provides 
novel insights into the mechanisms underlying the antiparkinsonian action of NOP receptor 
antagonists that may be used alone or as an adjunct to L-DOPA in the therapy of Parkinson’s 
disease. This indication has also been confirmed in non-human primates (Viaro et al., 2008; Visanji 
et al., 2008). 
 
Anxiolytic-like action 
 Different laboratories have reported anxiolytic-like effects in response to 
intracerebroventricular administration of N/OFQ in rodents in several models of anxiety. 
 The peptide and its receptor are found in a number of central nervous system loci involved 
in emotion and stress regulation, including the amygdala, septal region, locus coeruleus, and 
hypothalamus (Gavioli et al., 2006). 
A number of standard behavioural assays reveal the ability of supraspinal N/OFQ to block 
fear and anxiety in both rats and mice (Jenck et al., 1997). Interestingly, these effects of N/OFQ 
were evident at relatively low doses (<1 nmol), which do not modify animal gross behaviour and 
are inactive with regard to other functions (i.e., nociception, food intake, etc.). Later, other 
laboratories confirmed the anxiolytic-like effects of the natural peptide N/OFQ in mice in the 
elevated plus-maze test (Gavioli et al., 2002), in the holeboard test (Kamei et al., 2004), and in the 
defence test battery (Griebel et al., 1999; Vitale et al., 2006). Furthermore, at relatively low doses, 
several non-peptide agonists from Roche (Ro 65-6570 and Ro 64-6198) are generally reported as 
anxiolytic (Varty et al., 2005; Wichmann et al., 1999). After peripheral administration in the range 
of doses 0.1–3 mg/kg, Ro 64-6198 promoted anxiolytic-like effects in rats in the elevated plus-
maze, fear-potentiated startle, and operant conflict tests (Jenck et al., 2000). This hypothesis has 
been corroborated by the findings that genetically N/OFQ precursor deficient mice display an 
increased susceptibility to acute and repeated stress, as compared to their wild-type littermates 
(Koster et al., 1999). In a recent study from Schering-Plough the non-peptide agonist SCH 221510 
was shown to be anxiolytic but with a reduced side-effect profile when compared with 
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benzodiazepines (Varty et al., 2008). Pfizer has recently reported two new non-peptide NOP 
receptor agonists: PCPB (Hirao et al., 2008a) and MCOPPB (Hayashi et al., 2009; Hirao et al., 
2008b); both orally active compounds showed anxiolytic-like effect in mice. 
Importantly, very little information is present in the literature regarding the effects of 
selective NOP receptor antagonists on anxiety. It has been reported that the non-peptide molecule J-
113397 at 10 mg/kg i.p. antagonized the anxiolytic-like effect of Ro 64-6198 in the conditioned lick 
suppression test in rats without having any effect in this assay per se (Varty et al., 2005). Although 
very few studies have been performed to date on this topic, the available evidence obtained with 
two chemically unrelated NOP antagonists, i.e., J-113397 and UFP-101 (Gavioli et al., 2006; Vitale 
et al., 2006), suggest that the acute blockade of NOP receptor does not modify the level of anxiety 
in rodents. In other words, these results suggest that N/OFQergic signalling does not tonically 
control anxiety-related behaviour. 
Surprisingly, Fernandez et al. (2004) observed anxiogenic-like effects of N/OFQ given by 
i.c.v. injection in several anxiety-related procedures (i.e., open field, elevated plus maze, and dark-
light preference) in rats. Explanations given by the authors are a difference in baseline stress 
between studies, and/or strain differences. 
Even though a control experiment suggested that the anxiogenic-like effects were, at least in 
part, independent of effects on locomotion (Fernandez et al., 2004), a recent study by Vitale et al. 
(2006) may suggest the opposite. They replicated the anxiogenic-like effects of N/OFQ in the rat 
elevated plus-maze test, but observed anxiolytic-like effects after 2 subsequent administrations of 
N/OFQ (Vitale et al., 2006). This change from anxiogenic- to anxiolytic-like effect of N/OFQ was 
accompanied by tolerance to the hypolocomotor effects of N/OFQ, suggesting that the anxiolytic-
like effects of acute N/OFQ were masked by hypolocomotor effects. 
So far the anxiolytic mechanisms of N/OFQ are not well understood. It is likely that N/OFQ 
effects on anxiety may depend on the ability of this peptidergic system to modulate endogenous 5-
HTergic pathways since 5-HT is considered to play a pivotal role in the control of anxiety and fear 
(Millan, 2003). Moreover, recent findings suggested that the anxiolytic-like effects of N/OFQ might 
be mediated via activation of the GABA/benzodiazepine system and the effects of N/OFQ may 
relate to the regulation of anxiety states in the amygdala (Gavioli et al., 2008; Uchiyama et al., 
2008). 
Several lines of evidence also suggest that endogenous N/OFQ has an important role in 
anxiety and stress regulation. Enhanced anxiety was shown in ppN/OFQ(-/-) mice (Kest et al., 
2001; Ouagazzal et al., 2003; Reinscheid et al., 2002) and antisense-NOP treated rats (Blakley et 
al., 2004), but not in NOP(-/-) mice (Mamiya et al., 1998). Gavioli et al. (2007) demonstrated that 
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there are no clear differences between NOP(-/-) and NOP(+/+) mice in some classical models of 
anxiety (open-field, hole-board and marble-burying tests). In contrast, when subjected to other 
models of anxiety such as novelty-suppressed feeding behaviour and the elevated T-maze test, 
NOP(-/-) mice display lower anxiety-related behaviours compared to NOP(+/+) mice (Gavioli et 
al., 2007). In the elevated plus-maze and light-dark box, NOP(-/-) mice displayed increased anxiety-
related behaviour (Gavioli et al., 2007). 
Interestingly, the impact of ppN/OFQ deletion on the anxiety-like behaviours is more 
significant in group-housed, as compared with individual-housed mice, and male mice were more 
susceptible than females (Ouagazzal et al., 2003). In mice, differences in anxiety states are 
associated with differences in G protein coupling efficiency in the nucleus accumbens (but not in 12 
other brain regions) (Le Maitre et al., 2006). A likely explanation of this finding is that the observed 
increase in coupling in non-anxious mice leads to increased N/OFQ-mediated transmission and thus 
protects from anxiety (Le Maitre et al., 2006). 
It has also been suggested that N/OFQ can act as a functional corticotrophin releasing factor 
(CRF) antagonist, since it is able to revert the hypophagia induced by either stress or the central 
administration of CRF (Ciccocioppo et al., 2001). Since CRF is a major mediator of stress and a 
potent anxiogenic agent, the functional relationships between the N/OFQ and CRF systems are 
worthy of further investigation aimed at clarifying the mechanisms by which N/OFQ exerts its 
anxiolytic-like effects. 
However, the information that has been available to date has been too limited to propose a 
mechanistic interpretation of the anxiolytic-like effects of N/OFQ. Other studies aimed to the 
identification of the brain areas involved in this action are needed for a better understand N/OFQ 
role in this field. 
 
Antidepressant-like action 
 Studies performed in rodents subjected to behavioural despair tests support a role of the 
N/OFQ-NOP receptor system in the modulation of mood behaviours. 
NOP receptor antagonists, including [Nphe1]N/OFQ(1-13)-NH2, J-113397, UFP-101 and 
SB-612111 reduced immobility time in both the forced swim and tail suspension tests. N/OFQ 
(i.c.v.) alone did not affect immobility time (Gavioli et al., 2004; Redrobe et al., 2000; Rizzi et al., 
2007a). 
In our laboratories, using a combined pharmacological and genetic approach, we 
demonstrated that blockade of N/OFQ-NOP receptor signalling in the brain produces 
antidepressant-like effects in the mouse and rat forced swimming test and in the mouse tail 
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suspension test. I.c.v. injection of N/OFQ did not induce any behavioural modification in mice, but 
the co-administration of 1 nmol of N/OFQ reversed the antidepressant-like effect induced by the 
NOP receptor antagonists UFP-101 (Gavioli et al., 2003; Gavioli et al., 2004). In addition, N/OFQ 
(1 nmol) also reverted the effects induced by the non-peptide NOP receptor antagonist J-113397 in 
the mouse forced swimming test (Gavioli et al., 2006). Whereas the immobility time in NOP(-/-) 
mice is less than that in NOP(+/+), the antidepressant-like effects of NOP receptor antagonists were 
not observed in NOP(-/-) mice (Gavioli et al., 2003), suggesting that endogenous N/OFQ plays a 
role in those depression-like behaviours. Treatment with UFP-101 (10 nmol) reduced immobility 
time in NOP(+/+) mice, while it was inactive in mice lacking the NOP receptor (Gavioli et al., 
2003). Systemic administration of J-113397 (20 mg/kg) promoted a statistically significant 
reduction in immobility time in the forced swimming test in NOP(+/+), but not in NOP(-/-) animals. 
Additionally, SB-612111 (10 mg/kg, i.p.) reduced the immobility time in NOP(+/+) mice while 
being inactive in NOP(-/-) animals (Rizzi et al., 2007a). 
Moreover, it has been demonstrated that antidepressant-like effects elicited by the selective 
NOP receptor antagonist UFP-101 are probably due to the block of the inhibitory effects of 
endogenous N/OFQ on brain monoaminergic (in particular serotonergic) neurotransmission 
(Gavioli et al., 2004). 
Vitale and colleagues investigated the effect of UFP-101 in the chronic mild stress paradigm 
in rats; UFP-101 (10 nmol/rat, i.c.v. continuously infused by means of minipumps for 24 days) did 
not influence sucrose intake in non stressed animals, but reinstated the basal sucrose consumption in 
stressed animals, beginning from the second week of treatment as did fluoxetine (10 mg/kg, i.p.), 
used as reference drug (Vitale, 2008). 
There is just one human study (Gu et al., 2003) in which plasma N/OFQ level was elevated 
in post-partum depressive women. This limited small study agrees with the notion that post-partum 
depression results from reduced 5-HT levels and that this is accompanied by elevated N/OFQ with 
the increase in N/OFQ possibly causing the fall in 5-HT (Lambert, 2008). Thus, NOP receptor 
antagonists may have the potential to be novel antidepressants. 
Overall, these pharmacological and genetic findings suggest that the blockade of N/OFQ 
signaling induces antidepressant-like effects in rodents. Importantly, all these observations were 
performed after acute drug administration, and no data are currently available subsequent to chronic 
drug exposure. Thus, further studies aimed at the evaluation of the antidepressant-like effects of 
NOP receptor antagonists in animal models based on chronic stress may generate important 
information about the role of this peptidergic system in mood disorders. 
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Food intake 
 Soon after the isolation of N/OFQ, Pomonis and colleagues (Pomonis et al., 1996) showed 
that supraspinal N/OFQ (1–10 nmol) increased food intake in the satiated rat. N/OFQ effects are 
short-lasting, specific to food intake with neither water intake nor 1% sucrose intake affected, and 
accompanied by transient hypolocomotion (Polidori et al., 2000a). 
 N/OFQ hyperphagia can be blocked by antisense treatment to NOP mRNA (Leventhal et al., 
1998), competitive NOP antagonism (Polidori et al., 2000a) and functional antagonism by 
nocistatin (Olszewski et al., 2000). Surprisingly, naloxone/naltrexone pretreatment also blocks 
N/OFQ effects on food intake (Leventhal et al., 1998; Pomonis et al., 1996), although this is 
probably due to classical opioid receptors being involved in feeding control at a distal site or 
affecting motivational processes related to food intake. In addition, it was shown that the orexigenic 
action of 1 nmol of N/OFQ was prevented by SB-612111 (1 mg/kg) and no longer evident in NOP(-
/-) animals, indicating that the orexigenic effects induced by N/OFQ are exclusively due to NOP 
receptor activation (Rizzi et al., 2007a). 
 The orexigenic action of N/OFQ is suggested to be attributed to both the inhibition of 
anorexigenic systems and the activation of orexigenic systems (Olszewski et al., 2004). N/OFQ has 
been found to inhibit pathways that promote termination of food intake in the hypothalamic satiety 
centers, such as oxytocinergic neurons in the paraventricular nucleus and neurons in the arcuate 
nucleus (Olszewski et al., 2004). 
Moreover, Ciccocioppo et al. (2004) found that N/OFQ, at doses without hyperphagic 
effects, inhibited stress-induced anorexia and that this anti-anorexic effect is due to the fact that 
N/OFQ acts as a functional antagonist of corticotrophin-releasing factor (CRF) at the bed nucleus of 
the stria terminalis (Ciccocioppo et al., 2004). [Nphe1]N/OFQ(1-13)-NH2 did not affect food 
consumption per se in satiated rats, but reduced that in food-deprived rats (Polidori et al., 2000a). 
UFP-101 also did not affect free feeding in the rat (Economidou et al., 2006b). This suggested that 
endogenous N/OFQ plays a role in orexigenic tone in response to food deprivation but not in 
normal feeding. On the contrary, Rizzi et al. (2007a) showed that the antagonist SB-612111 (1 and 
10 mg/kg, i.p.), tested in food deprived mice, did not modify food intake. Thus, the data obtained 
with SB-616211 suggest that in mice, unlike rats (Polidori et al., 2000a), the N/OFQ-NOP receptor 
system does not play a major role in controlling food intake induced by food deprivation. 
All these studies indicate that the hyperphagic and the anti-anorectic effect of N/OFQ are 
mediated by separate brain structures and that synthetic N/OFQ agonists might have therapeutic 
potential as orexigenic drugs (Ciccocioppo et al., 2004; Economidou et al., 2006b). 
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Reward and addiction 
 In animal models aimed at elucidating the rewarding properties of drugs of abuse the 
conditioned place preference (CPP) test is commonly used. In this assay N/OFQ has been shown to 
reduce CPP to alcohol (Ciccocioppo et al., 1999; Kuzmin et al., 2003), amphetamines (Kotlinska et 
al., 2003), cocaine (Kotlinska et al., 2003; Sakoori et al., 2004), and morphine (Sakoori et al., 
2004) indicating that this peptide was reducing reward to these stimuli. N/OFQ alone was inactive. 
All these experiments measured the acquisition or reinstatement of drug preferences, either as a 
conditioned response (place preference) or self-administration of the drug itself. However, it should 
be mentioned that N/OFQ failed to block heroin self-administration (Walker et al., 1998). Another 
study also showed that N/OFQ was effective in preventing stress-induced alcohol-seeking 
behaviour but not cocaine-seeking behaviour (Martin-Fardon et al., 2000). Finally, one study 
demonstrated that N/OFQ was able to block sensitization to cocaine, independent of context (Lutfy 
et al., 2002). 
 Since the mesolimbic dopaminergic system plays a pivotal role in opioid rewarding 
properties (Wise, 1989), it has been suggested that N/OFQ attenuates conditioned place preference 
to any type of drug of abuse by inhibiting its stimulatory effect on mesolimbic dopamine release 
from the nucleus accumbens (Murphy et al., 1999). In fact, i.c.v. N/OFQ effectively inhibits 
dopamine release (as evaluated by in vivo microdialysis) in the nucleus accumbens of the rat 
stimulated by systemically injected morphine (Di Giannuario et al., 1999). Alternatively, the 
inhibitory effects of N/OFQ could be explained by the finding that N/OFQ inhibits GABAergic 
transmission and blocks ethanol-induced increase of GABA release in the central amygdala 
(Roberto et al., 2006). Interestingly, Ciccocioppo et al. (2007) found that buprenorphine, a partial 
agonist at MOP and NOP receptors, increased alcohol intake at lower doses through MOP receptors 
while decreased it at higher doses through NOP receptors. It is suggested that the therapeutic 
potential of buprenorphine in drug addiction might be attributed to its NOP receptor activation, but 
not to its activation of classical opioid receptors.  
 Recent findings demonstrated that the psychostimulant and rewarding actions of 
buprenorphine were enhanced in NOP(-/-) mice as compared to their NOP(+/+) littermates. 
However, these actions of morphine were not altered in mutant mice. Buprenorphine displaced 
specific binding of [3H]-N/OFQ in brain homogenates of NOP(+/+) mice; together these results 
suggest that the ability of buprenorphine to interact with NOP receptor compromises its acute motor 
stimulatory and rewarding actions (Marquez et al., 2008). 
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 Even though more work is obviously necessary to fully understand the effects of N/OFQ on 
drug reward and the mesolimbic dopamine system, it appears that N/OFQ agonists might provide 
useful compounds to control the rewarding aspects of drugs. 
 
Learning and memory 
 N/OFQ may play a role in memory and learning processes since there is a high density of 
NOP receptors in the anterior cingulate, frontal cortex, basolateral complex of the amygdala and 
hippocampus. In fact N/OFQ injected into the hippocampus impairs spatial learning (Sandin et al., 
1997) and in vitro it inhibits synaptic transmission and long-term potentiation in rat hippocampal 
slices (Yu et al., 1997). Recently it was also seen that endogenously released N/OFQ interacts with 
noradrenergic activity within the basolateral complex of the amygdala in modulating memory 
consolidation (Roozendaal et al., 2007). 
 In line with these findings, NOP(-/-) mice show greater learning ability and have better 
memory retention than wild-type control mice (Manabe et al., 1998). The impairment of learning 
induced by N/OFQ can be reversed by nocistatin (Hiramatsu et al., 1999b) or by the non-selective 
NOP receptor antagonist NalBzOH (Mamiya et al., 1999). Moreover, a peptidic NOP receptor 
antagonist Ret-Noc-OMe, has been reported to strengthen memory retention in a passive avoidance 
test in mice (Jinsmaa et al., 2000). 
It is worthy of note that pre-treatment with [Nphe1]N/OFQ(1-13)-NH2, a NOP receptor 
antagonist, prevented NOP-induced deficits. Using a pure pharmacological approach, i.e. NOP 
receptor blockade, a role for the N/OFQ and its receptor in learning and memory has been 
demonstrated (Redrobe et al., 2000). 
Very recent study showed that intracerebroventricular or intrahippocampal infusions of 
N/OFQ impair long-term memory formation in the mouse object recognition task. The synthetic 
NOP receptor agonist Ro 64-6198, administered systemically, also produced amnesic effects that 
were blocked by coinfusion of the NOP receptor antagonist UFP-101, into the dorsal hippocampus. 
In contrast, Ro 64-6198 had not effect on short-term memory or recall performances (Goeldner et 
al., 2008). Immunoblotting analysis revealed a strong suppressive action of Ro 64-6198 on 
learning-induced upregulation of hippocampal extracellular signal-regulated kinase (ERK) 
phosphorylation, which is crucial for long-term information storage (Goeldner et al., 2008). Thus, 
N/OFQ-NOP receptor system negatively regulates long-term recognition memory formation 
through a hippocampal ERK signalling mechanism (Goeldner et al., 2008). 
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Collectively, these findings suggest that the N/OFQ-NOP receptor system may play negative 
roles in learning and memory, and that NOP receptor antagonists might be worthy of testing as 
drugs for memory disorders. 
 
Effects in the gastrointestinal tract 
Like morphine or other opioid receptor agonists, N/OFQ inhibits in vitro neurogenic 
contractions of the stomach and the small intestine in a variety of species, including guinea pigs 
(Calo et al., 1996; Zhang et al., 1997), pigs (Osinski et al., 1999b), rats (Yazdani et al., 1999) and 
rabbits (Pheng et al., 2000). This depressor effect is resistant to blockade by naloxone. In contrast, 
N/OFQ causes concentration-dependent contractions in proximal rat colon, without changes in 
stomach, jejunum or ileum (Taniguchi et al., 1998; Yazdani et al., 1999). N/OFQ also contracts 
proximal and distal segments of mouse colon (Menzies et al., 1999; Osinski et al., 1999a; Rizzi et 
al., 1999a). 
In vivo, similarly to opioids, central administration of N/OFQ also inhibits colon transit in 
the mouse (Osinski et al., 1999a). On the other hand, Taniguchi and collegues (Taniguchi et al., 
1998) reported that N/OFQ administered subcutaneously in rats actually accelerated transit rate in 
the large intestine, an action opposite to that induced by morphine or selective opioid receptor 
agonists. Broccardo and colleagues demonstrated that the NOP receptor antagonist 
[Nphe1]N/OFQ(1-13)-NH2 blocked the N/OFQ-evocked gastrointestinal anti-transit effect 
(Broccardo et al., 2004). It is worthy of note that [Nphe1]N/OFQ(1-13)-NH2 per se stimulated 
gastric acid secretion.  
Distal colonic contractions induced by N/OFQ were also dose-dependently antagonized by 
the NOP non-peptide antagonist J-113397 that behaves as selective NOP antagonist in the rat colon 
(Tada et al., 2002). 
All these findings led suggest that the N/OFQ-NOP receptor system is pharmacologically 
distinct from opioids but functionally very similar, and could represent a new target for the 
development of drugs (NOP receptor agonists) to reduce intestinal motility. 
In addition to the well-characterized inhibition of gastric motility, recent studies 
demonstrated that N/OFQ increases gastric mucosal resistance to ethanol induced lesions by 
operating both in the central nervous system and in the periphery (Morini et al., 2005). This effect is 
mediated by the NOP receptor since the selective N/OFQ antagonist UFP-101 completely prevents 
the protective effects of N/OFQ (Morini et al., 2005). There is evidence for central and peripheral 
components to the regulation of gastrointestinal function: vagal cholinergic and sympathetic 
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pathways mediate the central activity of N/OFQ, whereas vagal non-muscarinic pathways mediate 
the peripheral activity of the peptide (Broccardo et al., 2004; Ishihara et al., 2002).  
An elegant study recently showed that N/OFQ and UFP-112, a novel highly potent NOP 
agonist, when administered intracerebroventrically and intraperitoneally decreased bead expulsion 
time and reduce the percentage of rats with castor oil-induced diarrhoea; UFP-112 showed greater 
efficacy, higher potency and longer-lasting effects than N/OFQ (Broccardo et al., 2008). These 
findings indicate that, in the rat, the central and peripheral N/OFQ system has an inhibitory role in 
modulating distal colonic propulsive motility under physiological and pathological conditions 
(Broccardo et al., 2008). 
Further studies are necessary to investigate the mechanism(s) accounting for this interesting 
effect of N/OFQ. 
 
Effects in the airways 
N/OFQ was found to inhibit contractions of the guinea pig isolated bronchus (Fischer et al., 
1998; Rizzi et al., 1999b) of the rat isolated trachea and bronchus (Wu et al., 2000) induced by 
electrical field stimulation and of the cholinergic contractions of human bronchus (Basso et al., 
2005). 
N/OFQ inhibited the cough responses provoked by capsaicin in guinea pigs or by 
mechanical stimulation of intrathoracic airways in cats (Bolser et al., 2001; McLeod et al., 2001). 
These antitussive actions might be mediated at both central and peripheral sites. 
N/OFQ decreased capsaicin-induced Ca2+ influx in nodose ganglia (McLeod et al., 2004), 
the sensory ganglia involved in the cough reflex (Reynolds et al., 2004), and the airway contraction 
in a manner blocked by tertiapin, an inwardly rectifying K+ channel blocker (Jia et al., 2002). In the 
brain, there are dense NOP receptors in the medullar nucleus tractus solitarius (Judd et al., 1996), 
which provides polysynaptic inputs to second-order neurons that modulate respiratory neuron 
activities (Reynolds et al., 2004). 
This antitussive effect can be mimicked by the non-peptide agonist Ro 64-6198 in a J-
113397-sensitive manner (McLeod et al., 2004). Codeine is the current gold-standard antitussive 
agent but has a poor side-effect profile that is typical of MOP opioid receptor agonists (such as 
nausea, constipation, tolerance and dependence). So, orally active NOP agonists might represent a 
viable alternative for the treatment of cough (Lambert, 2008). 
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Cardiovascular system 
When given intravenously (i.v.) in anaesthetised rats, N/OFQ induces transient hypotension 
and bradycardia (Champion et al., 1997; Giuliani et al., 1997b). Similar results have been obtained 
in conscious rats (Kapusta et al., 1997) and mice (Madeddu et al., 1999), indicating that anaesthesia 
does not affect the cardiovascular effects of N/OFQ and that these effects are not restricted to the 
rat. Interestingly, N/OFQ induces similar cardiovascular effects when injected i.c.v. (Kapusta et al., 
1997) or into the rostral ventrolateral medulla of the rat (Chu et al., 1999). The effects occur at both 
central and peripheral sites. The most compelling evidence for peripheral effects is in the 
hypotension and bradycardia produced by intravenous administration of N/OFQ, a peptide that does 
not cross the blood-brain barrier (Lambert, 2008). It has been suggested that as the sympatholytic 
guanethidine reduced the hypotensive effects of N/OFQ, then this peptide acts to inhibit 
sympathetic control of the cardiovascular system (Giuliani et al., 1997b). In addition, the 
bradycardic effects of N/OFQ were reduced by vagotomy, indicating that N/OFQ increased 
parasympathetic activity (Giuliani et al., 1997b). 
On the other hand, N/OFQ has been shown to increase blood pressure and heart rate in sheep 
following i.v. administration (Arndt et al., 1999). Thus, there may be important differences in the 
cardiovascular effects of N/OFQ in different species. 
N/OFQ also produces vasodilation in several isolated arteries of the cat (Gumusel et al., 
1997) and in pial arteries of the pig (Armstead, 1999) and in the mesenteric resistance arteries of the 
rat (Champion et al., 1998). These studies also demonstrated that the vasodilator responses to 
N/OFQ were not prevented by naloxone, nitric oxide synthase inhibitors, atropine, phentolamine or 
by a CGRP receptor antagonist. Recently a study showed that in a rat mesenteric microcirculation 
model, intravenous administration of N/OFQ dilated arterioles and venules (Brookes et al., 2007); 
dilation of these non-innervated vessels was blocked by histamine antagonists and mast-cell 
stabilizers, suggesting that the N/OFQ-mediated dilation of the microcirculation is secondary to 
mast-cell release of histamine.  
 
Renal function 
 The i.v. infusion of N/OFQ produces a marked increase in urine flow rate and a decrease in 
urinary sodium excretion (Kapusta et al., 1997). Concurrent with diuresis, N/OFQ infusion 
produced hypotension with no change in heart rate; this is in contrast to the concurrent bradycardia 
and hypotension elicited by N/OFQ when this peptide is administered as an i.v. bolus (Bigoni et al., 
1999; Champion et al., 1997; Giuliani et al., 1997b; Madeddu et al., 1999), intrathecally (Lai et al., 
2000), or when microinjected into the lateral cerebroventricle (Kapusta et al., 1999a; Kapusta et al., 
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1999b; Kapusta et al., 1997; Shirasaka et al., 1999). Low doses of N/OFQ (i.v. infusion) also 
tended to decrease urinary sodium excretion without changes in heart rate or mean arterial pressure. 
These findings also suggest that the i.v. infusion lower doses of N/OFQ can be used to separate the 
cardiovascular and renal responses produced by this compound, with the peptide having a more 
pronounced effect on the renal handling of water (Kapusta, 2000). Following i.c.v. microinjection, 
N/OFQ produced a marked diuresis, antinatriuresis and renal sympathoinhibition in conscious rats 
(Kapusta et al., 1999a; Kapusta et al., 1999b; Kapusta et al., 1997; Shirasaka et al., 1999) 
It is worthy of note that a class of NOP ligands, the partial agonists (i.e. Ac-RYYRWK-NH2, 
Ac-RYYRIK-NH2 (Dooley et al., 1997), [F/G]N/OFQ(1-13)-NH2 (Guerrini et al., 1997), ZP120 
(Larsen et al., 2001) have been shown to behave as full agonists on cardiovascular and renal 
functions, mimicking the effects of N/OFQ, when given i.c.v. (Kapusta et al., 1999b). In contrast, 
the i.v. bolus injection of the same NOP receptor partial agonists produced responses unlike 
N/OFQ; N/OFQ evoking profound bradycardia and hypotension with no change in urine output, 
and i.v. bolus NOP receptor partial agonists eliciting water diuresis without altering cardiovascular 
function (Kapusta et al., 2005a; Kapusta et al., 2005b). Indeed, Kapusta et al. showed that ZP120 
(i.v. bolus or i.v.infusion) produced, in rats, a sodium-potassium-sparing aquaresis and a mild 
vasodilatory response without reflex tachycardia (Kapusta et al., 2005b). 
Activation of NOP receptors in the paraventricular nucleus (PVN) of the hypothalamus by 
N/OFQ produces bradycardia, renal sympathoinhibition, and water diuresis. Recently, the group of 
Kapusta (Krowicki et al., 2006) showed that endogenous N/OFQ produces a tonic inhibition on 
PVN activity since UFP-101, when injected into the PVN, increased heart rate and renal 
sympathetic nerve activity and decreased urine flow rate. 
In summary, it was seen that in conscious rats NOP receptor partial agonists produced 
functionally selective effects on cardiovascular and renal function ranging from full agonist (i.c.v., 
cardiovascular depressor; i.c.v. and i.v., water diuresis), partial agonist (i.v., submaximal 
hypotension without altering heart rate) to antagonist (i.v., blockade of N/OFQ-evoked bradycardia 
and hypotension) behaviour. Based on their ability to produce a selective water diuresis after i.v. 
bolus injection without apparent adverse cardiovascular or CNS effects, it can be proposed that 
metabolically stable NOP receptor partial agonists (e.g., ZP120; (Kapusta et al., 2005b)) may be 
useful therapeutically as novel peripherally acting aquaretics for the acute management of severe 
water retention and/or hyponatremia; ZP120 was, hence, filed for phase II clinical trials for the 
treatment of acute decompensated heart failure. 
 
 
 
 40 
Micturition reflex 
In anaesthetised rats, i.v. N/OFQ produced a dose-dependent suppression of the micturition 
reflex induced by bladder distension or by topical application of capsaicin (Giuliani et al., 1998). 
Similar results were obtained by administering the peptide i.c.v. or i.t. indicating that N/OFQ 
inhibits the micturition reflex by acting at peripheral, spinal and supraspinal sites (Lecci et al., 
2000). 
All these effects are not affected by naloxone, thus excluding the involvement of opioid 
receptors. These animal studies were later confirmed in clinical studies. Indeed, the urodynamic and 
clinical effects of N/OFQ were evaluated in normal subjects and in patients with neurogenic 
bladder. A preliminary report (Lazzeri et al., 2001) and a subsequent randomized, placebo 
controlled, double-blind study (Lazzeri et al., 2003) demonstrated that intravescical instillation of 1 
µM N/OFQ solution produce an inhibitory effect on micturition reflex in selected groups of patients 
suffering from neurogenic incontinence but not in normal subjects. These effects of N/OFQ are due 
to its ability to selectively activate the NOP receptor as suggested by the fact that [desPhe1]N/OFQ, 
a N/OFQ metabolite which does not bind NOP receptor, is inactive in these patients (Lazzeri et al., 
2003). Moreover, a recent study (Lazzeri et al., 2006) demonstrated that a daily treatment with 1 mg 
N/OFQ intravescically for 10 days, but not the placebo, inhibited the micturition reflex in patients 
suffering from neurogenic incontinence, thus demonstrating the clinical efficacy of a prolonged 
NOP receptor agonist treatment. Based on these findings N/OFQ selective and potent peptide 
agonists with long lasting effects in vivo may be proposed as innovative drugs for treating patients 
suffering from neurogenic incontinence. 
 
Immune system 
NOP receptors and N/OFQ are widely distributed throughout the immune system. NOP 
receptor mRNA and protein have been found in a variety of immune cells including mouse 
lymphocytes (Halford et al., 1995), human peripheral blood mononuclear cells (Wick et al., 1995) 
and human circulating granulocytes, lymphocytes and monocytes (Fiset et al., 2003; Peluso et al., 
1998). Neutrophils are thought to be a source of N/OFQ in inflammatory tissues (Fiset et al., 2003). 
N/OFQ can function as an immunosuppressant by suppressing antibody production in mouse 
lymphocytes, by decreasing proliferation of phytohemagglutinin-stimulated PBMCs, and by 
inhibiting mast cell function (Civelli, 2008). In addition, it was shown that N/OFQ stimulates 
human monocyte chemotaxis via NOP receptor activation (Trombella et al., 2005). The importance 
of the N/OFQ system in the immune response, however, remains to be clearly defined. 
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1.8 Pharmacology of NOP receptors 
From the numerous modulatory actions of N/OFQ in several pathways, it is clear that NOP 
may represent an important molecular target for the development of novel therapeutics for several 
pathological conditions. The identification of new molecules possibly of non-peptide nature that 
selectively activate (agonists) or block (antagonists) the NOP receptor will represent a major 
achievement in this research field, providing pharmacological tools for clarification of the 
physiological and pathophysiological roles of the this new system and ultimately for the 
identification of possible therapeutic agents acting at the NOP receptor. 
Peptide compounds usually show high selectivity and specificity but metabolic instability 
and limited distribution. In contrast, non-peptides demonstrate better pharmacokinetic features 
while their specificity is often low. There is an evident interest of academia and pharmaceutical 
companies in developing both agonist and antagonist ligands for the NOP receptor as potential 
drugs for various human disorders (see series of patents quoted by Zaveri (2003) and (Bignan et al. 
(2005)). 
 
Peptide ligands 
N/OFQ shows a significant homology with dynorphin A. The first four amino acids differ 
from the canonical opioid sequence only by the presence of Phe1 instead of Tyr1. This difference 
may be sufficient to prevent N/OFQ binding to opioid receptors. In fact, replacement of Phe1 by 
Tyr1 results in a peptide that also binds the opioid receptors (Calo et al., 1997; Varani et al., 1999). 
Amidation of the C-terminus (N/OFQ-NH2) maintains full potency and activity (Guerrini et al., 
1997). Early studies to determine the minimum active sequence showed that up to four C-terminal 
amino acids can be deleted without loss of activity. Although the free acid N/OFQ(1–13)-OH loses 
receptor affinity, amidation of the C-terminus to give N/OFQ(1–13)-NH2 restores potency and 
agonist activity comparable to the parent peptide (Calo et al., 1996; Dooley et al., 1996; Reinscheid 
et al., 1996). C-terminal amidation protects from degradation by carboxypeptidases and is now a 
standard feature of most N/OFQ-based peptide ligands. In fact, the truncated peptide N/OFQ(1–13)-
NH2 has been used as a chemical template for SAR studies aimed to investigation of novel ligands 
for NOP receptor. 
Initial structure-activity studies on N/OFQ(1–13)-NH2 by Guerrini et al. (1997) determined 
that the N-terminal peptide FGGF is essential for activity and that Phe4 and Phe1 appear to be 
important for receptor activation. Further studies on N-terminal modification resulted in the 
discovery of a purported NOP antagonist in which the Phe1-Gly2 amide bond was replaced with a 
pseudopeptide (CH2-NH) bond (Calo et al., 1998a; Guerrini et al., 1998). This peptide [Phe1Ψ(CH2-
 42 
NH)Gly2]N/OFQ(1–13)-NH2 abbreviated as [F/G]N/OFQ(1–13)-NH2, was shown to behave as a 
selective and competitive antagonist in the electrically stimulated guinea pig ileum and mouse vas 
deferens (Guerrini et al., 1998). This report initiated a surge of in vitro and in vivo studies (Calo et 
al., 2000a) which showed that this peptide behaved as an antagonist, partial agonist, or even full 
agonist, depending on the tissue preparation. Thus, while it showed different levels of partial 
agonist activity in [35S]GTPγS assays in CHO cells transfected with human or mouse NOP (Berger 
et al., 2000b; Burnside et al., 2000), it showed full agonist activity in several in vivo CNS assays 
(Calo et al., 1998b; Carpenter et al., 1998; Grisel et al., 1998; Xu et al., 1998). McDonald and 
colleagues demonstrated that agonism is primarily dependent upon receptor density and coupling 
efficiency (McDonald et al., 2003a). As these parameters are tissue/model dependent, intrinsic 
activity in different tissues can vary. Using the ecdysone-inducible expression system containing 
the human NOP receptor (hNOP) expressed in Chinese hamster ovary cells they performed 
[35S]GTPγS binding and inhibition of adenylyl cyclase studies to examine the activity of a range of 
partial agonists. They found that profile of [F/G]N/OFQ(1–13)-NH2 can be manipulated to 
encompass full and partial, agonism along, with antagonism (McDonald et al., 2003a). 
Further modifications of the N/OFQ N-terminus led to the design of [Nphe1]N/OFQ(1–13)-
NH2 by transposition of the Phe1 side chain from the α-carbon of Phe1 to the N-terminal nitrogen 
(Guerrini et al., 2000a). This peptide was the first pure NOP peptide antagonist; it had low potency 
(pA2 values 6.0–6.4) (Calo et al., 2000a) but was devoid of any residual agonist activity. This 
modified N/OFQ peptide selectively antagonized the effects of N/OFQ in vitro in various isolated 
tissues and in CHO cells expressing the human recombinant NOP receptor (Berger et al., 2000b; 
Calo et al., 2000a; Hashimoto et al., 2000). In vivo, i.c.v. administration of this peptide inhibited the 
pronociceptive and antiopioid actions of N/OFQ (Rizzi et al., 2000) and reversed the effects of 
N/OFQ on memory impairment (Redrobe et al., 2000), food intake (Polidori et al., 2000a), and 
locomotor activity (Rizzi et al., 2001a). This compound, per se, is able to induce changes opposite 
to that evoked by N/OFQ such as antinociception (Calo et al., 2000a), prevention of ibotenate 
induced neurotoxicity (Laudenbach et al., 2001) and inhibition of food intake (Polidori et al., 
2000b), facilitation of the flexor reflex with no depression (Xu et al., 2002). Importantly, a study by 
Di Giannuario and colleagues has shown that no tolerance develops to the antinociceptive action of 
this antagonist, unlike with opioid analgesics, suggesting that NOP antagonists can be developed as 
a novel class of supraspinal analgesics (Di Giannuario et al., 2001). 
Modification of N/OFQ and N/OFQ(1–13)-NH2 has also produced peptide agonists more 
potent than N/OFQ. Okada et al. (2000) reported the synthesis of [Arg14Lys15]N/OFQ, which had 3-
fold greater binding affinity than N/OFQ at human NOP and was 17 times more potent in the 
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[35S]GTPγS functional assay. [Arg14Lys15]N/OFQ was the first NOP receptor agonist more potent 
than the natural ligand, in addition its effects are long lasting in vivo (Rizzi et al., 2002c). 
Guerrini et al. (2001) focused their attention on the Phe4 residue and found that para-
substituted electron-withdrawing groups such as pF and pNO2 increased binding affinity to NOP 
receptor 5- and 3-fold, respectively. These agonist peptides were more potent than N/OFQ at 
recombinant hNOP and at native NOP receptor sites expressed in isolated tissues (Bigoni et al., 
2002; McDonald et al., 2002). These agonists also display longer duration of action in vivo in 
several assays, compared to N/OFQ (Rizzi et al., 2002b). 
Another cyclic peptide having an intramolecular disulphide bridge: cyclo [Cys10, 
Cys14]N/OFQ(1-14)-NH2, was reported to be the first conformationally restricted derivative among 
the N/OFQ analogues. This peptide has agonist activity and may serve as a good template for 
studying the bioactive conformation of N/OFQ (Ambo et al., 2001). Combination of the cyclic 
analog with Nphe1 which previously led to pure antagonism, provided a partial agonist 
c[Nphe1Cys10,14]N/OFQ(1-14)-NH2 (Kitayama et al., 2003). 
Furthermore in a series of structure-activity studies (Guerrini et al., 2005) the chemical 
modifications which reduce ([Phe1Ψ(CH2-NH)Gly2]) or eliminate ([Nphe1]) agonist efficacy, in the 
N/OFQ-NH2 structure, were combined with those which increase agonist potency i.e. [(pF)Phe4] 
and [Arg14Lys15]. This study led to the identification of a very potent antagonist, 
[Nphe1Arg14Lys15]N/OFQ-NH2 (UFP-101) (Calo et al., 2002b), and [(pF)Phe4Arg14Lys15]N/OFQ-
NH2 (UFP-102) (Carra et al., 2005b), a highly potent and selective full agonist at NOP receptors. 
The gain in potency was accompanied by slow onset and relatively long duration of action that was 
observed in in vitro and especially in in vivo assays (Carra et al., 2005b; Economidou et al., 2006b). 
A very potent partial agonist [Phe1ψ(CH2-NH)-Gly2(pF)Phe4Arg14Arg15]N/OFQ-NH2 (Guerrini et 
al., 2005) was also identified. 
Regarding the potent and selective antagonist UFP-101 a detailed summary of its 
pharmacological characterization was reported by our group (Calo et al., 2005). Collectively data 
obtained in vitro in a variety of preparations with different approaches demonstrated that UFP-101 
behaves as a potent, competitive and selective antagonist at NOP receptors. In vivo, UFP-101 has 
been tested against N/OFQ in a series of experiments aimed at the investigation of the role of the 
N/OFQ-NOP receptor system in regulating various biological functions including pain 
transmission, locomotor activity, mood-related behaviours, drug abuse, food intake and 
cardiovascular, renal and gastrointestinal function. It has been demonstrated that UFP-101 
antagonizes the following actions of N/OFQ: hyperalgesia, reversal of stress-induced analgesia, 
inhibition of locomotor activity, stimulation of diuresis in mice, bradycardia, hypotension and 
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reduction of plasma NE levels in guinea pig ileum, stimulation of food intake and spinal analgesia 
in rats. Moreover UFP-101 (like other selective NOP antagonists) produced antidepressant-like 
effects in normal mice in the forced swimming or the tail suspension test. In mice lacking the NOP 
receptor gene these actions are absent (Calo et al., 2005). 
Recently (Economidou et al. (2006b) verified the hyperphagic effect of 3 new peptide 
agonists, termed OS-500, OS-462 and OS-461 which display an affinity for NOP receptors in the 
subnanomolar range: no selectivity data were provided. 
Previous structure–activity and NMR studies on N/OFQ demonstrated that Aib substitution 
of Ala7 and/or Ala11 increases peptide potency through an alpha helix structure induction 
mechanism (Zhang et al., 2002). Based on these findings Arduin et al. (2007) synthesised a series 
of N/OFQ-NH2 analogues substituted in position 7 and 11 with Ca,a-disubstituted cyclic, linear and 
branched amino acids. None of the 20 novel N/OFQ analogues produced better results than 
[Aib7]N/OFQ-NH2. Thus, this substitution was combined with other chemical modifications known 
to modulate peptide potency and/or efficacy generating [Nphe1Aib7Arg14Lys15]N/OFQ-NH2 (coded 
as UFP-111), [(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-112) and compound [Phe1Ψ(CH2–
NH)Gly2(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-113). These novel peptides behaved as highly 
potent NOP receptor ligands showing full (UFP-112) and partial (UFP-113) agonist and pure 
antagonist (UFP-111) activities in a series of in vitro functional assays performed on 
pharmacological preparations expressing native as well as recombinant NOP receptors (Arduin et 
al., 2007). In vitro data obtained in the electrically stimulated mouse vas deferens demonstrated that 
UFP-112 behaved as a high potency (pEC50 9.43) full agonist at the NOP receptor. UFP-112 effects 
were sensitive to the NOP antagonist UFP-101 but not naloxone and no longer evident in tissues 
taken from NOP(-/-) mice. In vivo, in the mouse tail withdrawal assay, UFP-112 (1–100 pmol, 
i.c.v.) mimicked the actions of N/OFQ producing pronociceptive effects after i.c.v. administration 
and antinociceptive effects when given i.t. In both cases, UFP-112 was approximately 100 fold 
more potent than the natural peptide and produced longer lasting effects. UFP-112 also mimicked 
the hyperphagic effect of N/OFQ producing a bell shaped dose response curve, this effect was 
absent in NOP(-/-) mice. Equi-effective high doses of UFP-112 (0.1 nmol) and N/OFQ (10 nmol) 
were injected i.c.v. in mice and spontaneous locomotor activity recorded for 16 h. N/OFQ produced 
a clear inhibitory effect which lasted for 60 min while UFP-112 elicited longer lasting effects (> 
6h). UFP-112 (0.1 and 10 nmol/kg, i.v.) produced a marked and sustained decrease in heart rate, 
blood pressure, and urinary sodium excretion and a profound increase in urine flow (Rizzi et al., 
2007b). 
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Small peptide ligands 
The small peptides in this group are identified by screening of synthetic peptide 
combinatorial libraries. Peptide III-BTD was identified from a combinatorial library of β-turn 
constrained peptides (Becker et al., 1999). This conformationally restricted peptide is a mixed NOP 
antagonist / opioid agonist (Bigoni et al., 2000b). Five hexapeptides (Ac-RYYRIK-NH2, Ac-
RYYRWK-NH2, Ac-RYYRWR-NH2, Ac-RYYLWR-NH2, Ac-RYYKWK-NH2) with high affinity 
and selectivity for the NOP receptor were identified from a peptide library containing about 52 
million compounds made considering all the natural amino acids except cysteine (Dooley et al., 
1997). Similar to [F/G]N/OFQ(1-13)-NH2, these peptides were partial agonists whose final effects 
vary from full agonist to antagonist depending on the tissue and system used in the study (Berger et 
al., 1999; Berger et al., 2000a; Dooley et al., 1997; Ho et al., 2000; Mason et al., 2001; Rizzi et al., 
1999a). These hexapeptides, the shortest peptide sequences interacting with the NOP receptor, have 
been used as chemical templates for SAR studies. The head to tail cyclization of Ac-RYYRWK-
NH2 produced a drastic decrease in binding affinity (Thomsen et al., 2000b) while the N-terminal 
acylation with a pentanoyl group (Judd et al., 2003) or the replacement of the Tyr2,3 residues with 
(pF)Phe (Judd et al., 2004) led to the discovery of high affinity low efficacy NOP receptor ligands. 
The N-terminal alkylation of the central core YYRW with groups bearing a guanidine function 
generated a NOP receptor agonist (Ishiama et al., 2001). Modifications on the Trp (W) were also 
preformed (Carra et al., 2005a) by our group. Finally, substitution of the C-terminal amide with an 
alcoholic function produced Ac-RYYRIK-ol, a NOP receptor ligand that displays high affinity (pKi 
7.91) for NOP receptor expressed in rat brain membranes. Ac-RYYRIK-ol antagonized N/OFQ 
effects in the vas deferens while it mimicked N/OFQ action in the colon. In vivo, the peptide 
consistently behaved as a NOP receptor agonist mimicking the supraspinal pronociceptive, 
orexigenic, and motor inhibiting actions and the spinal antinociceptive effects of N/OFQ (Gunduz et 
al., 2006). 
SinVax Inc. proposed the compound pentanoyl-RYYRWR-NH2 as NOP receptor antagonist. 
In [35S]GTPγS assays performed in CHO cells transfected with human NOP it displayed a very high 
affinity with a very low agonist activity (pA2 value of 8.99). When tested in vivo, this compound 
had a modest analgesic effect, somewhat less than has been reported with other NOP antagonists. 
Moreover this compound inhibited morphine-induced analgesia suggesting some agonist activity in 
vivo (Judd et al., 2003). 
In order to improve the stability and therapeutic utility of these small peptide ligands, a 
novel technology called structure inducing probes (SIP) (Larsen, 1999) was applied to the 
hexapeptide Ac-RYYRWK-NH2 (Dooley et al., 1997), resulting in the design of the peptide Ac-
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RYYRWKKKKKKK-NH2 (ZP120) (Larsen et al., 2001). ZP120 behaved as potent and selective 
NOP receptor partial agonist whose in vivo effects are long lasting (Rizzi et al., 2002a) and, after 
i.v. administration, confined to periphery. This pharmacological profile makes ZP120 an interesting 
drug candidate especially for those indications (i.e. aquaresis (Kapusta, 2000)) for which NOP 
partial agonists that produce renal but not cardiovascular effects are more selective than full 
agonists which are known to elicit both renal and cardiovascular actions (Kapusta et al., 2002).  
This hypotesis was recently confirmed by Kapusta and collegues that candidate ZP120 as 
aquaretic drug for its selectivity to produce renal but not cardiovascular effects (Kapusta et al., 
2005b). The further pharmacological characterization of ZP120 is one of the goals of this 
dissertation project. 
 
Although the design and pharmacological characterization of peptide ligands for NOP has 
facilitated great advances in elucidating the functional role of the N/OFQ-NOP receptor system, the 
therapeutic utility of NOP ligands, particularly for neurological disorders, can only be realized with 
potent non-peptide ligands. This is because as compared to peptide ligands, non-peptide would be 
expected to be more resistant to enzymatic breakdown following oral or parenteral administration 
and allow greater penetration into the CNS where they may have therapeutic utility. Many 
pharmaceutical companies and different groups have discovered potent non-peptide agonists and 
antagonists. These are summarized below. 
 
Non-peptide ligands 
Non-peptide ligands are generally discovered via high-throughput screening (HTS) in 
pharmaceutical industry laboratories. Since the NOP receptor represents the non-opioid branch of 
the opioid family, the search for non-peptide ligands was initiated by examining small-molecule 
opiate ligands. Among these compounds: i) σ-receptor ligands carbetapentane and rimcazole 
(Kobayashi et al., 1997); ii) MOP receptor ligands lofentanil (an anilidopiperidine) and etorphine 
(an oripavine derivative) (Butour et al., 1997); iii) anilidopiperidines, morphinans and 
benzomorphan classes of opiate ligands (Hawkinson et al., 2000); iv) MOP receptor ligand 
buprenorphine (Wnendt et al., 1999); v) naloxonebenzoylhydrazone (NalBzOH) (Noda et al., 
1998); vi) the 5-HT partial agonist spiroxatrine (Zaveri et al., 2001).  
The non-peptide NOP receptor ligands can be broadly divided into six structural classes. It is 
noteworthy that many of these ligands were first reported in the patent literature (patents from 
Pfizer, Banyu Pharmaceutical Co., Hoffmann La Roche, EuroCeltique S.A., NovoNordisk, 
Schering-Plough, Smith Kline Beecham, Japan Tobacco Inc, Toray Industries, etc). However, the 
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biological data of some of them are still not available, thus making it difficult to define clearly the 
structural requirements for NOP receptor affinity and selectivity. 
 
i) Morphinan-based ligands: Among this group TRK-820 was reported to antagonize the 
effects of N/OFQ on cAMP accumulation in CHOhNOP cells (Seki et al., 1999). Thus, the morphinan 
skeleton may provide a good lead for a unique profile of NOP antagonism coupled with opioid 
agonist activity for a novel class of analgesics. 
 
ii)  Benzimidazopiperidines: The first non-peptide pure NOP antagonist to be reported was a 
benzimidazolinone, J-113397 (Figure 8), reported by Kawamoto et al. (1999) and patented by 
Banyu Pharmaceutical Co. (Ozaki et al., 1998). J-113397 was shown to bind with nanomolar 
affinity to NOP receptors and to display 100-300 fold selectivity over classical opioid receptors 
(Hashiba et al., 2001; Ozaki et al., 2000). J-113397 antagonized N/OFQ effects at human NOP 
receptor in a competitive manner with pA2 values in the range of 7.5 – 8.9 in cAMP and 
[35S]GTPγS assays (Bigoni et al., 2000a; Hashiba et al., 2002a; Hashiba et al., 2002b; Ozaki et al., 
2000). The selective antagonist properties of J-113397 were confirmed at native NOP receptors 
expressed in isolated tissues (Bigoni et al., 2000a; Tada et al., 2002) and in brain preparations 
evaluated with biochemical (Olianas et al., 2002), neurochemical (Marti et al., 2003; Rominger et 
al., 2002) and electrophysiological (Chiou et al., 2002; Luo et al., 2002) techniques. J-113397 was 
also investigated in vivo where, in the range of 1-30 mg/kg, it prevented the actions of N/OFQ on 
pain transmission (Ko et al., 2002a; Ozaki et al., 2000; Ueda et al., 2000), on airways (Corboz et 
al., 2001) and the chough reflex (Bolser et al., 2001; McLeod et al., 2002), and on gastrointestinal 
functions (Ishihara et al., 2002; Tada et al., 2002). Moreover J-113397 produced per se 
pronociceptive effects in the rat (Yamamoto et al., 2001) and mouse (Rizzi et al., 2006) formalin 
test, antidepressant like effects (similar to NOP receptor peptide antagonists, (Gavioli et al., 2003; 
Redrobe et al., 2002) in the forced swimming test (Redrobe et al., 2002), reduction of kainate 
induced seizures (Bregola et al., 2002), potentiation of buprenorphine analgesia in wild type but not 
in NOP knockout mice (Lutfy et al., 2003), and facilitation of striatal dopamine release and 
locomotor performance on the rotarod in rats (Marti et al., 2004b). This latter effect was later 
confirmed in 6-hydroxydopamine lesioned animals (Marti et al., 2005). 
To date, J-113397 represents the most potent and selective non-peptide NOP receptor 
antagonist widely used in pharmacological studies. However, the synthesis, purification, and 
enantiomer separation of this molecule, which contains two chiral centers, is rather difficult and 
low-yielding. A series of simplified J-113397 analogues was synthesized and tested to investigate 
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the importance of the stereochemistry and the influence of the substituents at position 3 of the 
piperidine nucleus and on the nitrogen atom of the benzimidazolidinone nucleus. The compound 
coded as Trap-101 (Figure 8), an achiral analogue of J-113397, combines a pharmacological profile 
similar to that of the parent compound with a practical, high-yielding preparation (Trapella et al., 
2006). In in vitro N/OFQ sensitive preparations Trap-101 was a NOP selective antagonist with a 
potency 2-3 fold lower than the reference compound J-113397. In vivo, Trap-101 changed motor 
activity in naive rats and mice and alleviated parkinsonism in 6-hydroxydopamine hemilesioned 
rats: Trap-101 stimulated motor activity at 10 mg/kg and inhibited it at 30 mg/kg (Marti et al., 
2008). Trap-101 could be use as a novel template for a structure-activity study aimed at establishing 
the importance of both the C3 hydroxymethyl function and of the benzimidazolidinone nitrogen 
substituent. 
 
 
 
J-113397       Trap-101 
 
Figure 8. Structures of non-peptide NOP antagonist J-113397 and Trap-101. 
 
 
Pfizer has also reported a new series of benzimidazoles as NOP agonists, among them PCPB 
and MCOPPB (Figure 9). PCPB bound to the NOP receptor in mouse brain membranes (Ki = 0.12 
nM) and to recombinant human NOP receptor (Ki = 2.1 nM). Orally administered PCPB (30 mg/kg) 
exhibited anxiolytic activity in mice subjected to the Vogel conflict test that was comparable to the 
maximal response induced by diazepam (Hirao et al., 2008a). MCOPPB showed a high affinity for 
the human NOP receptor (pKi = 10.07) and selectivity for the NOP receptor over other members of 
the opioid receptor family: 12, 270 and >1000 fold more selective for the NOP receptor than for the 
MOP, KOP, and DOP receptors, respectively; in vivo MCOPPB (10 mg/kg, p.o.) elicited anxiolytic-
like effects in mice without affecting locomotor activity or memory. On the other hand, the 
benzodiazepine-type anxiolytic agent diazepam caused memory deficits (Hirao et al., 2008b). 
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 PCPB MCOPPB 
 
Figure 9. Structures of non-peptide NOP agonist PCPB and MCOPPB. 
 
 
iii)  Spiropiperidines: Hoffmann La Roche disclosed a series of 1,3,8-triazaspiro[4,5]decan-4-
ones, discovered through high throughput screening. Among them Ro 65-6570 and Ro 64-6198 
were two of those ligands widely used as pharmacological tools (Adam et al., 1998) (Figure 10). 
Although Ro 65-6570 was found to show anxiolytic effects (Wichmann et al., 1999), it was only 5 
to 10-fold selective over opioid receptors (Hashiba et al., 2001). Ro 64-6198, on the other hand, is 
far more selective and has shown an impressive anxiolytic profile comparable to benzodiazepines, 
in several in vivo anxiety paradigms (Jenck et al., 2000; Le Pen et al., 2002). As an agonist only 
slightly less potent than N/OFQ itself (Hashiba et al., 2002b), Ro 64-6198 can potentially be used 
as a therapeutic agent in disorders where a NOP agonist may prove beneficial, such as anorexia 
(Ciccocioppo et al., 2002), anxiety (Jenck et al., 2000), and inhibition of drug reward pathways 
(Dautzenberg et al., 2001). However, Ro 64-6198 was found not to affect cocaine-induced 
conditioned place preference (Kotlinska et al., 2003). Moreover, at higher doses, Ro 64-6198 was 
found to have affinity for dopamine and sigma receptors (Jenck et al., 2000) and increased alcohol 
drinking in genetically selected alcohol-preferring Marchigian Sardinian rats while other NOP 
agonists such as UFP-102 and UFP-112 reduce alcohol drinking; an effect probably induced by 
residual agonist activity of this compound at MOP receptors (Economidou et al., 2006a). For 
review see Shoblock (2007). 
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Ro 65-6570   Ro 64-6198 
 
Figure 10. Structures of Hofmann-La Roche lead compounds Ro 65-6570 and Ro 64-6198. 
 
 
Interestingly, Novo Nordisk has also reported on the synthesis and characterization of 1,3,8-
triazaspirodecanones, similar to the Roche compounds, starting  with spiroxatrine as their lead 
(Thomsen et al., 2000a). Their best ligand, NNC 63-0532 had binding affinity of 6.3 nM against 
human NOP but only a 12-fold selectivity for NOP over classical opioid receptors. This low 
selectivity was also seen in electrically stimulated mouse vas deferens where NNC 63-0532 
produced a concentration-dependent inhibition of the electrically induced twitches showing, in 
comparison with N/OFQ, lower potency and higher maximal effects. In addition, contrary to 
N/OFQ, the effects of NNC 63-0532 were insensitive to the NOP selective antagonist UFP-101 but 
were prevented by naloxone (Guerrini et al., 2004). Recently it was seen that NNC 63-0532 (0.01 
nM-10 µM) like N/OFQ induces a concentration-dependent endocytosis and recycling of the 
N/OFQ receptor. This mechanism contributes to maintain receptor signaling as it counteracts 
desensitization development and enhances a compensatory upregulation of adenylyl cyclase activity 
(Spampinato et al., 2006). 
 
iv) Aryl piperidines: Designing compounds in this group led several pharmaceutical companies 
(Schering Plough, Roche etc) to obtain patents. Recently SB-612111 was patented by 
GlaxoSmithKline (Zaratin et al., 2004) (Figure 11). The results describe SB-612111 as a high 
affinity and broadly selective NOP receptor antagonist in vitro and in vivo. Furthermore SB-612111 
can resensitize mice to morphine in animals which had been chronically treated with opiate, 
suggesting utility of this class of NOP receptor antagonist in prolonging the analgesic action of 
morphine (Zaratin et al., 2004). SB-612111 was synthesized by our laboratories and  investigated in 
vitro and in vivo. In vitro SB-612111 displayed subnanomolar affinity for the NOP receptor and 
high selectivity over classical opioid receptors (Spagnolo et al., 2007; Zaratin et al., 2004). 
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Functional studies ([35S]GTPγS binding and cAMP accumulation) in CHO cells expressing the 
human NOP receptor demonstrated pure, competitive and high potency antagonism exerted by this 
molecule against N/OFQ (pKB value of 9.70 and 8.63 in the [35S]GTPγS binding and cAMP 
accumulation experiments, respectively (Spagnolo et al., 2007). In isolated peripheral tissues of 
mice, rats, and guinea pigs and in mouse cerebral cortex synaptosomes preloaded with [3H]5-HT, 
SB-612111 competitively antagonized the inhibitory effects of N/OFQ, with pA2 values in the range 
of 8.20 to 8.50 (Spagnolo et al., 2007). In vivo, in the mouse tail withdrawal assay, SB-612111 
given i.p. up to 3 mg/kg prevented the pronociceptive and the antinociceptive action of 1 nmol of 
N/OFQ given i.c.v. and i.t., respectively (Rizzi et al., 2007a). In food intake studies performed in 
sated mice, SB-612111 (1 mg/kg i.p.) had no effect on food consumption but fully prevented the 
orexigenic effect of 1 nmol of N/OFQ i.c.v. (Rizzi et al., 2007a). In the mouse forced swimming 
and tail suspension tests, SB-612111 (1-10 mg/kg) reduced immobility time. The antidepressant-
like effect elicited by SB-612111 in the forced swimming test was reversed by the i.c.v. injection of 
1 nmol of N/OFQ and was no longer evident in mice knockout for the NOP receptor gene (Rizzi et 
al., 2007a). In conclusion, SB-612111 is among the most potent and NOP-selective non-peptide 
antagonists identified to date. 
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Figure 11. Structure of SB-612111. 
 
v) 4-Aminoquinolines: These are an entirely novel chemical class of NOP ligands disclosed by 
Japan Tobacco Inc. in a patent (Shinkai et al., 2000). The optimized ligand, JTC-801 (Figure 12), 
was obtained through an extensive structure-activity study of lead compound 25. Detailed 
pharmacological studies with JTC-801 were recently reported (Yamada et al., 2002). Its binding 
affinity for hNOP was 44.5 nM. It completely antagonized the inhibition of cAMP accumulation 
by N/OFQ. Furthermore, when administered in vivo orally or i.v., at doses of 0.1-1 mg/kg, it 
antagonized N/OFQ induced allodynia in mice and increased latency in the mouse hot plate test. 
These effects were not inhibited by naloxone. 
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Figure 12. Structure of JTC-801, a novel Japan Tobacco Inc compound. 
 
 
JTC-801 was chosen as a candidate for clinical trials for analgesia because of its oral 
bioavailability profile, which was more favourable than that of some other more potent analogs in 
this series. It was seen that JTC-801 alleviates heat-evoked hyperalgesia in chronic constriction 
injury rats (Suyama et al., 2003). 
 
vi) N-benzyl-D-proline: Recently Banyu Pharmaceuticals discovered a novel class of NOP 
antagonists using a focused library approach starting from a moderately active hit compound found 
in their chemical collection. The N-benzyl-D-proline analogue (Compound 24) (Figure 13) showed 
significantly improved antagonistic activity when compared with other reported NOP antagonists 
and showed good brain penetrability and in vivo antagonistic activity (Goto et al., 2006). 
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Figure 13. Structure of Compound 24, a novel Banyu Pharmaceuticals compound. 
 
Based on this novel antagonist structure we performed a structure activity analysis of 
Compound 24, focusing on its N-benzyl-D-proline, amide bond and benzoisofurane moieties; this 
latter structure was substituted with moieties taken from known non-peptide NOP ligands such as 
Ro 64-6198, SB-612111 and J-113397. Twelve new derivates were synthesized and evaluated for 
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their ability to bind the human recombinant NOP receptor. The molecule showing the highest 
affinity (Compound 35) has been further characterized. The pharmacological characterization of 
both Compound 24 and Compound 35 is one of the major goals of this thesis. 
 
Finally, there is a recent description of a 4-aryl-tropane NOP agonist, SCH 221510 (Varty et 
al., 2008) a new molecule discovered by Schering-Plough (Figure 14). SCH 221510 binds with high 
affinity (Ki 0.3 nM) to the NOP receptor and was shown to be anxiolytic with a reduced side-effect 
profile when compared with benzodiazepines (Varty et al., 2008). 
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Figure 14. Structure of SCH 221510. 
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Table 2. NOP receptor ligands available to date. 
 
 N/OFQ-RELATED PEPTIDE ANALOGUES NON-PEPTIDES 
AG
O
N
IS
TS
 
 
♦ N/OFQ 
♦ N/OFQ-NH2 
♦ [Tyr1]N/OFQ 
♦ N/OFQ(1-13)-NH2 
♦ [Arg14Lys15]N/OFQ 
♦ [(pF)Phe4]N/OFQ(1-13)-NH2 
♦ [(pF)Phe4Arg14Lys15]N/OFQ-NH2 (UFP-102) 
♦ [(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-112) 
♦ OS-461, OS-462, OS-500 
 
 
♦ Ro 65-6570 
♦ NNC-63-0532 
♦ Ro 64-6198 
♦ SCH 221510 
♦ PCPB 
♦ MCOPPB 
PA
R
TI
AL
 
AG
O
N
IS
TS
 
♦ [Phe1ψ(CH2-NH)-Gly2]N/OFQ(1-13)-NH2 
♦ [Phe1ψ(CH2NH)Gly2(pF)Phe4Arg14Lys15]N/OFQ-NH2 (UFP-103) 
♦ [Phe1ψ(CH2NH)Gly2(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-113) 
 
AN
TA
G
O
N
IS
TS
 
♦ [Nphe1]N/OFQ(1-13)-NH2 
♦ [Nphe1Arg14Lys15]N/OFQ-NH2 (UFP-101) 
♦ [Nphe1(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-111) 
♦ NalBzoH 
♦ J-113397 
♦ JTC-801 
♦ SB-612111 
♦ Trap-101 
♦ Compound 24 
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1.9 Aims 
 
The main objectives of this work have been to: 
 
♦ Produce a detailed characterization of the pharmacological profile of NOP receptors coupled 
with calcium signalling via the chimeric protein Gαqi5 using a large panel of full and partial 
agonists as well as pure antagonists. [Ca2+]i levels were monitored using the fluorometer 
FlexStation II. This has the potential to provide a rapid screening tool for novel NOP ligands. 
♦ Further investigate the pharmacological profile of ZP120 using mouse and rat preparations, J-
113397 and UFP-101, as well as NOP(-/-) mice. 
♦ Fully characterize the pharmacological profile of the novel non-peptide NOP antagonist 
Compound 24. 
♦ Screen a new series of non-peptide ligands deriving from SAR studies on the potent antagonist 
Compound 24. Compound 35, the best compound of this series, has been further investigated. 
 
To pharmacologically characterize these molecules, in vitro studies on N/OFQ-sensitive 
isolated tissues from different species and on transfected cells expressing the recombinant NOP 
and classical opioid receptors, were performed. In addition, in vitro experiments were also 
assessed in CHO cells co-expressing the recombinant NOP and classical opioid receptors and 
the chimeric protein Gαqi5. Moreover, some compounds were studied using an in vivo assay in 
mice, the tail withdrawal assay. Some in vitro and in vivo experiments were performed using 
NOP(+/+) and NOP(-/-) mice. 
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2. MATERIALS & METHODS 
 
2.1 Drugs and reagents 
The peptides used in this study were synthesized in the laboratory of Prof Salvadori 
(Department of Pharmaceutical Sciences and Biotechnology Centre, University of Ferrara) using 
standard solid-phase synthesis techniques and purified using High Pressure Liquid 
Chromatography, according to previously published methods (Guerrini et al., 1997). Amino acids, 
protected amino acids, and chemicals were purchased from Bachem, Novabiochem, Fluka 
(Switzerland) or Chem-Impex International (U.S.A).  
The compound [F/G]N/OFQ(1-13)-NH2 was prepared as described by Guerrini et al. (2003), 
[Nphe1]N/OFQ(1-13)-NH2 was obtained by the shift of the side chain of Phe1 from the C to the N 
atom in the template N/OFQ(1-13)-NH2. NNC 63-0532-COOH was obtained following literature 
methods (Watson et al., 1999) and UFP-111, UFP-112 and UFP-113 were prepared as previously 
described (Arduin et al., 2007). Ac-RYYRIK-NH2, Ac-RYYRIK-ol and all the other modified 
hexapeptides were synthesized accordingly to Kocsis et al. (2004) in the laboratory of Dr Anna 
Magyar (Research Group of Peptide Chemistry, Eötvös Loránd University, Budapest, Hungary) 
using solid-phase peptide synthesis techniques. 
ZP120 was provided by Zealand Pharma (Copenhagen, Denmark), [D-Pen2,D-
Pen5]enkephalin (DPDPE) and dynorphin A were purchased from NeoMPS (Strasbourg, France). 
Ro 64-6198 was provided by Dr. Wichmann (Hoffmann-La Roche, Basel, Switzerland). The 
non-peptide compound Compound 24 was synthesized following the procedures described in detail 
by Goto et al. (2006). 
J-113397 was prepared as a racemic mixture, according to De Risi et al. (2001), Trap-101 is 
obtained through treatment with LiAlH4 on a common intermediate from the J-113397 synthesis. 
The compound SB-612111 was synthesized following the experimental conditions and protocols 
described in detail in the patent (WO 03/040099 A1) by Palombi et al. (2003).  
Captopril, amastatin, bestatin, phosphoramidon, naloxone, bovine serum albumin (BSA), 
guanosine 5’-O-(3-thiotri-phosphate) (GTPγS), GDP, unlabelled GTPγS, bacitracin and probenecid 
were from Sigma Chemical Co. (Poole, U.K.) or E. Merck (Darmstadt, Germany). All tissue culture 
media and supplements were from Invitrogen (Paisley, U.K.). [35S]GTPγS (1250 Ci mmol-1), 
[3H]Diprenorphine ([3H]DPN, 75-133 Ci/mmol) were from Perkin Elmer Life Sciences (Boston, 
Mass., USA) and [leucyl-3H]N/OFQ ([3H]-N/OFQ, 150 Ci/mmol) was from Amersham Pharmacia 
Biotech (Buckinghamshire, UK). All other consumables and reagents were of the highest purity 
available. 
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For in vitro experiments, the peptides were solubilized in H2O and stock solutions (1 mM or 
2 mM) were stored at -20 °C until use; the non-peptide compounds were solubilized in dimethyl 
sulfoxide at a final concentration of 10 mM, and the successive dilutions were made in saline or 
water, stock solutions were kept at -20 °C until use. For in vivo studies, Compound 24 was 
dissolved in 2% DMSO and 10% encapsin (hydroxypropyl-beta-cyclodextrin) just before 
performing the experiment. 
 
2.2 Buffer composition 
 
• Tissue culture buffers: 
Harvest: HEPES (10 mM), EDTA (1.1 mM), NaCl (154 mM), pH 7.4 with NaOH. 
 
• [35S]GTPγS buffers: 
[35S]GTPγS Homogenising: Tris-HCl (50 mM), EGTA (0.2 mM), pH 7.4 with NaOH. 
[35S]GTPγS Assay: Tris-HCl (50 mM), EGTA (0.2 mM), NaCl (100 mM), MgCl2 (1 mM), pH 
7.4 with NaOH. 
 
• [3H]-N/OFQ competition buffers: 
Wash/Homogenising: Tris-HCl (50 mM), MgSO4 (5 mM), pH 7.4 with KOH. 
Assay: Tris-HCl (50 mM), MgSO4 (5 mM), pH 7.4 with KOH, 0.5% BSA. 
 
• [3H]-Diprenorphine competition buffers:  
Wash/Homogenising: Tris-HCl (50 mM), pH 7.4 with KOH. 
Assay: Tris-HCl (50 mM), pH 7.4 with KOH, 0.5% BSA. 
 
• Calcium mobilization assay buffers: 
HBSS (Hanks’ Balanced Salt Solution): KCl (5.4 mM), KH2PO4 (0.44 mM), NaCl (137 mM), 
NaHCO3 (4.2 mM), Na2HPO4 x 7 H2O (0.25 mM), CaCl2 (1.3 mM), MgSO4 x 7 H2O (1 mM), 
glucose (5 mM). 
Loading solution: cell culture medium, HEPES (20 mM), probenecid (2.5 mM), calcium-
sensitive fluorescent dye Fluo 4AM (3 µM), pluronic acid (0.01%). 
Dye loading solution: HBSS, HEPES (20 mM), probenecid (2.5 mM), Brilliant Black (500 
µM). 
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• Bioassay buffers composition: 
The tissues were suspended in the following Krebs solution (mM): NaCl 118.5, KCl 4.7, 
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, CaCl2 2.5, glucose 10. For the experiments on the mouse 
vas deferens and rat vas deferens, a Mg++-free and 1.8 mM CaCl2 Krebs solution were used, 
respectively. For the experiments on guinea pig ileum the normal medium was added with 
hexamethonium (0.0008%) and benadryl (0.00001%). 
 
 
2.3 In vitro studies 
 
CHO expressing the recombinant NOP/DOP/MOP/KOP receptors 
2.3.1 Cell harvesting and membranes preparation 
Chinese Hamster Ovary cells (CHO) stably expressing the human NOP receptor (CHOhNOP) 
cells were cultured consisting of Dulbecco's MEM/HAMS F12 (50/50) supplemented with 5% 
foetal calf serum (FCS), penicillin (100 IU/ml), streptomycin (100 µg/ml), fungizone (2.5 µg/ml), 
geneticin (G418; 200 µg/ml) and hygromycin B (200 µg/ml) at 37˚C in 5% CO2/humidified air. 
CHO cell stocks expressing the human DOP/MOP/KOP receptors (CHOMOP/DOP/KOP) were 
maintained in Ham F12 containing 10% FCS, 100 IU/ml P, 100 µg/ml S and 400 µg/ml G418, for 
CHO non-transfected cells G-418 and hygromycin B were omitted. Cell cultures were kept at 37˚C 
in 5% CO2/humidified air. In all cases experimental cultures were free from selection agents 
(hygromycin B, G418). When confluence was reached (3-4 days), cells were sub-cultured as 
required using trypsin//EDTA and used for experimentation. Cells were harvested from sterile 
tissue culture flasks using harvest buffer and gentle agitation. Cells were suspended in either wash 
buffer (displacement assay) or homogenising buffer (GTPγ[35S] assay), homogenised using an Ultra 
Turrax, for 10 seconds followed by 6 consecutive 1-second bursts. The homogenate was then 
centrifuged at 13,500 rpm for 10 min at 4°C, this was carried out a total of three times. The 
membrane fraction was resuspended in an appropriate volume of assay buffer and the total protein 
content determined as set out below. 
 
2.3.2 Displacement binding assay 
5 µg protein of CHOhNOP homogenate were assayed in a total volume of 0.5 ml comprising 
competition homogenising buffer supplemented with 0.5% (w:v) BSA, 10 µM peptidase inhibitors 
(amastatin, bestatin, captopril and phosphoramidon), 0.2 nM [Leucyl-3H]N/OFQ and 100 nM – 0.1 
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pM of competing ligands. Non-specific binding (NSB) was determined in the presence of 1 µM 
N/OFQ. 50 µg (CHOhMOP), 25 µg (CHOhDOP) and 40 µg (CHOhKOP) membrane protein were 
incubated in 0.5 ml homogenising buffer supplemented with 0.5% BSA, approximately 0.7 nM 
[3H]Diprenorphine. NSB binding was defined in the presence of 10 µM naloxone. Reactions were 
incubated for 1 hour at room temperature and harvested under vacuum filtration using a Brandel 
cell harvester. Whatman GF/B filters were soaked in 0.5% polyethylenimine, to reduce NSB, and 
loaded onto the harvester wet. Radioactivity was determined following filter extraction (8 hours, 
Optiphase Safe) using liquid scintillation spectroscopy. 
 
2.3.3 [35S]GTPγS stimulation binding assay 
Experimentation was performed essentially as described by Berger et al. (2000b). Freshly 
prepared CHOhNOP membranes (20 µg) were incubated in 0.5 ml volumes of buffer consisting Tris 
(50 mM), EGTA (0.2 mM), GDP (100 µM), bacitracin (0.15 mM), BSA (1 mg/ml), peptidase 
inhibitors (amastatin, bestatin, captopril, phosphoramidon; 10 µM), [35S]GTPγS (~150 pM) and 
ligands in the concentration range of 10-12 – 10-5 M. NSB was determined in the presence of 10 µM 
unlabelled GTPγS. Assays were incubated for 1 h at 30oC with gentle shaking and bound and free 
radiolabel were separated by vacuum filtration onto Whatman GF/B filters. Polyethylenimine was 
not used. In all cases radioactivity was determined following filter extraction (8 hours) using liquid 
scintillation spectroscopy. 
 
2.3.4 Protein assay 
The protein concentration was determined for membrane fractions using the method of 
Lowry (Lowry et al., 1951): BSA protein standards at set concentrations of 0, 50, 100, 150, 200, 
250 µg protein/ml were made up in 0.1 M NaOH. Samples of unknown protein concentration were 
diluted in 0.1 M NaOH. 0.5ml volumes of standards and samples were incubated for 10 min in 2.5 
ml of solution consisting of, A (NaHCO3 in 0.1 M NaOH) B (1% CuSO4) and C (2% Na+ K+ 
tartrate) mixed to the ratio 100:1:1. Folin’s reagent (diluted 1:4 in dH2O) was then added and 
incubated at room temperature for a further 30min. The absorbance at 750 nm for standards and 
samples was then determined using a spectrophotometer. Linear regression of the known BSA 
protein concentrations was used to produce a standard curve (Figure 15) from which sample protein 
concentrations were determined. 
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Figure 15. Example of protein assay standard curve used to determine the protein mass of unknown 
samples. 
 
 
Calcium mobilization assay 
2.3.5 Experimental protocols  
 CHO cell lines stably co-expressing MOP/DOP/KOP/ NOP receptors and the C-terminally 
modified Gαqi5 were generated as described by Camarda et al. (2009). CHOhMOP, CHOhDOP, 
CHOhKOP and CHOhNOP stably expressing the Gαqi5 protein were seeded at a density of 40,000 
cells/well into 96-well black, clear-bottom plates. After 24 hours incubation the cells were loaded 
with medium supplemented with 2.5 mM probenecid, 3 µM of the calcium sensitive fluorescent dye 
Fluo-4 AM and 0.01% pluronic acid, for 30 min at 37 °C (Figure 16). Afterwards the loading 
solution was aspirated and 100 µl/well of assay buffer: HBSS buffer supplemented with 20 mM 
HEPES, 2.5 mM probenecid and 500 µM Brilliant Black was added. Stock solutions (1 mM) of 
ligands were made in distilled water and stored at -20 °C. Serial dilutions of ligands for 
experimental use were made in HBSS/HEPES (20 mM) buffer (containing 0.02% BSA fraction V). 
After placing both plates (cell culture and compound plate) into the FlexStation II (Molecular 
Device, Union City, CA 94587, US), fluorescence changes were measured at room temperature. 
On-line additions were carried out in a volume of 50 µl/well. 
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Figure 16. Diagram depicting the experimental protocol of the calcium mobilization assay. Cells are 
incubated with Fluo-4 AM, de-esterification of the ester group (AM) traps the dye in the cells and further 
leakage of the dye is prevented by blockage of organic anion-transport inhibitors using probenecid. 
Background fluorescence is reduced by addition of Brilliant Black dye which blocks extracellular signalling 
from any leaked Fluo-4. 
 
 
2.3.6 Cell counting 
 Accurate numbers in a cell suspension can be calculated by counting the cells in a cell 
counting chamber (Burker’s chamber, Figure 17). A small volume of the cell suspension (10 µl) 
was pipetted onto the chamber, the capillary action under the cover slip will draw the suspension 
into the counting chamber. The space between the cover slip and the counting chamber ensures a 
specific volume of cell suspension is present. 
 
 
 
 
Figure 17. Burker’s chamber. 
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 Under a microscope the number of cells in diagonally opposite counting areas were counted, 
Figure 18.  
 
Figure 18. Schematic representation of the counting grid of the Burker’s chamber. 
 
 The Burker’s chamber is formed of 3x3 major squares, each of these major squares is 
subdivided into a grid of 4x4 squares. The number of cells present in three major cells are counted, 
cells in contact with two of the squares sides are included and the average taken. The volume of a 
major square is 0.1 mm3 which is equal to 0.0001 ml. To determine the number of cells per ml the 
average number of cells determined is increased by a factor of 104. 
 
2.3.7 Instruments 
 [Ca2+]i levels were monitored using a FlexStation II fluorimeter (Figure 19). The FlexStation 
II system includes: 
• Xenon-lamp light source 
• Automatic eight-channel pipettor 
• Tip rack drawer 
• Compound plate drawer 
• Reading chamber drawer 
 
 
 The Xenon-lamp light source and dual monochromators permit the use of essentially all 
dual-wavelength dyes for functional cellular assays. 
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Figure 19. Diagram of FlexStation II used for calcium mobilization assay. 
 
 
Isolated tissues 
The in vitro experiments were performed on mouse vas deferens (mVD), rat vas deferens 
(rVD) and guinea pig ileum (gpI). The animals (Morini, Reggioemilia, Italy) were handled 
according to guidelines published in the European Communities Council directives (86/609/EEC), 
National regulation (D.L 116/92). They were housed in 425 x 266 x 155 mm cages (Techniplast, 
Milan, Italy), fifteen animals/cage, under standard conditions (22ºC, 55 % humidity, 12-h light/dark 
cycle, light on at 7:00 am) with food (MIL, standard diet; Morini, Reggio Emilia, Italy) and water 
ad libitum. 
 
2.3.8 Tissue preparation  
Tissues were taken from male Swiss mice (25-30 g), guinea pigs (300-350 g) and Sprague 
Dowley rats (300-350 g). On the day of the experiments the animals were killed by a lethal injection 
of urethane. From the mouse and rat the prostatic portion of the vas deferens was isolated, and 
prepared according to Hughes et al. (1975) and Schulz et al. (1979), respectively; from the guinea 
pig segments of ileum (1.5-2 cm in length) were taken as described by Paton (1957). The tissues 
were suspended in 5 ml organ baths containing heated Krebs solution oxygenated with 95% O2 and 
5% CO2 (pH 7.4). The temperature was set at 33 °C for the mVD and at 37 °C for the other tissues 
(Hughes et al., 1975; Paton, 1957; Schulz et al., 1979). A resting tension of 0.3 g was applied to the 
mVD, 1 g to the gpI and rVD. 
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2.3.9 Experimental protocols 
The mVD, gpI and rVD were continuously stimulated through two platinum ring electrodes 
with supramaximal voltage rectangular pulses of 1 msec duration and 0.05 Hz frequency. The 
electrically evoked contractions (twitches) were measured isotonically with a strain gauge 
transducer (Basile 7006; UgoBasile s.r.l., Varese, Italy). After an equilibration period of about 60 
min the contractions induced by electrical field stimulation were stable; at this time, cumulative 
concentration-response curves to N/OFQ, N/OFQ related peptides, or to opioid ligands were 
performed (0.5 log unit steps). The concentration-response curve consists of progressive 
administration of increasing concentrations of peptide without changing the Krebs solution in which 
the tissue is bathed; the injection of a certain concentration of ligand must be done only when the 
previous concentration produced a stable effect (plateau). About 1 hour with 3 changes of Krebs 
solution (wash out) is needed to the tissue to recover the original twitch. 
When required, in all the preparations described above, the NOP receptor antagonists, at 
adequate concentrations, were added to the medium 15 min before performing the challenge with 
agonists. 
 
2.3.10  Instruments 
For the in vitro bioassays two chamber-glass bathes for isolated organs were utilized (Figure 
20). The outer chamber contains water heated at 33 or 37 °C, while the inner chamber contains 5 ml 
of oxygenated Krebs solution. One end of the tissue is fixed to the bottom side of the inner chamber 
and the other end is linked to a force transducer by a surgery thread. The role of the transducer is to 
convert the mechanical signal in electrical signal, then amplified and recorded with a PC-based 
acquisition system Power Lab 4/25 (model ML845, ADInstrument, USA). 
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Figure 20. Diagram of the tissue chamber used for isolated tissues assays. 
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2.4 In vivo studies 
Experimental protocol 
2.4.1 Animals 
Male Swiss and male CD1/C57-BL6J/129 NOP(+/+) and NOP(-/-) mice weighing 20-25 g 
were used. All transgenic animals were genotyped by PCR. Details of the generation and breeding 
of mutant mice have been published previously (Gavioli et al., 2003). The animals were handled as 
described above in the isolated tissues section. 
I.c.v. injections (2 µl/mouse) were given, under light isofluoran anesthesia (just sufficient to 
produce a loss of the righting reflex), in the left ventricule according to the procedure described by 
Laursen and Belknap (Laursen et al., 1986). Briefly, the syringe was held at an approximate 45° 
angle to the skull. Bregma was found by lightly rubbing the point of the needle over the skull until 
the suture was felt. Once found, care was taken to maintain the approximate 45° angle and the 
needle was inserted about 2 mm lateral to the midline. The skull is relatively thin at this point, so 
only mild pressure was required to insert and remove the needle. The solutions of drugs were then 
injected slowly (2 µl in about 20 s). 
I.t. injections (5 µl/mouse) were adapted according to the method of Hylden and Wilcox 
(Hylden et al., 1980). A 28-gauge stainless steel needle attached to a 50 µl 65 Hamilton 
microsyringe was inserted, with an angle of about 20° in the spinal subarachnoid space between the 
L5 and L6 segments in mice. 1-3 hours before the i.t. injection a caudal cutaneous incision was 
performed under isofluoran anesthesia. 
I.p. injections 100 µl/mouse of non-peptide compounds were given 30 min before N/OFQ 
administration. 
 
2.4.2 Tail withdrawal assay 
All experiments were started at 10.00 a.m. and performed according to the procedure 
previously described in detail (Calo et al., 1998b). Briefly, the mice were placed in a holder and the 
distal half of the tail was immersed in water at 48 °C. Withdrawal latency time was measured by an 
experienced observer blind to drug treatment. A cut off time of 20 s was chosen to avoid tissue 
damage. For each experiment four mice were randomly assigned to each experimental group, and 
the experiment was repeated at least four times: therefore each experimental point is the mean of the 
results obtained in >16 mice. 
Tail-withdrawal latency was determined immediately before and 5, 15, 30, and 60 min after 
i.c.v. or i.t. injection of saline (control) or N/OFQ (1 nmole). Compound 24 (10 mg/kg) was given 
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i.p. 30 min before N/OFQ administration. Increased and decreased tail withdrawal latencies 
compared with baseline indicated antinociceptive and pronociceptive effects, respectively. 
 
2.5 Data analysis and terminology 
All data are expressed as means ± standard error of the mean (s.e.m.) of n experiments. For 
potency values 95% confidence limits were indicated. Data have been statistically analyzed with the 
Student’s t test for unpaired data or one way ANOVA followed by the Dunnett’s test, as specified in 
table and figure legends; p values less than 0.05 were considered to be significant. The 
pharmacological terminology adopted in this manuscript is consistent with the IUPHAR 
recommendations (Neubig et al., 2003). 
[35S]GTPγS data are expressed as a stimulation factor i.e. the ratio between agonist-
stimulated [35S]GTPγS specific (minus NSB) binding and basal specific binding. Receptor binding 
data are expressed as pKi derived from the Cheng and Prusoff (Cheng et al., 1973) equation: 
 
Ki = IC50 / (1+([R]/KD)) 
 
where IC50 is the concentration of the competitor producing 50 % displacement, [R] is the 
concentration of the radiolabel and KD is the radiolabel affinity for the receptor under investigation. 
The [3H]N/OFQ KD was 83 pM while those of [3H]Diprenorphine were 125, 323, and 134 pM (in-
house laboratory values) at MOP, DOP, and KOP, respectively. pKi is the antilogarithm of the Ki 
values obtained after the calculations. 
Calcium mobilization data are expressed as fluorescence intensity units (FIU) in percent 
over the baseline. Isolated tissue data are expressed as percent of the twitch induced by electrical 
field stimulation.  
Agonist potencies are given as pEC50 = the negative logarithm to base 10 of the molar 
concentration of an agonist that produces 50% of the maximal possible effect of that agonist. 
Concentration response curve to agonists were fitted with the following equation: 
 
Effect = baseline + (Emax-baseline)/(1+10^((LogEC50 - X)*HillSlope)) 
 
where X is the agonist concentration. 
 
The Emax is the maximal effect that an agonist can elicit in a given tissue. In the electrically 
stimulated tissues, the Emax of agonists is expressed as % of inhibition of the control twitch. 
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Antagonist potencies are expressed in terms of pA2. pA2 is the negative logarithm to base 10 
of the antagonist molar concentration that makes it necessary to double the agonist concentration to 
elicit the original response (Schild, 1997). The pA2 values are calculated using Schild’s linear 
regression, that correlates the log of concentrations of antagonists (x axis) to the log of (CR-1) (y 
axis), where CR is the ratio between the EC50 (nM) values of agonist, in the presence and in absence 
of antagonist. The value of x for y=0 represents the pA2 value, and the slope not significantly 
different from the unity means that the antagonist is competitive. When one single concentration of 
antagonist is utilized, the pKB value is calculated with the Gaddum Schild equation: 
 
KB = ((CR - 1)/[antagonist]) 
 
assuming a slope equal to unity. Curve fitting was performed using PRISM 5.0 (GraphPad Software 
In., San Diego, U.S.A.) 
For calcium mobilization experiments pKB values were derived from inhibition response 
curves using the following equation:  
 
KB = IC50/([2 +([A]/EC50)n]1/n – 1) 
 
where IC50 is the concentration of antagonist that produces 50% inhibition of the agonist response, 
[A] is the concentration of agonist, EC50 is the concentration of agonist producing a 50% maximal 
response and n is the Hill coefficient of the concentration response curve to the agonist (Kenakin, 
2004). In addition the pKB for Compound 24 evaluated at different concentrations against the 
concentration response curve to N/OFQ was calculated using the following equation: 
 
KB = [antagonist]/(slope – 1) 
 
where slope is calculated from a double-reciprocal plot of equieffective concentrations of agonist in 
the absence and presence of antagonist (Kenakin, 2004). 
For in vivo studies, raw data from tail withdrawal experiments were converted to the area 
under the time versus tail withdrawal latency curve (AUC min/s), as described by Grisel et al. 
(1996). For ZP120 experiments AUC data for the time interval 0-180 min was calculated and used 
for statistical analysis. For Compound 24 experiments AUC data for the time interval (0-15 and 0-
30 min for i.c.v. and i.t. studies, respectively) was used for statistical analysis. 
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3. RESULTS & DISCUSSION 
 
3.1 Pharmacological profile of NOP receptors coupled to calcium signalling via the chimeric 
protein Gαqi5 
 
Innovative drugs interacting selectively with the NOP receptor are under development in 
several companies. However target validation studies in this field are limited by the relative paucity 
of pharmacological tools which are the non-peptide agonist Ro 64-6198 (Jenck et al., 2000) and the 
antagonists J-113397 (Ozaki et al., 2000) and SB-612111 (Zaratin et al., 2004), and a few peptide 
ligands including the antagonist UFP-101 (Calo et al., 2002b), the partial agonists [F/G]N/OFQ(1-
13)-NH2 (Guerrini et al., 1998), Ac-RYYRWK-NH2 (Dooley et al., 1997) and ZP120 (Rizzi et al., 
2002a), and the agonists UFP-102 (Carra et al., 2005b) and UFP-112 (Rizzi et al., 2007b) (for 
reviews see (Calo et al., 2005; Chiou et al., 2007; Lambert, 2008; Shoblock, 2007; Zaveri, 2003).  
The identification of novel GPCR ligands are nowadays mainly based on the use of 
automated fluorometers and calcium dyes. To extend this approach to Gi coupled receptors several 
strategies have been developed including the use of chimeric G proteins (Conklin et al., 1993; 
Kostenis et al., 2005). This strategy has been validated with a large panel of Gi coupled receptors 
(Kostenis et al., 2005) including classical opioid and the NOP receptor (Coward et al., 1999). 
However, in the study by Coward et al. (1999) only N/OFQ has been used as NOP agonist and no 
receptor antagonists were tested. Thus, in the present study we performed a detailed 
characterization of the pharmacological profile of NOP receptors coupled to calcium signalling via 
the chimeric protein Gαqi5 using a large panel of full and partial agonists as well as pure 
antagonists. 
 
Results 
Figure 21 (left panel) displays the response in terms of calcium mobilization of CHOhNOP 
cells expressing the Gαqi5 protein to increasing concentrations of N/OFQ: the peptide evoked 
immediate calcium transients in a concentration-dependent manner displaying high potency (pEC50 
≈ 9.5) and maximal effects (≈ 200% over the basal values). N/OFQ was found completely inactive 
up to 1 µM concentrations in wild type CHO stably expressing the Gαqi5 protein. In CHOhNOP cells 
(not expressing the Gαqi5 protein) N/OFQ produced a modest stimulatory effect (≈ 50% over the 
basal values) only at high concentrations i.e. 0.1 and 1 µM. On the contrary ATP produced 
superimposable concentration response curves (pEC50 ≈ 6, Emax ≈ 250%) in the three cell lines (i.e. 
CHOhNOP, CHO-Gαqi5, and CHOhNOP-Gαqi5). 
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Figure 21. Raw data from a single representative experiment of the concentration response curve to N/OFQ 
(left panel) and to UFP-112 (right panel) in calcium mobilization experiments performed in CHOhNOP cells 
stably expressing the Gαqi5 protein. 
 
 
 
In order to perform a detailed characterization of NOP receptors coupled to calcium 
signalling via the chimeric protein Gαqi5 a large panel of NOP receptor agonists, partial agonists 
and antagonists were tested. The pharmacological activities of all these ligands are summarized in 
Table 3 in terms of pEC50 and Emax values for full and partial agonists and pKB values for 
antagonists. 
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Table 3. Effects of N/OFQ and NOP receptor ligands in CHO
 
cells coexpressing the Gαqi5 chimeric 
protein and the human NOP receptor. 
 
 Agonist Antagonist 
 pEC50 (CL95%) Emax ± s.e.m. pKB (CL95%) 
N/OFQ 9.54 (9.27-9.81) 167 ± 12% - 
N/OFQ(1-13)-NH2 9.30 (8.84-9.76) 161 ± 12% - 
UFP-112 9.05 (8.39-9.71) 173 ± 29% - 
Ro 64-6198 7.98 (7.45-8.51) 178 ± 24% - 
NNC 63-0532 6.80 (6.60-7.00) 111 ± 23% - 
[F/G]N/OFQ(1-13)-NH2 8.03 (7.45-8.61) 91 ± 16% - 
Ac-RYYRWK-NH2 8.68 (8.07-9.29) 97 ± 34% - 
Ac-RYYRIK-NH2 8.16 (7.80-8.52) 99 ± 22% - 
Ac-RYYRIK-ol 8.05 (7.45-8.65) 170± 23% - 
UFP-113 7.97 (7.38-8.56) 104 ± 29% - 
ZP120 7.15 (6.60-7.70) 97 ± 26% - 
UFP-101 Inactive 7.66 (7.06-8.26) 
Trap-101 Inactive 7.93 (7.39-8.47) 
J-113397 Inactive 7.88 (7.43-8.33) 
[Nphe1]N/OFQ(1-13)-NH2 Inactive 6.29 (5.89-6.75) 
SB-612111 Inactive 8.16 (7.55-8.77) 
Naloxone Inactive Inactive 
 
Data are means ± s.e.m. of 4 separate experiments made in duplicate. 
Inactive: inactive up to 10 µM. 
 
 
As shown in Figure 22, concentration response curves to NOP receptor agonists were 
performed and compared to that to N/OFQ. All the agonists tested evoked immediate calcium 
transients similar to those stimulated by N/OFQ (see as an example the raw data relative to an UFP-
112 experiment in Figure 21 right panel). The peptides N/OFQ(1-13)-NH2 and UFP-112 mimicked 
the effects of N/OFQ showing similar potency and maximal effects as the natural peptide. The non-
peptide ligands Ro 64-6198 and NNC 63-0532 stimulated calcium levels in a concentration-
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dependent manner with maximal effects similar to those of N/OFQ but approximately 30 and 500 
fold lower potency. 
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Figure 22. Concentration response curve to NOP receptor agonists in calcium mobilization experiments 
performed in CHOhNOP cells stably expressing the Gαqi5 protein. Ligand effects were expressed as % over the 
baseline. Data are the mean of 4 separate experiments performed in duplicate. 
 
 
Under the same experimental conditions, the pharmacological profile of a series of NOP 
receptor partial agonists was investigated (Figure 23). Although the maximal effects elicited by 
these peptides were lower that those of N/OFQ these differences did not reach statistical 
significance (see the comparison of N/OFQ and NOP ligands maximal effects obtained in parallel 
experiments showed in Figure 22). Ac-RYYRWK-NH2, Ac-RYYRIK-NH2, Ac-RYYRIK-ol, 
[F/G]N/OFQ(1-13)-NH2, and UFP-113 displayed approximately 30 fold lower potency than 
N/OFQ. ZP120 was found to be the weaker compound of the series; in fact, ZP120 was able to 
stimulate calcium levels only at very high concentrations i.e. 100 and 1000 nM. 
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Figure 23. Concentration response curve to NOP receptor partial agonists in calcium mobilization 
experiments performed in CHOhNOP cells stably expressing the Gαqi5 protein. Ligand effects were expressed 
as % over the baseline. Data are the mean of 4 separate experiments performed in duplicate. 
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The effects of a panel of peptide and non-peptide antagonists have been also evaluated. 
Inhibition response experiments were performed by testing increasing concentrations of antagonists 
(10 pM – 10 µM) against a fixed concentration of N/OFQ (10 nM), approximately corresponding to 
the EC80. 
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Figure 24. Inhibition experiments obtained by challenging 10 nM N/OFQ with increasing concentrations of 
NOP receptor antagonists in the calcium mobilization assay performed in CHOhNOP cells stably expressing 
the Gαqi5 protein. N/OFQ effects were expressed as % over the baseline. Data are the mean of 4 separate 
experiments performed in duplicate. 
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As shown in Figure 24, UFP-101, J-113397 and Trap-101 were able to inhibit in a 
concentration manner the stimulatory effect of 10 nM N/OFQ, showing similar pIC50 values. pKB 
values of 7.66, 7.88 and 7.93 were calculated from these experiments for UFP-101, J-113397 and 
Trap-101, respectively. [Nphe1]N/OFQ(1-13)-NH2 behaved as a low potency antagonist since it was 
able to counteract the effect of N/OFQ only at the higher concentration tested, i.e. 10 µM. 
Assuming a complete inhibition for higher concentrations, a pIC50 of 4.92 was calculated for 
[Nphe1]N/OFQ(1-13)-NH2 which corresponds to a pKB value of 6.29. SB-612111 was the most 
potent antagonist, with a pIC50 of 6.69 and a pKB of 8.16. Naloxone, up to 10 µM, did not modify 
the actions of 10 nM N/OFQ.  
 
Finally, a Schild analysis has been performed for the compound J-113397 which has been 
tested at the concentrations of 0.1, 1 and 10 µM against the effects of increasing concentrations of 
N/OFQ. As showed in Figure 25, J-113397 produced a rightward shift of the concentration response 
curve to N/OFQ in a concentration-dependent manner without modifying the maximal effect 
elicited by the agonist. The corresponding Schild plot was linear with a slope value not significantly 
different from the unity. The calculated pA2 value, 7.32, is close to the potency value (7.88) 
obtained in inhibition response experiments. 
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Figure 25. Concentration-response curve to N/OFQ obtained in the absence (control) and in presence of 
increasing concentrations of J-113397 (0.1-10 µM) (left panel); the corresponding Schild plot is shown in the 
right panel. Data are the mean of 4 separate experiments performed in duplicate. 
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Discussion  
The results of the present study confirmed previous findings (Coward et al., 1999) 
demonstrating that it is possible to use the Gαqi5 chimeric protein to force NOP receptors to signal 
via the calcium pathway. Moreover, the detailed pharmacological characterization of NOP receptors 
artificially coupled to calcium signalling demonstrated that this strategy is not associated with major 
distortions of the pharmacological profile of this receptor. However some important 
pharmacological differences were demonstrated comparing the present data with those from 
literature for a subset of partial or full agonists characterized by slow kinetics of interaction with the 
NOP receptor.  
In CHOhNOP, CHO-Gαqi5, and CHOhNOP-Gαqi5 cell lines ATP stimulated calcium 
mobilization generating superimposable concentration response curves. This demonstrates that the 
expression of the chimeric protein does not interfere with normal calcium signalling. On the 
contrary, N/OFQ consistently stimulated calcium mobilization only in the CHOhNOP-Gαqi5 cells, 
indicating that this response derives from the ability of the chimeric protein to force the NOP 
receptor to signal via calcium. The efficiency of this artificial coupling, measured in terms of 
N/OFQ Emax, indicated a signal to noise ratio in the range 2.5 – 3. Although details regarding this 
point are not presented in the (Coward et al., 1999) paper, the analysis of the results reported in 
Figure 2 of that article suggests a similar efficiency. Thus the calcium mobilization response to 
N/OFQ in CHOhNOP-Gαqi5 cells is large and robust enough for performing both agonist and 
antagonist protocols.  
To comprehensively characterize NOP receptors coupled to calcium signalling full and 
partial agonists as well as pure antagonists were used. As far as antagonists are concerned, all the 
compounds tested were found to be inactive per se up to 10 µM while they inhibited in a 
concentration-dependent manner the effect evoked by 10 nM N/OFQ. The following order of 
potency of antagonist has been recorded: 
SB-612111 > J-113397 = Trap-101 > UFP-101 > [Nphe1]N/OFQ(1-13)-NH2 (naloxone 
inactive). These results are superimposable to those obtained by testing the antagonists in 
[35S]GTPγS binding experiments performed on CHOhNOP cell membranes (McDonald et al., 2003b; 
Spagnolo et al., 2007; Trapella et al., 2006) as well as in mouse vas deferens bioassay studies 
(Bigoni et al., 2000a; Calo et al., 2000a; Calo et al., 2002b; Spagnolo et al., 2007; Trapella et al., 
2006). The correlation analysis of the present data with those previously obtained in the mouse vas 
deferens assay (data taken from the quoted articles) yielded a determination coefficient r2 of 0.90. 
Therefore it can be proposed that at least for ligand devoid of efficacy (i.e. pure antagonists), the 
Gαqi5 NOP receptor calcium assay generate results superimposable to those obtained with classical 
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techniques useful for studying Gi coupled receptors. This applies not only to antagonist potency but 
also to the type of antagonism as demonstrated, at least for J-113397, by the results of the Schild 
analysis. In fact a competitive type of NOP antagonism was demonstrated for J-113397 both by the 
present study and by previous investigations performed in the mouse vas deferens preparation 
(Bigoni et al., 2000a). 
 
All the NOP receptor full agonists evaluated in the present study were able to evoke 
maximal effects similar to those obtained with N/OFQ with the following order of potency: N/OFQ 
= N/OFQ(1-13)-NH2 > UFP-112 > Ro 64-6198 > NNC 63-0532 
These results are only partially in agreement with findings from literature. In fact, data 
regarding N/OFQ, N/OFQ(1-13)-NH2 and NNC 63-0532 perfectly match those obtained with 
[35S]GTPγS binding (McDonald et al., 2003b; Thomsen et al., 2000b) and mouse vas deferens and 
guinea pig ileum assays (Calo et al., 1996; Guerrini et al., 2004). On the contrary, in the same 
assays Ro 64-6198 displayed potency values similar to those of N/OFQ (Hashiba et al., 2002b; 
Jenck et al., 2000; Rizzi et al., 2001c) while UFP-112 was found to be 30 fold more potent than the 
naturally occurring peptide (Arduin et al., 2007; Rizzi et al., 2007b). Thus, the potency of both Ro 
64-6198 and UFP-112 is significantly lower in the Gαqi5 NOP receptor calcium assay than in other 
assays. The interpretation of these discrepant results is far from obvious. The chemical nature of the 
small molecule Ro 64-6198 and that of the N/OFQ analogue UFP-112 is very different suggesting 
that chemical features are not relevant. It is worthy of note that isolated tissue experiments 
demonstrated an important characteristic which is common to UFP-112 and Ro 64-6198. Indeed, as 
described in detail in previous publications (Arduin et al., 2007; Rizzi et al., 2007b), the kinetics of 
the inhibitory effect elicited by N/OFQ on the electrically induced twitch response is rapid and 
immediately and completely reversible after washing while that of both UFP-112 and Ro 64-6198 is 
characterized by slow onset, and slow and partial reversibility after washing. The slow kinetics of 
action of these ligands may be relevant for the estimation of their potency in the Gαqi5 NOP 
receptor calcium assay. In fact, the long time required to obtain full activation of NOP receptors 
with these agonists may be incompatible with the rapid kinetics which characterized the calcium 
transient response. The different kinetics of N/OFQ and UFP-112 recorded in isolated tissues could 
not be detected in the present calcium mobilization experiments (see Figure 21). However, we 
cannot exclude that the relative low potency displayed by UFP-112 and Ro 64-6198 in the calcium 
assay merely depends on subtle changes of the receptor pharmacological profile induced by the 
chimeric protein.  
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Results obtained with the panel of NOP partial agonists are different from those described in 
the literature in terms of ligand efficacy and, for a subset of compounds, ligand potency. All the 
ligands evaluated in the present study induced maximal effects lower than that of the natural peptide 
N/OFQ although these differences did not reach statistical significance. Thus ligand efficacy 
estimated in the Gαqi5 NOP receptor calcium assay is higher than in other assays. However this 
result is not completely unexpected. NOP receptor partial agonists displayed consistent efficacy 
often behaving as full agonists in the cAMP assay (Butour et al., 1998; Dooley et al., 1997; Kapusta 
et al., 2005b; Mason et al., 2001) while the same compounds showed limited and sometimes 
negligible efficacy in [35S]GTPγS binding studies (Berger et al., 2000b; Dooley et al., 1997; Kocsis 
et al., 2004; Mason et al., 2001). Thus, the estimated efficacy of this kind of ligand strongly 
depends on the efficiency of the stimulus-response coupling which is different in the different 
assays. Those tests in which signal amplification phenomena make the efficiency of the stimulus-
response coupling high (i.e. cAMP and calcium assays) tend to overestimate efficacy while those 
tests in which there is no amplification and the efficiency of the stimulus-response coupling is low 
(i.e. [35S]GTPγS binding) tend to underestimate efficacy. This concept has been experimentally 
validated in the study by McDonald et al. (2003a) where stimulus-response coupling of both the 
cAMP and [35S]GTPγS binding assays was modulated by changing the number of membrane 
receptors using a NOP inducible expression system. In this study partial agonist efficacy could be 
manipulated to encompass full and partial agonism along with pure antagonism (McDonald et al., 
2003a). 
In the present study the partial agonist order of potency was as follows: Ac-RYYRWK-NH2 
> Ac-RYYRIK-NH2 = Ac-RYYRIK-ol = [F/G]N/OFQ(1-13)-NH2 = UFP-113 > ZP120. Similarly 
to that found with full agonists these results are only partially in line with literature findings. 
Indeed, the following order of potency, which is in good agreement with the present results, has 
been described using classical tests for Gi coupled receptors: Ac-RYYRWK-NH2 > Ac-RYYRIK-
NH2 = Ac-RYYRIK-ol > [F/G]N/OFQ(1-13)-NH2 (Dooley et al., 1997; Gunduz et al., 2006; Kocsis 
et al., 2004; Mason et al., 2001). In contrast, UFP-113 (Arduin et al., 2007) and ZP120 (Kapusta et 
al., 2005b; Rizzi et al., 2002a) displayed potency values 10-30 fold higher than their templates 
([F/G]N/OFQ(1-13)-NH2 and Ac-RYYRWK-NH2 respectively). Interestingly, in the electrically 
stimulated mouse vas deferens ZP120 showed kinetics of action comparable to those described for 
Ro 64-6198 and UFP-112 (inhibitory effects slow to develop and slowly and only partially 
reversible after washing (Rizzi et al., 2002a). This kind of evidence is not available for UFP-113 
because this peptide produced variable agonist effects mainly behaving as a NOP antagonist in the 
mouse vas deferens (Arduin et al., 2007). However, a similar type of kinetics of action can be 
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hypothesized for UFP-113 based on its close structural similarities with UFP-112 (Arduin et al., 
2007). Therefore, as proposed for the NOP full agonists Ro 64-6198 and UFP-112, the relatively 
low potency of UFP-113 and ZP120 in the Gαqi5 NOP receptor calcium assay may be the 
consequence of the long time required to activate the NOP receptor with these ligands which is not 
compatible with the rapid kinetics of the calcium transient response.  
 
In conclusion, the present study confirmed and extended previous findings demonstrating 
that the chimeric protein Gαqi5 is indeed capable of coupling to NOP receptors to the Ca2+ 
signalling pathway. Moreover, results obtained from the detailed pharmacological characterization 
of the NOP receptor with the Gαqi5 calcium assay demonstrated that this approach represents a very 
useful strategy for the screening of NOP receptor antagonists. Results obtained with this class of 
ligands in the Gαqi5 NOP receptor calcium assay are superimposable to those collected with Gi 
based biochemical assays performed at recombinant or native NOP receptors or with bioassays 
performed on isolated tissues expressing native NOP receptors. In contrast, the usefulness of this 
assay for the screening of partial and full agonists appears to be limited by its tendency to estimate 
high efficacy for partial agonists and low potency for partial and full agonists characterized by slow 
kinetics of action. 
 
 
3.2 Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor 
ligand ZP120 
 
ZP120 is NOP receptor ligand (Larsen et al., 2001) which has been generated by applying 
the structure inducing probes technology (Larsen, 1999) to the NOP selective partial agonist Ac-
RYYRWK-NH2 (Dooley et al., 1997) with the aim of improving its metabolic stability and potency 
without modifying its pharmacodynamic properties. This strategy appeared to be successful since 
ZP120 has been demonstrated in in vitro experiments to bind to the NOP receptor with high 
affinity, to inhibit forskolin induced cAMP accumulation in HEK293hNOP cells and electrically 
induced contractions of the mouse vas deferens showing compared to N/OFQ higher potency and 
lower maximal effects (Kapusta et al., 2005b; Rizzi et al., 2002a). Furthermore in in vivo 
experiments ZP120 mimicked N/OFQ actions including the pronociceptive and locomotor 
inhibitory effects after supraspinal administration (Rizzi et al., 2002a) and the diuretic effects after 
intravenous administration (Kapusta et al., 2005b), showing a longer duration of action. 
Interestingly, unlike N/OFQ, ZP120 did not modify per se cardiovascular parameters but rather 
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antagonized the bradycardic and hypotensive action of N/OFQ (Kapusta et al., 2005b). This 
confirmed the findings obtained with other NOP receptor partial agonists i.e. [F/G]N/OFQ(1-13)-
NH2, Ac-RYYRWK-NH2 and Ac-RYYRIK-NH2 and corroborate the proposal that NOP receptor 
partial agonists produce functionally selective effects on cardiovascular and renal functions ranging 
from full agonist (water diuresis) to antagonist (bradycardia and hypotension) action (Kapusta et al., 
2005a). 
As far as the ZP120 receptor mechanism is concerned, we have previously reported that the 
effects of this peptide in the mouse vas deferens assay are resistant to naloxone while sensitive to 
the NOP selective antagonist J-113397 (Ozaki et al., 2000) which displayed similar pA2 values 
against ZP120 (7.80) and N/OFQ (7.81) (Rizzi et al., 2002a). Recently, it has been reported that 
N/OFQ and ZP120 are both able to inhibit in a concentration-dependent manner the contractions 
evoked by electrical field stimulation in rat mesenteric arteries (Simonsen et al., 2008). However, 
in this preparation, the NOP selective peptide antagonist UFP-101 (Calo et al., 2005; Calo et al., 
2002b) antagonized the action of N/OFQ but not that of ZP120 (Simonsen et al., 2008). Several 
important differences in terms of molecules (J-113397 vs UFP-101), preparations (vas deferens vs 
mesenteric arteries), and species (mouse vs rat) used in the two above mentioned studies do not 
allow an easy interpretation of these contrasting findings. Therefore the aim of the present study 
was to extensively investigate the pharmacological features of ZP120 by comparing its effects with 
N/OFQ in the mouse and rat vas deferens and by challenging the actions of these NOP agonists 
with both J-113397 and UFP-101. Moreover the in vitro (inhibition of electrically stimulated vas 
deferens) and in vivo (supraspinal pronociceptive effect) actions of ZP120 were reassessed in 
tissues taken from and in mice knockout for the NOP receptor gene, respectively. 
 
Results 
Electrically stimulated isolated tissues - The NOP receptor ligands N/OFQ and ZP120 inhibited the 
electrically induced contraction of the mouse and rat vas deferens in a concentration-dependent 
manner (Figure 26). N/OFQ displayed similar values of potency (pEC50 ≈ 7.3) and maximal effects 
(≈ 80% inhibition of control twitch) in mouse and rat tissues. ZP120 (pEC50 ≈ 8.8) was about 30 
fold more potent than N/OFQ but produced maximal effects (≈ 60% inhibition of control twitch) 
significantly lower than those of the natural peptide in both preparations. 
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Figure 26. Concentration response curves to N/OFQ and ZP120 in the electrically stimulated mouse (left 
panel) and rat (right panel) vas deferens. Data are the mean ± s.e.m. of 5 separate experiments. *p<0.05 vs 
N/OFQ, according to the Student t-test. 
 
 
In addition and confirming previous findings obtained in the mouse vas deferens (Rizzi et 
al., 2002a), the kinetics of the inhibitory effects elicited by ZP120 was different from that of 
N/OFQ in both preparations. The action of the natural peptide took place immediately after adding 
the peptide to the bath, was rapidly reversible after washing, and could be repeated in the same 
tissue, on the contrary, the effects of ZP120 were slow to develop, slowly reversible after washing, 
and could not be repeated in the same tissue. Typical tracings showing the concentration response-
curve to N/OFQ and ZP120 in the rat vas deferens are displayed in Figure 27. 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Typical tracings showing the concentration response curve to N/OFQ (0.1 nM-10 µM, left panel) 
and ZP120 (10 pM-100 nM; right panel) in the electrically stimulated rat vas deferens. 
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As shown in the Figure 28, the effects of N/OFQ and ZP120 were evaluated in the presence 
of the NOP selective antagonists UFP-101 (1 µM) and J-113397 (100 nM) in both preparations. 
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Figure 28. Concentration-response curves to N/OFQ (left panels) and ZP120 (right panels) measured in the 
absence and in presence of UFP-101 (1 µM) and J-113397 (100 nM) in the electrically stimulated mouse 
(top panels) and rat (bottom panels) vas deferens. Data are the mean ± s.e.m. of 4 separate experiments. 
 
 
Both the antagonists did not modify per se the control twitches. In the mouse and rat vas 
deferens J-113397 produced a rightward shift of the concentration-response curve to N/OFQ 
without significantly affecting the maximal agonist response. J-113397 pKB values derived from 
these experiments were 7.69 and 8.04, respectively. Superimposable results were obtained by 
challenging J-113397 vs ZP120. J-113397 competitively antagonized ZP120 effects in the mouse 
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and rat tissues with the following pKB values: 7.76 and 7.89. In the mouse and rat vas deferens the 
NOP selective antagonist UFP-101 displaced to the right the concentration-response curve to 
N/OFQ yielding pKB values of 7.37 and 6.79, respectively. UFP-101 did not modify the inhibitory 
effect of ZP120 in both preparations. Antagonist pKB values obtained from these experiments are 
summarized in Table 4. 
 
Table 4. pKB values of UFP-101 and J-113397 vs N/OFQ and ZP120 in the electrically stimulated mouse 
and rat vas deferens. Data are mean of 4 separate experiments. CL95%: confidence limit. 
 
 Mouse Vas Deferens Rat Vas Deferens 
 pKB (CL95%) pKB (CL95%) 
   
 UFP-101 J-113397 UFP-101 J-113397 
     
N/OFQ 7.37 (7.13-7.61) 
7.69 
(7.17-8.22) 
6.79 
(6.45-7.13) 
8.04 
(7.54-8.54) 
ZP120 <6 7.76 (7.67-7.85) <6 
7.89 
(7.02-8.76) 
 
 
The effects of N/OFQ and ZP120 and those elicited by the selective DOP agonist DPDPE, 
were investigated in the electrically stimulated mouse vas deferens taken from NOP(+/+) and 
NOP(-/-) mice (Figure 29). 
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Figure 29. Electrically stimulated mouse vas deferens. Concentration response curve to N/OFQ, ZP120 and 
DPDPE in tissues taken from NOP(+/+) and NOP(-/-) mice. Data are the mean ± s.e.m. of 4 separate 
experiments. 
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In NOP(+/+) tissues, ZP120 mimicked the inhibitory effect of N/OFQ (pEC50 7.62; Emax 91 
± 1%) showing higher potency (pEC50 9.10) but lower maximal effects (Emax 73 ± 3%). In tissues 
taken from NOP(-/-) mice, N/OFQ was found inactive and ZP120 slightly inhibited the electrically 
induced contraction only at the highest concentration tested (0.3 µM). In parallel experiments, the 
DOP receptor selective agonist DPDPE displayed similar potency (pEC50 8.40 and 8.20) and 
maximal effects (Emax 93 ± 3% and 91 ± 5%) in tissues taken from NOP(+/+) and NOP(-/-) mice, 
respectively. The values of potency and maximal effects derived from concentration response 
curves to N/OFQ and ZP120 in the electrically stimulated vas deferens taken from rats and mice 
(Swiss, NOP(+/+) and NOP(-/-)) are summarized in Table 5. 
 
Table 5. Effects of N/OFQ and ZP120 in the electrically stimulated mouse and rat vas deferens. Data are 
mean of 5 separate experiments. CL95%: confidence limit. ND: could not be determined. *p<0.05 vs N/OFQ, 
according to the Student t-test. 
 
 Mouse Vas Deferens  Rat Vas Deferens 
 Swiss mice NOP(+/+) mice NOP(-/-) mice   
 
pEC50 
(CL95%) 
Emax ± 
s.e.m. 
pEC50 
(CL95%) 
Emax ± 
s.e.m. 
pEC50 
(CL95%) 
Emax ± 
s.e.m. 
 
pEC50 
(CL95%) 
Emax ± 
s.e.m. 
          
N/OFQ 7.37 (7.27-7.47) 80 ± 2% 
7.62 
(7.56-7.68) 91 ± 1% < 6 ND  
7.25 
(7.08-7.42) 83 ± 2% 
ZP120 8.78 (8.61-8.95) 56 ± 3%* 
9.10 
(8.88-9.32) 73 ± 3%* < 6 ND  
8.80 
(8.41-9.19) 64 ± 4%* 
 
 
Mouse tail withdrawal assay - NOP(+/+) mice injected i.c.v. with saline did not show any 
modification of gross behaviour. Those injected with high doses of N/OFQ (10 nmol) or ZP120 (1 
nmol) displayed a clear decrease in locomotor activity and muscular tone, ataxia, and partial loss of 
the righting reflex. These actions on mice gross behaviour were previously reported in Swiss mice 
both for N/OFQ (Calo et al., 1998b) and ZP120 (Rizzi et al., 2002a). The i.c.v. injection of these 
peptides in NOP(-/-) mice did not produce any obvious modifications of their spontaneous 
behaviour. 
Results summarized in Figure 30 (left panel) show that baseline tail withdrawal latency of 
NOP(+/+) mice was 5.04 ± 0.73 s. In animals treated with saline this parameter was stable around 
5-6 s over the time course of the experiment. The i.c.v. administration of 10 nmol N/OFQ produced 
an immediate (peak effect at 5 min) pronociceptive action which lasted for approx 1 h. The 
injection of 1 nmol ZP120 mimicked the pronociceptive effect of N/OFQ, however it was 
characterized by a slow onset of action (peak effect at 120-180 min) and was longer lasting with the 
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reduction of tail withdrawal latency still evident after 3h from peptide injection. This pattern of 
effects of N/OFQ and ZP120 is superimposable to that previously reported in Swiss mice (Calo et 
al., 1998b; Rizzi et al., 2002a). 
In line with previous findings (Nishi et al., 1997), baseline latency of NOP(-/-) mice (5.21 ± 
0.90 s) was similar to that of NOP(+/+) mice. The injection of saline in NOP(-/-) animals produced 
a slight increase in tail-withdrawal latency which was then stable over the time course of the 
experiment (Figure 30, right panel). In NOP(-/-) mice, the i.c.v. injection of both N/OFQ and ZP120 
did not produce any effect with tail withdrawal latencies superimposable to that of saline treated 
animals (Figure 30, right panel). 
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Figure 30. Effects of 10 nmol N/OFQ and 1 nmol ZP120 given i.c.v. in the tail withdrawal assay performed 
in NOP(+/+) (left panel) and NOP(-/-) (right panel) mice. Data are the mean ± s.e.m. of 4 separate 
experiments. *p<0.05 and **p<0.01 versus saline according to ANOVA followed by the Dunnett's test. 
 
 
Discussion 
This study provides novel evidence that confirms and extends our knowledge of the 
pharmacological profile of ZP120 in rodents. This peptide behaves as a selective NOP receptor 
partial agonist and displays kinetics of action characterized by slow onset and long lasting effects. 
The antagonist sensitivity of ZP120 effects (J-113397 sensitive, naloxone and UFP-101 resistant) is 
not superimposable to that of the endogenous NOP ligand N/OFQ (J-113397 and UFP-101 
sensitive, naloxone resistant). However the exclusive involvement of the NOP receptor protein in 
the in vitro as well as in vivo effects of ZP120 (and N/OFQ) was clearly demonstrated by knockout 
studies. Therefore the different sensitivity of N/OFQ and ZP120 to UFP-101 can be attributed to 
their diverse way of binding to and activating the NOP receptor. 
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The present data obtained in parallel experiments performed on mouse and rat tissues 
confirmed previous finding (Kapusta et al., 2005b; Rizzi et al., 2002a; Simonsen et al., 2008) 
demonstrating that ZP120 behaves as a NOP receptor partial agonist. The following evidence and 
considerations make this pharmacological feature of ZP120 extremely important. Partial agonists 
may discriminate between the different pharmacological effects evoked by full agonists in different 
systems/organs depending on the efficiency of the stimulus-response coupling that characterize 
each of the systems/organs (Kenakin, 2004). This has been demonstrated for the cardiovascular and 
renal effects of NOP ligands. I.v. administration of the full agonist N/OFQ produce in rodents 
cardiovascular inhibitory effects (i.e. hypotension and bradycardia) associated with diuretic, in 
particular aquaretic, effects (Kapusta, 2000). In contrast, i.v. administration of NOP receptor partial 
agonists ([F/G]N/OFQ(1-13)-NH2, Ac-RYYRWK-NH2 and Ac-RYYRIK-NH2) only mimicked the 
renal effects of N/OFQ without modifying cardiovascular parameters (Kapusta, 2000). This same 
pattern of effects was demonstrated for ZP120 (Kapusta et al., 2005b). Therefore in water-retaining 
states with hyponatremia such as heart failure, NOP receptor partial agonists like ZP120 represent a 
better therapeutic option than full agonists. In addition to partial agonist behaviour, ZP120 displays 
slow onset, long lasting effects with high potency. These features have been confirmed in the 
present study both in vitro and in vivo and are in line with that reported in the literature. ZP120 has 
been shown to mimic with higher potency and longer lasting effects the following N/OFQ actions: 
inhibition of locomotor activity and pronociceptive effects after supraspinal administration in mice 
(Rizzi et al., 2002a) and sodium-sparing aquaretic activity after i.v. administration in rats (Kapusta 
et al., 2005b). Collectively these pharmacological features make ZP120 a promising and innovative 
drug candidate for treating heart failure (Lambert, 2008). 
The receptor mechanisms involved in ZP120 actions was investigated by using two 
chemically unrelated and selective NOP receptor antagonists the peptide UFP-101 (Calo et al., 
2005; Calo et al., 2002b) and the non-peptide J-113397 (Ozaki et al., 2000) as well as mice knock 
out for the NOP receptor gene (Nishi et al., 1997). UFP-101 and J-113397 represent standard 
antagonists for NOP receptor investigations with more than 50 papers reported in literature for each 
of these molecules describing their antagonist properties vs N/OFQ (Chiou et al., 2007; Lambert, 
2008). In line with this picture, in the present study both molecules competitively antagonized 
N/OFQ effects in mouse and rat tissues showing the expected order of potency of antagonists i.e. J-
113397 (pKB ≈ 7.8) > UFP-101 (pKB ≈ 7.3). J-113397 was also found to be active against ZP120 
whose effects were antagonized in both preparations with pKB values superimposable to those 
obtained against N/OFQ. In contrast, UFP-101 was found inactive against ZP120. Similar findings 
were obtained in separate studies where the effects of N/OFQ and ZP120 in the mouse vas deferens 
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were found to be sensitive to J-113397 (Rizzi et al., 2002a) while those of N/OFQ but not ZP120 to 
be sensitive to UFP-101 in rat mesenteric arteries (Simonsen et al., 2008). Since we investigated in 
parallel studies both rat and mouse preparations obtaining consistent pharmacological results in 
tissues from the two species, we can rule out that species specific NOP receptor isoforms play a role 
in the pattern of antagonist sensitivity of ZP120 effects. As mentioned above ZP120 differs from 
N/OFQ in terms of kinetics of action and this might be relevant for antagonist sensitivity. However, 
other NOP selective peptide agonists such as UFP-102 (Carra et al., 2005b) and UFP-112 (Arduin 
et al., 2007) characterized by kinetics of action superimposable to that of ZP120 were found to be 
sensitive to the antagonist effect of UFP-101 (Carra et al., 2005b; Rizzi et al., 2007b), thus 
suggesting that the agonist kinetics of action are not important for the pattern of antagonist 
sensitivity. A different receptor mechanism can be suggested to interpret the diverse antagonist 
sensitivity of ZP120 and N/OFQ. However, the in vitro and in vivo knockout studies performed in 
the frame of the present study clearly demonstrated that the effects of both agonists, which are no 
longer evident in NOP(-/-) tissues and animals, are due to the selective activation of the NOP 
receptor protein. Therefore, the most reasonable suggestion that can be proposed to collectively 
interpret these findings is that by Simonsen et al. (2008) i.e. N/OFQ and the hexapeptide Ac-
RYYRWK-NH2 (from which ZP120 derives) have distinct modes of interaction with the NOP 
receptor and UFP-101 is able to discriminate between them by blocking N/OFQ binding but not that 
of ZP120. This suggestion is corroborated by the following evidence: in elegant photoaffinity 
labelling studies the group of Meunier investigated the NOP receptor regions that bind N/OFQ and 
hexapeptides; in particular N/OFQ binds to extracellular loop III and transmembrane helix VII 
(Mouledous et al., 2000) while the hexapeptides bind to transmembrane helix II (Bes et al., 2003). 
However, some overlapping of the NOP receptor regions that recognized N/OFQ and hexapeptides 
should be hypothesized because the binding of N/OFQ and hexapeptides to the NOP receptor is 
mutually exclusive as demonstrated by receptor binding studies (Dooley et al., 1997; Thomsen et 
al., 2000b) and by functional antagonist studies performed in those preparations/assays in which the 
hexapeptides (or their analogues) displayed small or no efficacy and where a competitive type of 
interaction has been reported for these peptides. These antagonist studies were performed 
investigating [35S]GTPγS binding to G proteins in membranes and sections of rat brain (Berger et 
al., 1999), chronotropic effect on neonatal rat cardiomyocytes (Berger et al., 1999), the electrically 
stimulated mouse vas deferens (Gunduz et al., 2006; Li et al., 2008) or the cardiovascular 
parameters of the rat (Kapusta et al., 2005a). On the other hand, the NOP receptor site recognized 
by UFP-101, which might be similar but not identical to that of N/OFQ, is not overlapping with that 
of the hexapeptides and this may explain the lack of effect of UFP-101 against ZP120 reported by 
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Simonsen et al. (2008) in rat mesenteric arteries and confirmed in the present study in vas deferens 
tissues from rats and mice. 
In conclusion, the present investigation demonstrated via in vitro and in vivo receptor 
knockout studies that ZP120 is a highly selective NOP receptor ligand. Moreover a diverse 
antagonist sensitivity of N/OFQ (J-113397 and UFP-101 sensitive) and ZP120 (J-113397 sensitive 
and UFP-101 resistant) which can not be explained in terms of species specific NOP receptor 
isoforms, diverse agonist kinetics of action, or different receptor mechanism, was reported. This 
diverse antagonist sensitivity may derive from different mechanisms of binding to the NOP receptor 
for N/OFQ, ZP120, and UFP-101. Collectively this study provides further evidence that ZP120 
behaves as a selective NOP receptor partial agonist characterized by high potency and able to evoke 
slow onset long lasting effects. Collectively these pharmacological features make ZP120 not only a 
useful pharmacological tool to be used in preclinical investigations but also a drug candidate for 
exploiting the therapeutic benefits derived by a prolonged partial activation of peripheral NOP 
receptors. 
 
 
3.3 Pharmacological characterization of the nociceptin/orphanin FQ receptor non-peptide 
antagonist Compound 24 
 
A novel NOP receptor non-peptide antagonist, 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4’-
piperidin-1-yl]propyl} pyrrolidine-2-carboxamide, has been recently identified by Banyu 
investigators and named Compound 24 (Goto et al., 2006). The synthesis of this novel ligand is 
relatively easy and the overall yield relatively high (25% in our laboratory, 31% in Goto et al. 
(2006)). This is particularly true when compared to the synthesis of other non-peptide NOP 
antagonists such as J-113397 and SB-612111 whose synthesis is very difficult and of low overall 
yield (≈ 1% for both molecules in our laboratories, C. Trapella personal communication). 
Thus, the aim of the present study was the synthesis and detailed investigation of the 
pharmacological profile of Compound 24. The novel ligand was investigated in vitro in receptor 
binding and [35S]GTPγS experiments performed in CHOhNOP cell membranes, in calcium 
mobilization experiments performed in CHOhNOP cells expressing the Gαqi5 protein, and in N/OFQ 
sensitive isolated tissues. Finally, the in vivo actions of Compound 24 were assessed in mice using 
the tail withdrawal assay. 
 
 
 89 
Results 
Receptor binding assay - In receptor binding experiments performed on CHOhNOP cell membranes 
Compound 24 displaced [3H]N/OFQ in a concentration-dependent manner with subnanomolar 
affinity (pKi 9.62, Table 6). Under the same experimental conditions, Compound 24 did not bind 
the hDOP receptor and showed low affinities for MOP and KOP sites (pKi 6.72 and 6.47, 
respectively). In contrast, the universal opioid receptor ligand naloxone did not bind the NOP 
receptor but displayed the expected rank order of affinity at classical opioid receptors i.e. MOP (pKi 
9.25) > KOP (pKi 8.35) > DOP (pKi 7.67) (Table 6). 
 
 
Table 6. Affinities of Compound 24 and naloxone at NOP and classical opioid receptors expressed in CHO 
cell membranes. 
 
receptor NOP MOP DOP KOP 
radioligand [3H]N/OFQ [3H]DPN [3H]DPN [3H]DPN 
     
naloxonea  < 6 9.25 (9.04 – 9.46) 
7.67 
(7.59 – 7.75) 
8.35 
(8.20 – 8.50) 
Compound 24 9.62 (9.47 – 9.77) 
6.72 
(6.43 – 6.97) < 6 
6.47 
(6.20 – 6.74) 
 
a: naloxone affinities at classical opioid receptors are from Vergura et al. (2008). Data are mean (CL95%) of 3 
separate experiments. 
 
 
 
[35S]GTPγS binding assay - In CHOhNOP cell membranes N/OFQ stimulated [35S]GTPγS binding in 
a concentration-dependent manner with a pEC50 value of 8.95 ± 0.05 and Emax of 11.71 ± 0.37 
(Figure 31, left panel). The antagonistic properties of Compound 24 were evaluated over the 1-100 
nM concentration range, in order to obtain data for a Schild analysis. Compound 24 up to 10 µM 
did not elicit any stimulation of [35S]GTPγS binding in CHOhNOP cell membranes, however it 
produced a concentration-dependent and parallel shift of the concentration response curve to 
N/OFQ without modifying the maximal effects induced by the agonist (Figure 31, left panel). 
Schild analysis of the data (Figure 31, right panel) demonstrated a linear (r2 = 0.95) plot with a 
slope not significantly different from unity. The extrapolated pA2 value was 9.98. 
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Figure 31. Left panel: concentration response curves to N/OFQ obtained in the absence (control) and 
presence of increasing concentrations of Compound 24 (1 – 100 nM) in the [35S]GTPγS binding assay 
performed on CHOhNOP cell membranes. The relative Schild Plot is shown in the right panel. Data are mean ± 
s.e.m. of 4 separate experiments. 
 
 
Calcium mobilization assay - In CHOhNOP cells stably expressing the Gαqi5 chimeric protein N/OFQ 
evoked a concentration-dependent stimulation of calcium release (pEC50 9.24 (CL 95% 9.10 – 9.38)). 
Compound 24 was inactive per se but in the range 0.01 nM–10 µM concentration-dependently 
inhibited calcium mobilization induced by 10 nM N/OFQ with a pKB value of 9.03 ± 0.20 (Table 
7).  
 
Table 7. Antagonist potencies of Compound 24 and naloxone evaluated in calcium mobilization experiments 
performed in CHO cells expressing NOP or classical opioid receptors and the Gαqi5 protein. 
 
receptor NOP MOP DOP KOP 
agonist N/OFQ 10 nM 
Dermorphin 
100 nM 
DPDPE 
100 nM 
Dynorphin A 
100 nM 
     
naloxone < 6 9.09 (8.73-9.45) 
7.32 
(6.11-8.53) 
7.14 
(6.60-7.68) 
Compound 24 9.03 (8.83-9.23) < 6 < 6 < 6 
 
Data are mean (CL95%) of 4 separate experiments. 
 
Naloxone was inactive up to 1 µM. To assess the selectively of action of Compound 24 
similar experiments were performed in CHO cells stably expressing Gαqi5 and classical opioid 
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receptors. Dermorphin, DPDPE and dynorphin A were used in these experiments as agonists for 
MOP, DOP and KOP receptors, respectively. They produced a concentration-dependent stimulation 
of calcium mobilization with the following values of pEC50 and Emax: dermorphin 7.93 (CL 95% 7.67 
– 8.19), 196 ± 9%; DPDPE 8.82 (CL 95% 8.43 – 9.21), 130 ± 10%; dynorphin A 8.47 (CL 95% 8.16 – 
8.78) 174 ± 14%. Naloxone inhibited the effects of these agonists showing higher potency at MOP 
(pKB 9.09) than KOP (pKB 7.14) and DOP (pKB 7.32) (Table 7). In contrast Compound 24 was 
inactive up to 1 µM against DPDPE, dynorphin A, and dermorphin (Table 7). 
 
To investigate the type of antagonism produced by Compound 24 in calcium mobilization 
experiments a Schild analysis has been performed by testing this molecule at various concentrations 
(0.01, 0.1 and 1 µM) against the concentration-response curve to N/OFQ. As shown in Figure 32, 
Compound 24 produced a rightward shift of the concentration-response curve to N/OFQ in a 
concentration-dependent manner. However, the maximal effects elicited by N/OFQ appear to be 
slightly but significantly reduced by Compound 24. A pKB value of 8.73 was derived from these 
experiments. It is worthy of note that this value is close to that obtained in inhibition response 
experiments (9.03). 
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Figure 32. Concentration response curves to N/OFQ obtained in the absence (control) and presence of 
increasing concentrations of Compound 24 (10 nM - 1 µM) in the calcium mobilization assay performed in 
CHOhNOP cells stably expressing the Gαqi5 protein. Data are mean ± s.e.m. of 4 separate experiments 
performed in duplicate. *p<0.05 versus control according to ANOVA followed by Dunnett’s test. 
 
 
Electrically stimulated isolated tissues - Compound 24 was assessed against N/OFQ in the 
electrically stimulated mouse and rat vas deferens and guinea pig ileum. In the mouse vas deferens 
N/OFQ inhibited the twitch response to electrical field stimulation in a concentration-dependent 
 92 
manner (pEC50 value 7.46, Figure 33 left panel). Compound 24, tested over the concentration range 
10 nM -1 µM, did not modify per se the electrically-induced twitches, but displaced to the right the 
concentration response curve to N/OFQ in a concentration-dependent manner. Curves obtained in 
the presence of Compound 24 were parallel to the control (Figure 33, left panel) with no 
modification of the agonist maximal effect. The corresponding Schild plot was linear (r2 = 1.00) 
with a slope not significantly different from unity, yielding a pA2 value of 8.44 (Figure 33, right 
panel). 
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Figure 33. Left panel: concentration response curves to N/OFQ obtained in the absence (control) and 
presence of increasing concentrations of Compound 24 (10 nM – 1 µM) in the electrically stimulated mouse 
vas deferens. The relative Schild Plot is shown in the right panel. Data are mean ± s.e.m. of 4 separate 
experiments. 
 
 
In the rat vas deferens and in guinea pig ileum Compound 24 was tested at the single 
concentration of 100 nM against the effects of N/OFQ. In both preparations the concentration 
response curves to N/OFQ obtained in the absence and presence of Compound 24 were parallel and 
reached similar maximal effects. The estimated pKB values were 8.28 ± 0.12 and 9.12 ± 0.19 in the 
rat vas deferens (Figure 34, left panel) and guinea pig ileum (Figure 34, right panel), respectively. 
In these preparations, Compound 24 up to 1 µM was per se inactive. 
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Figure 34. Concentration response curves to N/OFQ obtained in the absence (control) and presence of 100 
nM Compound 24 in the electrically stimulated rat vas deferens (left panel) and guinea pig ileum (right 
panel). Data are mean ± s.e.m. of 4 separate experiments. 
 
 
Finally, Compound 24 at 1 µM did not modify the inhibitory effects of DPDPE in the mouse 
vas deferens (control: pEC50 (95% confidence limit) 8.38 (8.20 - 8.56), Emax, 98 ± 1%; 1 µM 
Compound 24: pEC50 8.30 (7.80 - 8.80), Emax, 99 ± 1%) or those evoked by dermorphin in the 
guinea pig ileum (control: pEC50 8.52 (8.35 - 8.69), Emax, 98 ± 3%; 1 µM Compound 24: pEC50, 
8.51 (8.35 - 8.67), Emax, 95 ± 3%). 
 
Tail withdrawal assay - In tail withdrawal experiments, mice injected with vehicle (either i.c.v. or 
i.t.) displayed tail withdrawal latencies of approximately 5 s that were stable over the time course of 
the experiment (Figure 35). In line with previous studies, N/OFQ (1 nmole) applied i.c.v. 
significantly reduced tail withdrawal latency with a maximal effect (about 50% reduction in tail 
withdrawal latency) obtained at 5 min (AUC[0-15 min] vehicle 77 ± 5; 1 nmole of N/OFQ 51 ± 3, p< 
0.05). The i.p. administration of Compound 24 up to 10 mg/kg did not modify, per se, tail 
withdrawal latencies (AUC[0-15 min], 80 ± 7) but prevented the pronociceptive effects of the natural 
peptide (AUC[0-15 min], 66 ± 5) (Figure 35, left panel). When the same dose of N/OFQ was 
administered i.t., a statistically significant antinociceptive effect was recorded (AUC[0-30 min] vehicle, 
165 ± 14; 1 nmole of N/OFQ 346 ± 25, p < 0.05) (Figure 35, right panel). This antinociceptive 
effect was reduced by Compound 24 (AUC[0-30 min], 226 ± 25) (Figure 35, right panel). 
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Figure 35. Mouse tail withdrawal assay. Effects of Compound 24 (10 mg/kg i.p., 30 min pre-treatment) on 
the pronociceptive or antinociceptive effects induced by 1 nmole N/OFQ injected i.c.v. (left panel) or i.t. 
(right panel). Data are mean ± s.e.m. of 4 separate experiments. *p<0.05 versus vehicle according to 
ANOVA followed by the Dunnett's test. 
 
 
Discussion 
The present study extend previous findings (Goto et al., 2006) demonstrating that 
Compound 24 binds with high affinity to the NOP receptor and behaves as a pure and potent NOP 
receptor antagonist with high selectivity over classical opioid receptor. These pharmacological 
features of Compound 24 were consistently observed in various assays and preparations expressing 
the human recombinant as well as the animal native receptors. In addition, the NOP antagonistic 
properties of Compound 24 have been confirmed in vivo in mice in the tail withdrawal assay. 
Therefore, Compound 24 represents a valuable research tool that should be included in the class of 
selective NOP receptor antagonists and used in future target validations studies.  
In receptor binding studies Compound 24 displayed very high affinity for the NOP receptor. 
The pKi value calculated from the present experiments (9.62) is virtually superimposable to that 
previously reported by Goto et al. (2006) (pIC50 9.57). These values of affinity are similar to that 
reported for SB-612111 and higher than that of J-113397 (Ozaki et al., 2000; Spagnolo et al., 2007; 
Zaratin et al., 2004). In functional studies performed on the human recombinant receptor 
([35S]GTPγS binding and calcium mobilization assays) and on animal native receptors from various 
species (mouse, rat, guinea pig) Compound 24 consistently behaved as a pure NOP receptor 
antagonist showing, in line with receptor binding studies, high values of potency (range 8.28 – 
9.12). The only result which was out of this range is that obtained in [35S]GTPγS binding studies 
where Compound 24 displayed a pA2 of 9.98. However, this result, which is again superimposable 
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to that obtained by Goto et al. (2006) (pIC50 9.82), is expected on the basis of what we have 
observed with several NOP receptor antagonists, including the peptides [Nphe1]N/OFQ(1–13)-NH2 
and UFP-101 (Calo et al., 2005; Calo et al., 2002a), and the non-peptides J-113397, Trap-101, and 
SB-612111 (Spagnolo et al., 2007; Trapella et al., 2006), that consistently showed, in this particular 
assay, values of potency approximately 10 fold higher than in the other tests. As previously 
suggested (Spagnolo et al., 2007), this might be due to the higher receptor accessibility in 
membranes (where the [35S]GTPγS binding assay is performed) than in whole cells or tissue 
preparations (where the other assays are performed). Despite this minor difference, very similar 
antagonist potency values were obtained in the different assays for Compound 24 demonstrating the 
recombinant and native as well as species-specific NOP receptors are similarly sensitive to this 
antagonist. This also applies to the NOP receptors expressed in rat periaqueductal gray slices (Yan-
Yu et al., 2008) and sympathetic neurons (Ruiz-Velasco et al., 2008) although no quantitative data 
were reported in these latter studies. The consistency of Compound 24 potency values among 
preparations and species corroborates previous findings obtained with peptide (Calo et al., 2000a; 
Calo et al., 2005; Calo et al., 2002a; Calo et al., 2002b) and non-peptide (Bigoni et al., 2000a; 
Ozaki et al., 2000; Spagnolo et al., 2007; Trapella et al., 2006; Zaratin et al., 2004) NOP 
antagonists and enable the following rank order of antagonist potency to be proposed: Compound 
24 (≈8.5) = SB-612111 (≈8.5) > J-113397 (≈8.0) > UFP-101 (≈7.5) = Trap-101 (≈7.5) > 
[Nphe1]N/OFQ(1–13)-NH2 (≈6.5) as NOP receptor fingerprint.  
 
With respect to the type of antagonism exerted by Compound 24, results obtained in the 
[35S]GTPγS binding and mouse vas deferens assay by performing concentration response curve to 
N/OFQ in the presence of increasing concentrations of antagonist are clearly compatible with a 
competitive type of interaction between Compound 24 and N/OFQ. Similar results were obtained 
by testing Compound 24 in the calcium mobilization assay where a rightward displacement of the 
concentration response curve to N/OFQ was recorded in response to increasing concentration of 
antagonist. However in these experiments Compound 24 at the highest concentrations tested 
produced a slight but statistically significant reduction of N/OFQ maximal effect. This apparent 
insurmountable antagonism behaviour can be attributed to i) the transient nature of the calcium 
response that may not allow equilibrium between agonist–antagonist competition to be reached thus 
generating depression of the agonist response in the presence of high concentrations of antagonist 
(Kenakin, 2004), ii) lack of stirring in the 96 well plate which is another source of hemiequilibrium 
conditions (Kenakin, 2004), iii) a combination of the two factors. The observation that a truly 
competitive antagonist produces a reduction of agonist maximal effects in calcium mobilization 
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assay is not uncommon. For instance, the urotensin-II receptor antagonists urantide and UFP-803 
competitively antagonized the contractile effects of urotensin-II in the rat aorta bioassay while 
depressed maximal responses to the agonist in calcium experiments performed on cells expressing 
the rat recombinant urotensin-II receptor (Camarda et al., 2006). On this basis, we propose to 
classify Compound 24 as a competitive NOP receptor antagonist. 
 
Selectivity of action along with high affinity/potency and pure antagonist activity is another 
important feature of a valuable research tool. This property of Compound 24 has been evaluated in 
three sets of experiments over classical opioid receptors. In receptor binding studies Compound 24 
displayed approximately 1000 fold selectivity over classical opioid receptors. A superimposable 
value of selectivity was found in functional studies performed measuring calcium mobilization in 
cells expressing the Gαqi5 chimeric protein. Finally at least 300 fold selectivity of Compound 24 for 
NOP over MOP and DOP was obtained in bioassay experiments. These data confirm the impressive 
selectivity profile of Compound 24 reported by Goto et al. (2006). Thus, in terms of selectivity over 
classical opioid receptor Compound 24 seems to be similar to SB-612111 (Spagnolo et al., 2007; 
Zaratin et al., 2004) and UFP-101 (Calo et al., 2002b) and certainly more selective then J-113397 
(Ozaki et al., 2000; Spagnolo et al., 2007) for which NOP independent effects were reported in vivo 
(Koizumi et al., 2004). However more comprehensive selectivity studies are needed against a large 
panel of receptors and ion channels to firmly classify Compound 24 as a highly selective NOP 
receptor antagonist.  
Collectively, these in vitro data confirm and extend previous findings (Goto et al., 2006) 
demonstrating that Compound 24 is a pure, competitive, selective and potent NOP receptor 
antagonist. This excellent in vitro pharmacological profile is associated with good brain penetration 
after peripheral administration (Goto et al., 2006). Indeed, Compound 24 was reported to be active 
in vivo in mice where at 10 mg/kg it prevented the inhibitory effects on locomotor activity of a non-
peptide NOP agonist (Goto et al., 2006). Here we assessed the in vivo effects of Compound 24 in 
the mouse tail withdrawal assay. N/OFQ has been repeatedly demonstrated to exert in rodents 
pronociceptive and antinociceptive effects following supraspinal and spinal injection, respectively 
(Zeilhofer et al., 2003). The present results i.e. pronociceptive and antinociceptive response to 1 
nmole N/OFQ given i.c.v. and i.t., are therefore in line with the literature. Both of these in vivo 
actions of N/OFQ are due to selective NOP receptor activation as consistently demonstrated by 
knockout (Nazzaro et al., 2007; Nishi et al., 1997) and receptor antagonist (UFP-101 (Calo et al., 
2002b; Nazzaro et al., 2007), J-113397 (Ozaki et al., 2000; Ueda et al., 2000), SB-612111 (Rizzi et 
al., 2007a; Zaratin et al., 2004)) studies. In line with these findings, Compound 24 at 10 mg/kg 
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antagonised both the pronociceptive and antinociceptive effects evoked by N/OFQ when given 
spinally and supraspinally, respectively. This result confirms on the one hand that Compound 24 is 
an effective antagonist at NOP receptors regulating pain transmission in vivo and on the other that 
the effects of N/OFQ on pain transmission are exclusively due to NOP receptor activation. 
Interestingly, Compound 24 at 10 mg/kg counteracted rather than fully prevented the effects of 1 
nmole N/OFQ. Under the same experimental conditions SB-612111 completely blocked the actions 
of the same dose of N/OFQ at ten fold lower doses (i.e. 1 mg/kg) (Rizzi et al., 2007a). Therefore 
SB-612111 appeared to be more potent than Compound 24 in vivo in the mouse tail withdrawal 
assay. Since the in vitro potency of the two antagonists is similar (see above), it can be proposed 
that in vivo potency differences may derive from better pharmacokinetic properties of SB-612111 
than Compound 24. However, this is merely speculation that required rigorous experimental 
validation. Finally, the systemic administration of Compound 24 at pharmacologically active doses 
did not modify per se tail withdrawal latencies. Again this is in line with previous findings obtained 
with both receptor antagonists (Ozaki et al., 2000; Rizzi et al., 2007a; Ueda et al., 2000; Zaratin et 
al., 2004) and mice knockout for the NOP receptor gene (Nazzaro et al., 2007; Nishi et al., 1997), 
and indicates that the endogenous N/OFQ-NOP receptor system is not activated by the mild and 
acute stimulus employed for evoking the nociceptive response in this assay. However, endogenous 
N/OFQergic signalling can be activated using more intense and prolonged nociceptive stimuli such 
as formalin. In fact in the mouse formalin assay the spinal antinociceptive action of endogenous 
N/OFQ seems to prevail over the supraspinal pronociceptive effect as indicated by the 
pronociceptive phenotype of NOP knockout mice (Depner et al., 2003; Rizzi et al., 2006) (recently 
confirmed in the acetic acid-induced writhing test by Rizzi et al. (2008)) and by the pronociceptive 
effects elicited by NOP antagonists e.g. systemic J-113397 (Rizzi et al., 2006).  
 
In conclusion the present study demonstrated that Compound 24 is a pure, competitive, 
selective and potent NOP receptor antagonist. The NOP antagonist properties of Compound 24 
were demonstrated in a large panel of in vitro assays and in vivo in the mouse tail withdrawal assay. 
Based on its pharmacological profile, Compound 24 should be included (together with J-113397, 
SB-612111 and UFP-101) in the list of potent and selective NOP receptor antagonists to be tested in 
future target validation studies to firmly define their therapeutic potential as innovative drugs for 
treating depression, Parkinson’s disease and possibly sepsis.  
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3.4 Blending of chemical moieties of NOP receptor ligands: identification of a novel antagonist 
 
Compound 24 displays some chemical characteristics typical of N/OFQ related peptides 
(Figure 36), these include: i) a spacer of 12 atoms between the two phenyl rings which corresponds 
to the Phe-Gly-Gly-Phe sequence of the N/OFQ message domain; ii) an amide bond which is quite 
uncommon in non-peptide NOP ligands; iii) a N-benzyl amino acid, a chemical moiety also present 
in the N-terminal part of the NOP receptor peptide antagonists [Nphe1]N/OFQ(1-13)-NH2 (Guerrini 
et al., 2000a) and UFP-101 (Guerrini et al., 2005). Based on these considerations, in the present 
study, the importance of the N-benzyl D-Pro of Compound 24 was assessed by replacement with L- 
or D-Phe, and Nphe. In addition, the amide bond of Compound 24 was substituted with other amide 
bond isosters. Moreover, the Compound 24 spiroisobenzofurane nucleus was replaced with 
chemical moieties derived from other non-peptide NOP ligands i.e. Ro 64-6198, SB-612111 and J-
113397 (Figure 36). The novel molecules were evaluated for their ability to bind the human 
recombinant NOP receptor expressed in CHOhNOP cell membranes. The molecule showing the 
highest affinity, i.e. Compound 35 has been further characterized at the recombinant human NOP in 
the [35S]GTPγS binding and calcium mobilization assays and at native NOP receptors expressed in 
isolated animal (mouse, rat, guinea-pig) tissues. 
 
Figure 36. Chemical formulae of nociceptin/orphanin FQ receptor ligands. 
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Results and Discussion 
 Substitution into Compound 24 structure of the N-benzyl D-Pro with D or L-Phe 
(compounds 9 and 10) or Nphe (compound 11) produced a profound (> 100 fold) loss of NOP 
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affinity suggesting a pivotal role of the N-benzyl D-Pro moiety for Compound 24 bioactivity (Table 
8). This result is not surprising since the simple inversion of Pro chirality was reported to generate 
an analog 200 fold less potent than Compound 24 (Goto et al., 2006).  
 Modifications of the amide bond obtained by N-methylation (compound 12) or by 
replacement with a methyleneamino (compound 13), an ester (compound 17), a methyleneoxy 
(compound 20), or an alkene bond (compound 25), generated a drastic reduction in NOP receptor 
binding or, in the case of compound 25, complete loss of affinity. These results indicated that the 
amide bond represents a chemical feature crucial for the bioactivity of Compound 24. It is worthy 
of note at this regard, that an amide bond is a relatively uncommon chemical feature in non-peptide 
NOP ligands. However, this chemical bond is also present in the NOP receptor antagonist JTC-801 
and its chemical modification (i.e. N-methylation and retro-inverso bond) was reported to be 
detrimental to binding affinity (Shinkai et al., 2000). Thus, the amide bond might play a similarly 
important role in both Compound 24 and JTC-801. In particular, according to the pharmacophoric 
model for non-peptide NOP ligands proposed by Zaveri et al. (2005), the amide bond may be part 
of the B-moiety that links and contributes to maintain in the correct spatial disposition the A-moiety 
(important for affinity and selectivity) and the B-moiety (important for efficacy).  
 Next, we considered replacement of the benzoisofurane in position 4 of the Compound 24 
piperidine scaffold with chemical moieties taken from the same position of other high affinity NOP 
receptor ligands. The substitution in position 4 with 1-phenylimidazolidin-4-one, the chemical 
group of the NOP receptor agonist Ro 64-6198 (compound 28), or with 1-ethylbenzoimidazol-2-
one, the chemical group of the NOP receptor antagonist J-113397 (compound 41), generated 
inactive molecules. Interestingly, the insertion in position 4 of the piperidine scaffold of the 2,6-
dichlorophenyl moiety (Compound 35), a pharmacophore of the NOP receptor antagonist SB-
612111, generated a molecule with high affinity for the NOP receptor (pKi 9.14). 
 In particular Compound 35 is only 3 fold less potent than Compound 24. The results 
obtained with this limited series of chimeric compounds suggest that it is possible to combine 
pharmacophoric moieties taken from different NOP receptor ligands to generate novel biologically 
active molecules. In particular, the chemical groups benzoisofurane and 2,6-dichlorophenyl seem to 
contribute to NOP receptor binding in a very similar manner. This is corroborated by the finding 
that the substitution of D-Pro with L-Pro in the chimeric NOP ligand compound 36 produced a 100-
fold reduction in receptor affinity. This result is in agreement with that previously observed with 
compounds 22 and 23 of the Goto series (Goto et al., 2006). Thus, the D chirality of the Pro residue 
represents a crucial requirement for both Compound 24 and Compound 35 for high affinity NOP 
receptor recognition.  
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Table 8. Binding affinities at CHOhNOP cell membranes of Compound 24 and related compounds. 
Compound Structure pKi 
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 Based on its high affinity for the NOP receptor, Compound 35 was selected for further 
pharmacological characterization. As shown in Figure 37 (left panel) in CHOhNOP cell membranes 
N/OFQ concentration-dependently stimulated [35S]GTPγS binding with pEC50 and Emax values of 
8.91 and 10.93 ± 0.18 (stimulation factor), respectively. Over the concentration range of 1 – 100 
nM Compound 35 was inactive per se but produced a rightward shift of the concentration response 
curve to N/OFQ in a parallel manner and without modifying the maximal effect. Schild analysis of 
these data (Figure 37, right panel) is compatible with a competitive type of antagonism with a pA2 
value of 9.91. This potency value is close to that previously reported for Compound 24 by Goto et 
al. (2006) (pIC50 9.82) and by us (see Figure 31) (pA2 9.98). 
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Figure 37. Concentration response curve to N/OFQ in the absence and presence of increasing concentrations 
of Compound 35 on [35S]GTPγS binding in CHOhNOP cell membranes. The corresponding Schild plot is 
shown in the right panel. Data are means ± s.e.m. of 4 separate experiments. 
 
 
 These results suggest that the benzoisofurane and 2,6-dichlorophenyl moieties of 
Compound 24 and Compound 35 play a similar role not only in receptor binding but also in 
determining pharmacological activity i.e. pure and competitive antagonism. This may derive from 
the common ability of the spiro junction (Compound 24) and of the 2,6 dichloro substitution 
(Compound 35) to favor an orthogonal spatial disposition between their piperidine and phenyl 
nuclei. Therefore, this conformational feature may likely be crucial for both NOP receptor binding 
and antagonist activity.  
 The pharmacological actions of Compound 35 were further assessed at the hNOP receptor 
coupled to calcium signalling via the chimeric protein Gαqi5; this assay has been previously 
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validated with a large panel of NOP receptor full and partial agonists and antagonists (see section 
3.1). In CHO cells stably expressing the hNOP receptor and the Gαqi5 protein, N/OFQ produced a 
concentration-dependent stimulation of intracellular calcium levels with a pEC50 of 9.24 and an 
Emax of 198 ± 12 % over the basal values. Compound 35 was inactive per se up to 10 µM while 
inhibiting in a concentration-dependent manner the stimulatory effect of 10 nM N/OFQ. A pKB 
value of 8.47 was derived from these experiments (Table 9). This value of potency is approx 3 fold 
lower than that obtained with Compound 24 (pKB 9.03, see Table 7). 
 
 
Table 9. Compound 35 affinity/antagonist potency in various pharmacological assays. 
 CHOhNOP  
cell membranes 
CHOhNOP / Gαqi5 
cells 
Electrically stimulated  
tissues 
 receptor 
binding 
[35S]GTPγS 
binding 
Ca2+ 
mobilization 
mouse vas 
deferens 
rat vas 
deferens 
guinea pig 
ileum 
 
pKi pA2 pKB pA2 pKB pKB 
       
Compound 35 9.14 (9.04 – 9.24) 
9.91 
(9.23 – 10.59) 
8.47 
(8.31 – 8.63) 
8.00 
(7.32 – 8.68) 
8.06 
(7.58 – 8.54) 
8.84 
(8.64 – 9.04) 
 
Data are means (CL95%) of at least 4 separate experiments.  
 
 
 The competitive antagonist behaviour of Compound 35 was confirmed at the native NOP 
receptor expressed in the mouse vas deferens. In this preparation, N/OFQ inhibited electrically 
evoked twitches in a concentration-dependent manner with pEC50 and Emax values of 7.49 of -80 ± 2 
%, respectively (Figure 38, left panel). Compound 35 was inactive per se but caused a 
concentration-dependent (10 – 1000 nM) and parallel rightward shift of the concentration response 
curve to N/OFQ without modifying the agonist maximal effects. The relative Schild plot, depicted 
in Figure 38 (right panel), demonstrated a competitive type of antagonism with a pA2 value of 8.00. 
This value of potency is close to that previously reported for Compound 24 i.e. 8.44 (see Figure 33).  
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Figure 38 Concentration response curve to N/OFQ in the absence and presence of increasing concentrations 
of Compound 35 on the electrically stimulated mouse vas deferens. The corresponding Schild plot is shown 
in the right panel. Data are means ± s.e.m. of 4 separate experiments. 
 
 
 
Similar results were obtained in other N/OFQ sensitive preparations such as the rat vas 
deferens and guinea pig ileum where Compound 35 at 100 nM antagonized N/OFQ inhibitory 
action with pKb values of 8.06 and 8.84, respectively (Figure 39, Table 9). 
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Figure 39. Concentration response-curve to N/OFQ obtained in the absence (control) and presence of 
Compound 35 (100nM) in the electrically stimulated rat vas deferens (left panel) and in guinea pig ileum 
(right panel). Data are means ± s.e.m of 3 separate experiments. 
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 Finally the selectively of action of Compound 35 over classical opioid receptors was 
assessed in animal tissues expressing native receptors and at recombinant human proteins. 
Compound 35 at 1 µM was inactive per se and did not modify the inhibitory effects elicited by the 
DOP selective agonist DPDPE in the mouse vas deferens (control pEC50 8.38 (CL95% 8.20 – 8.56), 
Emax -98 ± 1%; 1 µM Compound 35 pEC50 8.44 (CL95% 8.26 – 8.62), Emax -98 ± 1%) or those 
produced by the MOP agonist dermorphin in the guinea pig ileum (control pEC50 8.52 (CL95% 8.35 
– 8.69), Emax -90 ± 3%; 1 µM Compound 35 pEC50 8.44 (CL95% 8.19 – 8.69), Emax -85 ± 5%).  
 Results obtained with Compound 35 and the universal opioid receptor antagonist naloxone 
in selectivity studies performed with receptor binding and calcium mobilization assays are 
summarized in tables 10 and 11, respectively. Compound 35 up to 10 µM did not displace [3H]DPN 
from DOP sites and showed very low affinity for MOP and KOP receptors (Table 10). In contrast, 
naloxone did not bind the NOP receptor up to 10 µM, while it displaced [3H]DPN from classical 
opioid receptors with very high affinity for MOP and lower affinities for KOP and DOP (Table 10). 
 
 
Table 10. Affinities of Compound 35 and naloxone at NOP and classical opioid receptors expressed in CHO 
cell membranes. 
 
receptor NOP MOP DOP KOP 
radioligand [3H]N/OFQ  [3H]DPN [3H]DPN [3H]DPN 
     
naloxone  < 6 9.25 (9.04 – 9.46) 
7.67 
(7.59 – 7.75) 
8.35 
(8.20 – 8.50) 
Compound 35 9.14 (9.04 – 9.24) 
6.72 
(6.47 – 6.97) < 6 
6.50 
(6.37 – 6.63) 
 
Data are mean (CL95%) of 4 separate experiments. Naloxone data on classical opioid receptors are from 
Vergura et al. (2008). 
 
 
 Similar results were found in functional studies performed measuring calcium mobilization 
in CHO cells stably expressing the hNOP receptor or classical opioid receptors and the Gαqi5 
protein (Table 11). Dermorphin, DPDPE and dynorphin A were used in these experiments as 
agonists for the MOP, DOP and KOP receptors, respectively. All produced a concentration-
dependent increase in calcium levels with the following pEC50 values: 7.93 (CL95% 7.67 – 8.19), 
8.82 (CL95% 8.43 – 9.21), 8.47 (CL95% 8.16 – 8.78). Naloxone inhibited the effects of these agonists 
showing higher potency at MOP than KOP and DOP (Table 11), and being inactive against N/OFQ. 
Compound 35 was at least 300 fold less potent at classical opioid receptors than at the NOP 
receptor (Table 11). 
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Table 11. Antagonist potencies of Compound 35 and naloxone evaluated in calcium mobilization 
experiments performed in CHO cells expressing NOP or classical opioid receptors and the Gαqi5 protein. 
 
receptor NOP MOP DOP KOP 
agonist N/OFQ 10 nM 
Dermorphin 
100 nM 
DPDPE 
100 nM 
Dynorphin A 
100 nM 
     
naloxone  < 6 9.09 (8.73 – 9.45) 
7.32 
(6.80 – 7.84) 
7.14 
(6.60 – 7.68) 
Compound 35 8.47 (8.31 – 8.63) 
6.11 
(5.92 – 6.30) < 6 < 6 
 
Data are mean (CL95%) of 4 separate experiments made in duplicate. 
 
  
 These pharmacological results confirmed that Compound 35 behaves as a pure, potent and 
competitive NOP receptor antagonist. Moreover selectivity studies demonstrated that the 
substitution of the benzoisofurane with the 2,6-dichlorophenyl moiety not only allows maintenance 
of a high affinity and antagonist potency but also high selectivity of action over classical opioid 
receptors. 
 
 
3.5 General conclusions 
The present thesis summarizes the work we performed in the last three years in the field of 
N/OFQ and its receptor. Part of this work was performed during 2007 in Prof. Lambert’s 
laboratories at University of Leicester as part of the Joint Ferrara-Leicester PhD programme. 
Following the formal identification of the receptor NOP and of its endogenous ligand 
N/OFQ, an extensive search has started to assess the biological functions regulated by this peptide-
receptor system and to foresee the therapeutic indications of drugs interacting selectively with the 
NOP receptor. In parallel, academic and industrial laboratories generated new molecules that 
selectively activate or block the NOP receptor thus providing the pharmacological tools needed for 
target validation studies. 
 
The major aim of this work was detailed in vitro and in vivo pharmacological 
characterization of novel ligands for the NOP receptor designed and synthesized by the medicinal 
chemistry group of Prof. Salvadori. To this aim, we develop and use different in vitro and in vivo 
assays: in vitro studies were performed measuring receptor and [35S]GTPγS binding and calcium 
mobilization in cells expressing the recombinant NOP receptor as well as using N/OFQ sensitive 
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tissues from different species (mouse, rat, guinea pig). In vivo studies were conducted using an 
analgesiometric assay such as the tail withdrawal tests after both supraspinal and spinal 
administration. Moreover some in vitro and in vivo experiments were performed using NOP(+/+) 
and NOP(-/-) mice for investigating the involvement of the NOP receptor in the actions exerted by 
the novel ligands. 
Our major contributions to this field can be summarized below: 
 
1) We confirmed that it is possible to use the Gαqi5 chimeric protein to force classical 
opioid and NOP receptors to signal via the calcium pathway. [Ca2+]i levels were 
monitored using the fluorometer FlexStation II. A panel of full and partial agonists as 
well as antagonists were assessed in calcium mobilization experiments demonstrating 
that that the FlexStation II – Gαqi5 NOP receptor calcium assay represents a very useful 
strategy for the screening of NOP receptor ligands particularly for antagonists. In fact, 
results obtained with this class of ligands in the Gαqi5 NOP receptor calcium assay are 
superimposable to those collected with more classical Gi based biochemical assays 
performed on recombinant or native NOP receptors or with bioassays performed on 
isolated tissues expressing native NOP receptors, with the exception of ligands 
characterized by slow kinetics of interaction with the NOP receptor. 
 
2) Parallel experiments, performed on mouse and rat tissues, confirmed previous finding 
demonstrating that ZP120 behaves as a high potency NOP selective partial agonist. In 
fact in both preparations ZP120 mimicked the effects of N/OFQ showing higher potency 
but lower maximal effects. The effects of N/OFQ and those elicited by ZP120 have been 
evaluated in the presence of two NOP receptor antagonists: UFP-101 and J-113397. The 
antagonist sensitivity of ZP120 effects (J-113397 sensitive and UFP-101 resistant) is not 
superimposable to that of the endogenous NOP ligand N/OFQ (J-113397 and UFP-101 
sensitive). However the exclusive involvement of the NOP receptor protein in the in 
vitro as well as in vivo effects of ZP120 (and N/OFQ) was clearly demonstrated by 
knockout studies. Therefore the different sensitivity of N/OFQ and ZP120 to UFP-101 
might be attributed to their diverse binding and activation of the NOP receptor. In vivo, 
ZP120 has been shown to mimic N/OFQ actions displaying higher potency and longer 
lasting effects than the natural ligand. These pharmacological features make ZP120 a 
promising and innovative drug candidate for treating heart failure and for exploiting the 
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therapeutic benefits deriving from a prolonged partial activation of peripheral NOP 
receptors. 
 
3) Compound 24 has been recently identified as a novel non-peptide selective antagonist 
(Goto et al., 2006). Our major goal was to perform an extensive in vitro and in vivo 
pharmacological characterization of the actions of this interesting molecule. Our 
findings derived from competition binding and functional studies on CHOhNOP, calcium 
mobilization assay on CHOhNOP co-expressing the Gαqi5 chimeric protein, bioassay 
studies on native receptors and in vivo in the tail withdrawal assay, demonstrated that 
Compound 24 behaves as one of the most potent and selective non-peptide NOP 
antagonists. It is worth noting that synthesis of Compound 24 is relatively easy when 
compared to that of other non-peptide NOP antagonists such as J-113397 and SB-
612111. 
 
4) A novel ligand has been identified from SAR studies of the NOP receptor antagonist 
Compound 24, this compound is named Compound 35. Based on the novel structure of 
Compound 24 the group of Prof. Salvadori synthesized twelve new derivates focusing 
on the N-benzyl-D-proline, amide bond and benzoisofurane moieties. This latter 
structure was substituted with moieties taken from known non-peptide NOP ligands such 
as Ro 64-6198, SB-612111 and J-113397. The new derivates were evaluated for their 
ability to bind the human recombinant NOP receptor and the molecule showing the 
highest affinity (Compound 35) has been further characterized. In vitro studies were 
performed measuring receptor and [35S]GTPγS binding and calcium mobilization in cells 
expressing the recombinant NOP receptor as well as using N/OFQ sensitive tissues. The 
pharmacological results confirmed that Compound 35 behaves as a pure, potent and 
competitive NOP receptor antagonist. Moreover selectivity studies demonstrated that the 
substitution of the benzoisofurane with the 2,6-dichlorophenyl moiety not only allows 
maintenance of a high affinity and antagonist potency but also high selectivity of action 
over classical opioid receptors. Based on its pharmacological profile Compound 35 
might be useful in future in vivo studies aimed at investigating the possible therapeutic 
indications of selective NOP antagonists. 
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The development of new NOP receptor antagonists has to be considered of primary interest 
particularly in the field of pain (Fioravanti et al., 2008; Zeilhofer et al., 2003), obesity (Przydzial et 
al., 2008), memory disorders (Jinsmaa et al., 2000), sepsis (Carvalho et al., 2008; Williams et al., 
2008) and mood (Gavioli et al., 2006). In addition, very recent studies performed by the group of 
Prof. Morari (Marti et al., 2005; Marti et al., 2004a; Marti et al., 2004b; Marti et al., 2008; Marti et 
al., 2007) provided very robust evidence that NOP antagonists are worthy of development as 
innovative drugs for Parkinson’s disease. 
 
A useful comparison between peptide and non-peptide NOP receptor antagonists is 
summarized in Table 12. 
 
 
Table 12. Affinity and potency values of the peptide and non-peptide NOP receptor antagonists in different 
in vitro assays. Data are mean of at least 4 experiments. 
 
CHOhNOP  
Cell membranes Whole cells 
Electrically 
Stimulated Tissues 
 Receptor Binding [35S]GTPγS Binding Calcium Assay mVD rVD gpI 
 pKi pA2 pKB pKB pKB pKB 
UFP-101 10.24 9.12 7.66 7.29 7.30 7.18 
J-113397 8.42 8.71 7.88 7.53 7.97 7.69 
Trap-101 8.65 8.55 7.93 7.75 7.68 7.51 
SB-612111 9.18 9.70 8.16 8.50 8.20 8.40 
Compound 24 9.62 9.98 9.03 8.44 8.28 9.12 
Compound 35 9.14 9.91 8.47 8.00 8.06 8.84 
 
 
As shown in Table 12, all the NOP receptor antagonists were found to bind to the NOP 
receptor with high affinity (in the nanomolar range). For each compound pA2 values obtained in 
[35S]GTPγS binding experiments on CHOhNOP were higher comparing with all the other tests. This 
might be due to the higher receptor availability in membranes (where the [35S]GTPγS is performed) 
than in whole cells or tissues preparations (where the other tests are performed). Despite this minor 
difference, very similar potency values were obtained in different assays for all the antagonists. 
UFP-101, represents the most potent NOP peptide antagonist. J-113397 has been largely used as a 
standard non-peptide NOP antagonist. Among non-peptide molecules, SB-612111 is one of the 
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most potent and selective NOP receptor antagonist identified to date. In vitro, in most of the 
preparations, Compound 24 has shown potency values higher than those obtained by SB-612111. 
However, the in vivo potency of Compound 24 seems to be lower than that of SB-612111. 
Moreover, synthesis of Compound 24 and Compound 35 is easier compared with that of both J-
113397 and SB-612111. Collectively these data suggest the following order of potency of 
antagonists: Compound 24 = Compound 35 = SB-612111 > J-113397 > UFP-101 = Trap-101. 
Based on the findings summarized in this thesis Compound 24 and Compound 35 should be 
included (together with J-113397, SB-612111 and UFP-101) in the list of potent and selective NOP 
receptor antagonists to be used in future target validation studies for firmly defining the therapeutic 
potential of selective NOP antagonists as innovative drugs. 
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